<SEC-DOCUMENT>0001013762-23-000753.txt : 20231003
<SEC-HEADER>0001013762-23-000753.hdr.sgml : 20231003
<ACCEPTANCE-DATETIME>20231003084630
ACCESSION NUMBER:		0001013762-23-000753
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231003
FILED AS OF DATE:		20231003
DATE AS OF CHANGE:		20231003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MDxHealth SA
		CENTRAL INDEX KEY:			0001872529
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C9

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40996
		FILM NUMBER:		231301631

	BUSINESS ADDRESS:	
		STREET 1:		CAP BUSINESS CENTER
		STREET 2:		RUE D'ABHOOZ, 31, B-4040
		CITY:			HERSTAL
		STATE:			C9
		ZIP:			00000
		BUSINESS PHONE:		949-271-9221

	MAIL ADDRESS:	
		STREET 1:		CAP BUSINESS CENTER
		STREET 2:		RUE D'ABHOOZ, 31, B-4040
		CITY:			HERSTAL
		STATE:			C9
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MDx Health SA
		DATE OF NAME CHANGE:	20210713
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea186179-6k_mdxhealth.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the month of October 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number 001-40996</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MDXHEALTH
SA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAP
Business Center</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zone
Industrielle des Hauts-Sarts</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4040
Herstal, Belgium</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+32
4 257 70 21</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MDXHEALTH
SA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023 and October 2, 2023, MDxHealth SA (the &ldquo;Company&rdquo;) issued press releases, copies of which are attached
hereto as Exhibits 99.1 and 99.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby furnishes the documents attached hereto as Exhibits 99.3-99.10 in connection with its Extraordinary General Shareholders&rsquo;
Meetings to be held on Friday, November 3, 2023 at 3:00 p.m., Belgian time, at the offices of the notary public Stijn Raes, at Kortrijksesteenweg
1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>The
information in the attached Exhibits <FONT STYLE="background-color: white">99.1-99.10</FONT> is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that
Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    <BR>
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 90%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Exhibit</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea186179ex99-1_mdxhealth.htm">Press
    Release, dated September 26, 2023</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea186179ex99-2_mdxhealth.htm">Press
    Release, dated October 2, 2023</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea186179ex99-3_mdxhealth.htm">Special
    Report of the Board of Directors</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea186179ex99-4_mdxhealth.htm">Letter
    from the Chairperson</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea186179ex99-5_mdxhealth.htm">Frequently
    Asked Questions Regarding Share Consolidation, Termination of ADS Program and Euronext De-Listing</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea186179ex99-6_mdxhealth.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convening Notice</FONT></A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea186179ex99-7_mdxhealth.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attendance Form</FONT></A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea186179ex99-8_mdxhealth.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Form</FONT></A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="ea186179ex99-9_mdxhealth.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting By Mail Form</FONT></A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea186179ex99-10_mdxhealth.htm">Outstanding Shares and Voting Rights</A></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MDXHEALTH SA</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 3, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael McGarrity</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael McGarrity</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea186179ex99-1_mdxhealth.htm
<DESCRIPTION>PRESS RELEASE, DATED SEPTEMBER 26, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>NEWS RELEASE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>September 26, 2023, 4:00PM EDT / 22:00 CET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mdxhealth Signs Research Collaboration with
University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate
Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IRVINE, CA, and HERSTAL, BELGIUM &ndash; September
26, 2023 &ndash; </B>MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a
research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and
prostate cancer progression following treatment for localized prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ian Mills, PhD, John Black Professor of Prostate
Cancer at University of Oxford, commented: </B>&ldquo;Prostate cancer is a prevalent male cancer that can develop into metastases in certain
cases, underscoring the urgent need for improved risk stratification through disease profiling and biological modeling. We are excited
to collaborate with mdxhealth to validate the GPS test&rsquo;s potential to enhance risk assessment in men diagnosed with localized prostate
cancer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a pivotal part of this collaboration, mdxhealth
will conduct GPS testing on patient samples derived from the Prostate Mechanisms of Progression and Treatment (ProMPT) cohort. Initiated
in 2002, the ProMPT collaborative translational research group involves the cooperation of multiple cancer research programs to collect
biological samples and clinical data from participants across the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Michael K. McGarrity, CEO of mdxhealth, commented,</B>
&ldquo;This groundbreaking research partnership between mdxhealth and University of Oxford marks a crucial step toward advancing the understanding
of prostate cancer progression and treatment outcomes. The outcomes of this collaboration can pave the way for more tailored and effective
treatments for patients with localized prostate cancer. We firmly believe that our Genomic Prostate Score test holds the potential to
accurately predict disease progression in patients undergoing treatment for localized prostate cancer.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About mdxhealth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mdxhealth is a commercial-stage precision diagnostics
company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company&rsquo;s tests are based
on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis
of urologic cancers and other urologic diseases. The Company&rsquo;s U.S. headquarters and laboratory operations are in Irvine, California,
with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen,
The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth
and linkedin.com/company/mdxhealth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For more information: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>mdxhealth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">info@mdxhealth.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LifeSci Advisors (IR &amp; PR)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US: +1 949 271 9223</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@mdxhealth.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains forward-looking
statements and estimates with respect to the anticipated future performance of mdxhealth and the market in which it operates, all of which
involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such
as &ldquo;potential,&rdquo; &ldquo;expect,&rdquo; &ldquo;will,&rdquo; &ldquo;goal,&rdquo; &ldquo;next,&rdquo; &ldquo;potential,&rdquo;
&ldquo;aim,&rdquo; &ldquo;explore,&rdquo; &ldquo;forward,&rdquo; &ldquo;future,&rdquo; and &ldquo;believes&rdquo; as well as similar expressions.
Forward-looking statements contained in this release include, but are not limited to, statements regarding the acquisition of Oncotype
DX&reg; GPS prostate cancer business from Exact Sciences including statements regarding the anticipated benefits of the acquisition; statements
regarding expected future operating results; statements regarding product development efforts; and statements regarding our strategies,
positioning, resources, capabilities and expectations for future events or performance. Such statements and estimates are based on assumptions
and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct.
Actual events are difficult to predict, may depend upon factors that are beyond the company&rsquo;s control, and may turn out to be materially
different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results,
product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important
factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements
include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects
on our operations, and the demand for our products; our ability to successfully and profitably market our products; the acceptance of
our products and services by healthcare providers; the willingness of health insurance companies and other payers to cover our products
and services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and comply
with applicable regulations; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the
Oncotype DX&reg; GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and
the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk
Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission.
Mdxhealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its
expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required
by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
mdxhealth in any jurisdiction. No securities of mdxhealth may be offered or sold within the United States without registration under the
U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities
laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NOTE:</I></B><I> The mdxhealth logo, mdxhealth,
Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth
SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts
and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay,
among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea186179ex99-2_mdxhealth.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 2, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex99-2_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>NEWS RELEASE &ndash; REGULATED INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>INSIDE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>OCTOBER 2, 2023, 4:00pm ET / 22:00 CET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MDxHealth Announces Proposed Transition to a
Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IRVINE, CA, and HERSTAL, BELGIUM</B> &ndash;
October 2, 2023 &ndash; MDxHealth SA <FONT STYLE="background-color: white">(NASDAQ/Euronext Brussels: MDXH) (the &ldquo;Company&rdquo; or
&ldquo;mdxhealth&rdquo;), a commercial-stage precision diagnostics company, </FONT>today announces a proposed transition from a dual listing
of the Company&rsquo;s American Depositary Shares (the &ldquo;ADSs&rdquo;) on Nasdaq and ordinary shares (the &ldquo;Shares&rdquo;) on Euronext
Brussels to a sole listing of Shares on Nasdaq (the &ldquo;Transaction&rdquo;), and, in view thereof, invites the holders of securities
issued by the Company to an extraordinary general shareholders&rsquo; meeting that will be held on Friday, November 3, 2023 at 3:00 p.m., Belgian
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Proposed Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s board of directors has determined
it is in the best interest of the Company, its investors and other stakeholders to consolidate all trading of the Company&rsquo;s securities
on one exchange in the United States. The Transaction involves (1) a share consolidation with respect to all outstanding Shares by means
of a 1-for-10 reverse stock split (the &ldquo;Share Consolidation&rdquo;), after which ten existing Shares will be represented by one new
Share, and each ADS will represent one new Share, (2) listing the Shares on Nasdaq, (3) a mandatory exchange under the Company&rsquo;s ADS facility
as a result of which ADS holders will receive Shares in exchange for their ADSs on the basis of a ratio of one ADS for one Share (the
&ldquo;Mandatory ADS Exchange&rdquo;), (4) a repositioning of the Shares from the Euronext Brussels trading system to the Nasdaq trading
system, and (5), following a transition period of at least three weeks after the Mandatory ADS Exchange (the &ldquo;Transition Period&rdquo;),
the de-listing of the Shares from listing and trading on Euronext Brussels (the &ldquo;De-Listing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors is proposing the
Transaction for a number of reasons but primarily because it is expected that consolidating the trading of the Company&rsquo;s
securities onto a single  exchange will improve trading liquidity and reduce the administrative and legal
costs associated with maintaining a presence on two exchanges. Upon termination of the ADS facility, ADSs held in brokerage accounts
will be automatically cancelled and exchanged for Nasdaq-listed Shares without ADS holders having to take any action. During the
Transition Period and following the Euronext Brussels De-listing, shareholders may reposition their Shares for trading on Nasdaq
after completing a procedure through their financial intermediary or broker. The Company expects that many financial intermediaries
will use their discretionary rights (under their terms of service to their clients) to automatically reposition their clients&rsquo;
Euronext Brussels-listed Shares on their behalf. The Company will provide more information regarding the
repositioning of Shares after the Share Consolidation and De-Listing have been approved by the general shareholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Michael K. McGarrity, CEO of mdxhealth, commented:
</B>&ldquo;A key priority for us has been to create a more attractive and efficient trading mechanism for our global investors and stakeholders
and to support increasing interest from new investors, while reducing our operating costs. We believe the transition to trade exclusively
on the Nasdaq accomplishes this objective. This is an exciting time for mdxhealth, and we look forward to  expanding
our shareholder base as we continue to execute and drive growth as a leading precision diagnostics company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information and details regarding the proposed Transaction, reference is made to the dedicated web page which can be found
on the Company&rsquo;s website website, which contains (among other things) (i) a Special Report describing the proposals that
will be submitted to the Company&rsquo;s LifeSci Advisors (IR &amp; PR) US: +1 949 271 9223 ir@mdxhealth.com mdxhealth info@mdxhealth.com extraordinary
general shareholders&rsquo; meeting, (ii) a letter from the chair of the board of directors summarizing the Transaction, and (iii) frequently
asked questions (FAQs) providing context and technical details with respect to the Transaction. This web page and the FAQs will be kept
up-to-date as and when necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Extraordinary Shareholders Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to implement the Transaction, it will
be necessary for the Company&rsquo;s shareholders to approve the Share Consolidation and the De-Listing. In view thereof, the board of
directors hereby convenes an extraordinary general shareholders&rsquo; meeting to be held on November 3, 2023 at 3:00 p.m., Belgian time,
to seek required shareholder approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The items on the agenda of the extraordinary general
shareholders&rsquo; meeting include the approval of the proposed Share Consolidation and De-Listing, as well as a number of technical amendments
to the Company&rsquo;s articles of association that allow for the De-Listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to participate in the extraordinary general
shareholders&rsquo; meeting of the Company, the holders of securities issued by the Company must comply with article 7:134, &sect;2, first
indent of the Belgian Companies and Associations Code and the articles of association of the Company, and fulfill the formalities described
in the convening notice. The convening notice, forms and other documents relating to the extraordinary general shareholders&rsquo; meeting
can be found on the dedicated web page which can be found on the Company&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recommends holders of its securities
to use e-mail for all communication with the Company regarding the general shareholders&rsquo; meeting. The Company&rsquo;s email address
for such communication is: agsm@mdxhealth.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Update of the 2023 Reporting Calendar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company plans to pre-release its third quarter
revenues and cash figures in light of the pendency of the proposed Transaction. In view thereof, the updated financial calendar for 2023
shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">October 9, 2023: Preliminary Q3-2023 business update</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">November 8, 2023: Q3-2023 business update</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About mdxhealth</B></FONT><B><SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mdxhealth is a commercial-stage
precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company&rsquo;s
tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis
and prognosis of urologic cancers and other urologic diseases. The Company&rsquo;s U.S. headquarters and laboratory operations are in
Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory
operations in Nijmegen, The Netherlands. For more information, visit&nbsp;mdxhealth.com&nbsp;and follow us on social media at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">twitter.com/mdxhealth,&nbsp;facebook.com/mdxhealth&nbsp;and&nbsp;linkedin.com/company/mdxhealth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For more information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>mdxhealth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B> info@mdxhealth.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>LifeSci Advisors (IR &amp; PR)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">US: +1 949 271 9223</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ir@mdxhealth.com &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Forward-looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains forward-looking
statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which
involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such
as &ldquo;potential,&rdquo; &ldquo;expect,&rdquo; &ldquo;will,&rdquo; &ldquo;goal,&rdquo; &ldquo;next,&rdquo; &ldquo;potential,&rdquo;
&ldquo;aim,&rdquo; &ldquo;explore,&rdquo; &ldquo;forward,&rdquo; &ldquo;future,&rdquo; and &ldquo;believes&rdquo; as well as similar expressions.
Forward-looking statements contained in this release include, but are not limited to, statements regarding timing and benefits of
the proposed transition from a dual listing of shares on Euronext Brussels and ADSs on Nasdaq to a sole listing of shares on Nasdaq; including
statements regarding the anticipated impacts on the trading market for MDxHealth&rsquo;s securities and operating costs; statements regarding
expected future operating results; statements regarding product development efforts; and statements regarding our strategies, positioning,
resources, capabilities and expectations for future events or performance. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct.
Actual events are difficult to predict, may depend upon factors that are beyond the company&rsquo;s control, and may turn out to be materially
different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results,
product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important
factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements
include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects
on our operations, and the demand for our products; our ability to successfully and profitably market our products; the acceptance of
our products and services by healthcare providers; the willingness of health insurance companies and other payers to cover our products
and services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and comply
with applicable regulations; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the
Oncotype DX&reg; GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and
the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk
Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission.
MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its
expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required
by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the
U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities
laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NOTE:</I></B><I> The mdxhealth logo, mdxhealth,
Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth
SA. All other trademarks and service marks are the property of their respective owners.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ea186179ex99-3_mdxhealth.htm
<DESCRIPTION>SPECIAL REPORT OF THE BOARD OF DIRECTORS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MDxHealth
SA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAP
Business Center<BR>
Zone Industrielle des Hauts-Sarts<BR>
4040 Herstal, Belgium</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Special
Report<BR>
regarding the Proposed Share Consolidation and<BR>
De-Listing of Shares from<BR>
the Regulated Market of Euronext Brussels</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
special report (the &ldquo;<B>Special Report</B>&rdquo;) has been prepared by the board of directors of MDxHealth SA, a limited liability
company organized under the laws of Belgium, registered with the Belgian legal entities register (Li&egrave;ge, division Li&egrave;ge)
under enterprise number 0479.292.440, with LEI number 549300J3MG9F9B5FY646, and with its registered office located at CAP Business Center,
Zone Industrielle des Hauts-Sarts, Rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium (the &ldquo;<B>Company</B>&rdquo; and, together with
its consolidated subsidiaries from time to time, &ldquo;<B>MDxHealth</B>&rdquo;). It relates to the proposed consolidation of the Company&rsquo;s
ordinary shares (the &ldquo;<B>Shares</B>&rdquo;) by means of a 1-for-10 reverse stock split (the &ldquo;<B>Share Consolidation</B>&rdquo;),
followed by a de-listing (the &ldquo;<B>De-Listing</B>&rdquo;) of the Company&rsquo;s Shares from listing and trading on the regulated
market of Euronext Brussels (&ldquo;<B>Euronext Brussels</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed Share Consolidation and De-Listing will be submitted for approval to an extraordinary general shareholders&rsquo; meeting of
the Company (the &ldquo;<B>EGM</B>&rdquo;) to be held on 3 November 2023. If the attendance quorum for the items on the agenda of the
EGM were not to be reached, a second EGM will be held for these items on 23 November 2023, unless, as the case may be, decided otherwise
on behalf of the Company&rsquo;s board of directors. Provided that the proposed Share Consolidation and De-Listing will be approved by
the EGM, the Company&rsquo;s board of directors will further implement the Share Consolidation and De-Listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Shares are currently admitted to listing and trading on Euronext Brussels under the symbol &ldquo;<I>MDXH</I>&rdquo;.
The Shares are all ordinary shares, are fully paid, and rank <I>pari passu</I> in all respects with all other existing and outstanding
shares of the Company. The international securities identification number (ISIN) of the Shares is BE0003844611. The Company currently
also has outstanding American Depositary Shares (&ldquo;<B>ADSs</B>&rdquo;) listed on the Nasdaq Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;)
under the symbol &ldquo;<I>MDXH</I>&rdquo;. The ADSs represent outstanding Shares of the Company on a 1-for-10 basis, whereby each ADS
represents 10 outstanding Shares. The international securities identification number (ISIN) of the ADSs is <FONT STYLE="background-color: white">US58286E1029
</FONT>and their CUSIP number is 58286E102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Share Consolidation has been approved and has become effective, each ADS will thereafter represent one Share on a 1-for-1 basis.
The Company&rsquo;s board of directors also intends to terminate the ADS programme, and to request the admission of the underlying Shares
directly on Nasdaq. As a result, following such admission, the Company&rsquo;s shareholders that will have Shares at that time admitted
to trading on Euronext Brussels will be able to trade their Shares on Nasdaq, subject to certain formalities in order to reposition the
Shares from the trading system used for trading the Shares on Euronext Brussels into the trading system used for trading the Shares on
Nasdaq (the &ldquo;<B>Market Repositioning</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided
that the De-Listing will be approved by the EGM, the Share Consolidation has become effective and the Company&rsquo;s shares have been
admitted to trading on Nasdaq, the Company intends to request the De-Listing to become effective, subject to a transition period of at
least three weeks after the Share Consolidation has become effective (the &ldquo;<B>Transition Period</B>&rdquo;). During the Transition
Period, the Shares will remain tradable on Euronext Brussels. However, after the expiry of the Transition Period, the Shares will no
longer be tradeable on Euronext Brussels. A Market Repositioning of the Shares will remain possible during and after the Transition Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
2 October 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Information and Notices</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
    this Special Report</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability
    of this Special Report</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Information regarding the EGM</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
    to Investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary
    Statement regarding Forward-Looking Statements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    Share Consolidation and De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposals
    in relation to the Share Consolidation and De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    other Approvals</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
    for the Proposed Share Consolidation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
    for the Proposed De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
    for the termination of the ADS programme</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers
    to further implement the Share Consolidation and De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicative
    timetable for the Share Consolidation and De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Practical
    implementation of the Market Repositioning</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences
    of the Proposed Share Consolidation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of the Share Consolidation for Holders of Shares</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation
    and Sale of Fractions of new Shares resulting from the Share Consolidation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of the Share Consolidation for Holders of Subscription Rights</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences
    of the Proposed De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in Legal Framework</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    and Corporate Governance of the Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
    of Directors and Executives</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
    of Shareholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
    by the Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
    by Shareholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    when the Company no longer is a Foreign Private Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Nasdaq</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
    taxation of dividends on Shares</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
    taxation of capital gains and losses on Shares</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
    tax on stock exchange transactions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">28</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
    annual tax on securities accounts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Reporting Standard</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proposed Financial Transaction Tax (FTT)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda
    and Proposals Submitted to the EGM</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glossary
    of Selected Terms</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
Information and Notices</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
this Special Report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Special Report has been prepared by the board of directors of the Company, as far as needed and applicable in accordance with the Belgian
Act of 21 November 2017 relating to the infrastructures for markets for financial instruments and regarding the transposition of Directive
2014/65/EU (the &ldquo;<B>Belgian Markets for Financial Instruments Act</B>&rdquo;), for the purposes of the proposed Share Consolidation
and De-Listing that will be submitted for approval to an EGM of the Company. The Company is responsible for the information contained
in this Special Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in this Special Report is accurate only as of the date on the front cover of this Special Report, and the information
incorporated by reference into this Special Report is accurate only as of the date of the document incorporated by reference, in each
case, unless expressly stated otherwise and regardless of the time of delivery of this Special Report. The Company&rsquo;s business,
financial condition, results of operations and prospects may have changed since such dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares and other securities of the Company should rely only on the information contained in or incorporated by reference into this
Special Report. The Company has not authorized anyone to provide it with different information. If anyone provides you with different
or inconsistent information, you should not rely on it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution or possession of this Special Report in or from certain jurisdictions may be restricted by law. This Special Report is not
an offer to sell Shares, ADSs or other securities, and is not soliciting an offer to buy Shares, ADSs or such securities in any jurisdiction
where the offer or sale is not permitted or where the person making the offer or sale is not qualified to do so or to any person to whom
it is not permitted to make such offer or sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Language
versions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Special Report has been prepared in English and translated into French. The Company is responsible for the consistency between the English
and French language versions of the Special Report. Investors can rely on the French language version of this Special Report in their
contractual relationship with the Company. In any event, in the case of discrepancies between the different language versions of this
Special Report, the English language version will prevail.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability
of this Special Report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Special Report is available in Belgium at no cost at the Company&rsquo;s registered office, located at CAP Business Center, Zone Industrielle
des Hauts-Sarts, Rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to country restrictions, the Special Report is also available on the Company&rsquo;s website (under the section &ldquo;<I>Special Reports</I>&rdquo;)
free of charge (see mdxhealth.com/investors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
posting of the Special Report or any summary thereof on the internet does not constitute an offer to sell or a solicitation of an offer
to buy any Shares, ADSs or other securities to or from any person in any jurisdiction in which it is unlawful to make such offer or solicitation
to such person. The electronic version may not be copied, made available or printed for distribution. Although certain references are
made to the Company&rsquo;s website, information on the Company&rsquo;s website (www.mdxhealth.com) (other than the Special Report or
any documents incorporated by reference herein) or any other website does not form part of the Special Report. This Special Report nor
any of the documents incorporated by reference herein, nor any information on the Company&rsquo;s website has been scrutinized or approved
by a competent authority.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
Information regarding the EGM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information on date, hour and venue of the EGM, the manner in which the holders of securities issued by the Company can participate
to the EGM, reference can be made to the notice convening the EGM, which is available on the Company&rsquo;s website (under the section
&ldquo;<I>Shareholder Information</I>&rdquo;) free of charge (see mdxhealth.com/investors). The agenda and proposed resolutions that
are submitted to the EGM are also set out in the section &ldquo;&mdash;Agenda and Proposals Submitted to the EGM&rdquo;.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
to Investors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Special Report is intended to provide information to holders of Shares in the context of and for the sole purpose of evaluating the Share
Consolidation and De-Listing. It contains selected and summarized information (including information incorporated by reference). It does
not express any commitment or acknowledgement or waiver, and does not create any right, express or implied, towards anyone other than
a holder of Shares or ADSs. Holders of Shares or ADSs must assess, with their own advisors if necessary, whether the Company&rsquo;s
Shares or ADSs are a suitable investment for them, considering their personal income and financial situation. In case of any doubt about
the risks involved in investing in the Shares or ADSs, investors should abstain from investing in the Shares or ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making a decision to approve the Share Consolidation, De-Listing or making an investment in Shares or ADSs, shareholders and investors
must rely on their own assessment, examination, analysis and enquiry of MDxHealth, the terms of the Share Consolidation and De-Listing,
and the contents of this Special Report, including the merits and risks involved. Any acquisition or disposal of Shares or ADSs should
be based on the assessments that an investor may deem necessary and including possible tax consequences that may apply, before deciding
whether or not to acquire or dispose of the Shares or ADSs. In addition to their own assessment of MDxHealth and the terms of the Share
Consolidation and De-Listing, investors should rely only on the information contained in this Special Report, including the considerations
described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summaries and descriptions of legal provisions, accounting principles or comparisons of such principles, legal company forms or contractual
relationships reported in the Special Report may under no circumstances be interpreted as a basis for credit or other evaluation, or
as investment, legal or tax advice for investors. Investors are urged to consult their own financial adviser, accountant or other advisers
concerning the legal, tax, economic, financial and other aspects associated with the trading or investment in the Shares or the ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, or any of its respective representatives, is not making any representation to any holder of Shares or ADSs regarding the legality
of an investment in the Shares or ADSs by such person under the laws applicable to such purchaser. Each investor should consult with
its own advisers as to the legal, tax, business, financial and related aspects of an acquisition or disposal of the Shares or ADSs.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary
Statement regarding Forward-Looking Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Special Report contains forward-looking statements. All statements other than statements of historical facts contained in this Special
Report, including statements (as the case may be) regarding the decisions by the EGM, and the Company&rsquo;s strategy, future operations,
future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are
forward-looking statements. Forward-looking statements give the Company&rsquo;s current expectations or forecasts of future events. Many
(but not all) of these statements can be found by looking for words such as &ldquo;approximates&rdquo;, &ldquo;believes&rdquo;, &ldquo;hopes&rdquo;,
&ldquo;expects&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;estimates&rdquo;, &ldquo;projects&rdquo;, &ldquo;intends&rdquo;, &ldquo;plans&rdquo;,
&ldquo;would&rdquo;, &ldquo;should&rdquo;, &ldquo;could&rdquo;, &ldquo;may&rdquo; or other similar expressions in this Special Report.
The sections in the Company&rsquo;s periodic reports, including its Annual Report for the fiscal year ended 31 December 2022, titled
&ldquo;<I>Principal Risks &amp; Uncertainties</I>&rdquo; and &ldquo;<I>Business Review</I>&rdquo;, as well as other sections in this
Special Report, discuss some of the factors that could contribute to these differences. Forward<FONT STYLE="background-color: white">-looking
statements contained in this Special Report include, but are not limited to, </FONT>statements <FONT STYLE="background-color: white">regarding
the Company&rsquo;s future plans and strategies, statements regarding the trading and liquidity of the Company&rsquo;s Shares and ADSs,
statements regarding the Company&rsquo;s ability to attract future funding, statements regarding the benefits of the Share Consolidation,
De-Listing and </FONT>Market Repositioning<FONT STYLE="background-color: white">, and statements regarding the Company&rsquo;s strategies,
positioning, resources, capabilities and expectations for future events or performance. </FONT>These statements reflect the Company&rsquo;s
views with respect to future events as of the date of this Special Report and are based on assumptions and subject to risks and uncertainties.
Given these uncertainties, <FONT STYLE="background-color: white">the reader is advised not to place any undue reliance </FONT>on these
forward-looking statements. These forward-looking statements represent the Company&rsquo;s estimates and assumptions only as of the date
of this Special Report and, except as required by law, the Company undertakes no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or otherwise after the date of this Special Report. The Company anticipates
that subsequent events and developments will cause its views to change. This Information, together with the documentation incorporated
by reference, should be read in its entirety and with the understanding that the Company&rsquo;s actual future results may be materially
different from what the Company expects. All of the forward-looking statements are qualified by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
Share Consolidation and De-Listing</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposals
in relation to the Share Consolidation and De-Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
2 October 2023, the Company&rsquo;s board of directors announced to convene an EGM to approve the proposed Share Consolidation and De-Listing
of the Company&rsquo;s Shares from listing and trading on Euronext Brussels. The proposals regarding the De-Listing also contain a number
of technical amendments to the Company&rsquo;s articles of association that allow for the De-Listing. The agenda and proposed resolutions
that are submitted to the EGM are also set out in the section &ldquo;&mdash;Agenda and Proposals Submitted to the EGM&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding Shares must be present or represented
at the EGM in order to consider and vote on the proposed Share Consolidation and De-Listing. If this attendance quorum is not reached
at the first EGM (which is to be held on 3 November 2023), a second EGM will be convened for these agenda items (which is to be held
on 23 November 2023), unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance quorum requirement
will not apply to such second EGM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with applicable law, the proposed resolutions shall be passed if they are approved by a 75% majority of the votes validly
cast by the shareholders at the EGM. Subject to applicable legal provisions, each Share shall have one vote at the EGM. Pursuant to article
7:135 of the Belgian Companies and Associations Code, the holders of subscription rights will have the right to participate to the EGM,
but only with an advisory vote.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
other Approvals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval of the De-Listing by the EGM, the De-Listing has been approved by Euronext Brussels. In addition, subject to approval of
the De-Listing by the EGM, pursuant to the Belgian Markets for Financial Instruments Act, the Belgian Financial Services and Markets
Authority (&ldquo;<B>FSMA</B>&rdquo;) did not object to the De-Listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval of the Share Consolidation and De-Listing by the EGM and no objection to the De-Listing by the FSMA and in advance of the
termination the ADS programme, the Company will submit a company event notification to Nasdaq to effect (i) the termination of the listing
of the ADSs on Nasdaq in connection with the delivery of the Shares to the ADS holders as a result of the termination of the ADS programme
and (ii) the listing of such Shares directly on the Nasdaq exchange.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
for the Proposed Share Consolidation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s ADSs, which are trading on Nasdaq, currently represent outstanding Shares of the Company on a 1-for-10 basis, whereby
each ADS represents 10 outstanding Shares. As a result of the Share Consolidation, the ADS will represent Shares of the Company on a
1-for-1 basis. This would simplify an exchange of the ADSs for Shares upon termination of the ADS programme and a Market Repositioning
of the Shares to Nasdaq.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
for the Proposed De-Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
De-Listing has been proposed by the Company&rsquo;s board of directors on the basis of the following considerations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>A
                                            listing on Nasdaq is in line with the Company&rsquo;s focus on the U.S.</I>&nbsp;&ndash;&nbsp;The
                                            Company is domiciled and listed as a public company in Belgium, and its Shares have been
                                            admitted to listing and trading on Euronext Brussels since June 2006. The Company&rsquo;s
                                            primary commercial focus, however, is in the United States, where over 95% of its tests are
                                            performed and revenues are generated. The Company&rsquo;s leadership change in 2019 and coincident
                                            organizational and operational discipline implemented throughout the MDxHealth group of companies
                                            has further focused the Company&rsquo;s commitment to U.S.-sourced growth, with its entire
                                            executive management team and over 95% of staff based in or reporting to the Company&rsquo;s
                                            U.S. headquarters in Irvine, California or one of the Company&rsquo;s laboratories in Irvine,
                                            California or Plano, Texas. In view hereof, and with a view to align its investor base also
                                            with its geographical core market, the Company carried out an initial public offering (IPO)
                                            in the U.S. in 2021, and its ADSs have been trading on Nasdaq since November 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trading
                                            on one single market may simplify trading for investors, and could lead to greater liquidity
                                            and more efficient pricing and trading activity&nbsp;</I>&ndash;&nbsp;As further detailed
                                            below, the trading on Nasdaq and Euronext Brussels has so far not led to increased liquidity
                                            or trading. By bringing all trading to one market, namely Nasdaq, the board of directors
                                            believes that this could simplify the trading process for investors and increase liquidity,
                                            potentially narrow the trading spreads and improve the overall efficiency of price discovery
                                            between buyers and sellers, all of which could further improve the attractiveness of the
                                            Company&rsquo;s Shares, and hence lead to an improved trading activity for the Company&rsquo;s
                                            Shares. Since its February 2023 public offering of ADSs in the U.S., average daily liquidity
                                            of the Company&rsquo;s ADSs on Nasdaq has exceeded by over 3-times the average daily liquidity
                                            of Shares on Euronext Brussels. No guarantees, however, can be given that the De-Listing
                                            will effectively lead to such improved liquidity and better pricing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasdaq
                                            has become a more important source for equity fund raising than Euronext Brussels</I>&nbsp;&ndash;&nbsp;Since
                                            the U.S.&nbsp;IPO in 2021, the focus on the U.S. as a source for equity funding has only
                                            increased in importance. Notably, in August 2022, the Company acquired the GPS (formerly
                                            Oncotype DX GPS) prostate cancer business from Genomic Health, Inc., a subsidiary of Exact
                                            Sciences Corporation. This transaction was partly paid in ADSs of the Company, and subject
                                            to certain conditions, outstanding earn-out payments can also be settled in ADSs. Furthermore,
                                            in February 2023, the Company carried out a new public offering of ADS in the U.S., with
                                            listing on Nasdaq. As a result, the Company&rsquo;s listing on Nasdaq has become a more important
                                            source for equity fund raising than the Company&rsquo;s listing on Euronext Brussels.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            legal regime in terms of investor protection will remain similar&nbsp;</I>&ndash;&nbsp;While
                                            the Company is still considered a &ldquo;foreign private issuer&rdquo; under U.S. securities
                                            laws for the time being, the legal regime that would apply in terms of transparency and investor
                                            protection if it is only listed on Nasdaq would remain similar to the regime that applies
                                            if it remained listed on Euronext Brussels only. This particularly applies to the rules regarding
                                            the publication of annual and interim financial information, the disclosure of material non-public
                                            information, and the disclosure of trading by significant shareholders. In addition, in accordance
                                            with the listing requirements of Nasdaq, the Company&rsquo;s foreign private issuer status
                                            entitles it to rely on home country governance requirements and certain exemptions thereunder
                                            rather than complying with the corporate governance requirements of Nasdaq.&nbsp;For further
                                            information, see also the section &ldquo;&mdash;Reporting by the Company&rdquo; under &ldquo;&mdash;Consequences
                                            of the Proposed De-Listing&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            dual listing on Euronext Brussels and Nasdaq has not led to increased liquidity or trading</I>&nbsp;&ndash;&nbsp;The
                                            trading on Nasdaq and Euronext Brussels takes place in different currencies (U.S. dollars
                                            on Nasdaq and EUR on Euronext Brussels), and at different times (resulting from different
                                            time zones, different trading days and different public holidays in the United States and
                                            Belgium). The Company believes that, at times, this has negatively affected the trading prices
                                            of the Shares and ADSs on these two markets. The Company believes that this may have reduced
                                            the interest of potential investors to invest in the Company&rsquo;s Shares or ADSs. The
                                            trading on both markets also seems to have reduced the liquidity of the Shares and ADSs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            Company incurs substantial compliance costs due to the listing on Euronext Brussels and Nasdaq&nbsp;&ndash;</I>&nbsp;As
                                            a result of the listing on both Euronext Brussels and Nasdaq, the Company not only needs
                                            to comply with the Belgian legal framework for listed companies, but also with the U.S. rules
                                            for listings in the United States. This entails significant legal, accounting, and other
                                            expenses. For example, an offering of new Shares in the U.S. (directly or in the form of
                                            ADSs) not only requires the Company to comply with U.S. securities laws but also requires
                                            the Company to apply for the admission of the new Shares on Euronext Brussels, which entails
                                            the preparation of a listing prospectus in accordance with Belgian and European law (unless
                                            an exemption is available). Compliance with both legal frameworks entails significant (legal
                                            and financial) compliance costs. Furthermore, the Company is required to prepare annual and
                                            interim financial statements not only in accordance with International Financial Reporting
                                            Standards (IFRS) as adopted by the European Union and Belgian accounting rules, but also
                                            in accordance with International Financial Reporting Standards (IFRS) as issued by the International
                                            Accounting Standards Board (IASB), and certain U.S. accounting rules, with separate reports
                                            that are filed with the U.S.&nbsp;Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).
                                            If the Company no longer has Shares admitted to listing and trading on Euronext Brussels,
                                            a significant portion of these legal and accounting rules would no longer apply, while the
                                            impact in terms of disclosure and transparency for investors would be limited. See also below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compliance
                                            with two sets of rules also creates additional uncertainty regarding compliance</I>&nbsp;&ndash;&nbsp;Being
                                            a U.S. listed company and a Belgian public company requires compliance with two sets of applicable
                                            rules. From time to time, this may result in uncertainty regarding compliance matters and
                                            result in additional costs necessitated by legal analysis of dual legal regimes, ongoing
                                            revisions to disclosure and adherence to heightened governance practices. The applicable
                                            rules and regulations are often subject to varying interpretations, in many cases due to
                                            their lack of specificity, and, as a result, their application in practice may evolve over
                                            time as new guidance is provided by regulatory and governing bodies. This could result in
                                            continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing
                                            revisions to disclosure and governance practices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            Company may lose its &ldquo;foreign private issuer&rdquo; status under U.S. securities laws
                                            in the future, which would lead to a further substantial compliance cost increase</I>&nbsp;&ndash;&nbsp;On
                                            the date hereof, the Company is considered a &ldquo;foreign private issuer&rdquo; under U.S.
                                            securities laws. In its capacity as a foreign private issuer, the Company is exempt from
                                            certain rules under U.S. securities law rules that impose certain disclosure obligations
                                            and procedural requirements for proxy solicitations, and for reporting and disclosure requirements
                                            for members of the board of directors and important shareholders with respect to their purchases
                                            and sales of the Company&rsquo;s securities. Moreover, the Company is not required to file
                                            periodic reports and financial statements with the SEC as frequently or as promptly as U.S.
                                            companies whose securities are registered under the U.S. securities law rules. In addition,
                                            the Company is not subject to all of the rules of Nasdaq in terms of governance and disclosure
                                            that would otherwise apply to U.S. companies. The Company may take advantage of these exemptions
                                            until such time as it is no longer a foreign private issuer. The Company will remain a foreign
                                            private issuer until such time that more than 50% of its outstanding voting securities are
                                            held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the
                                            majority of the members of the board of directors are U.S. citizens or residents; (ii)&nbsp;more
                                            than 50% of the Company&rsquo;s assets are located in the United&nbsp;States; or (iii)&nbsp;the
                                            Company&rsquo;s business is administered principally in the United States. The determination
                                            of foreign private issuer status will be made annually on the last business day of the Company&rsquo;s
                                            most recently completed second fiscal quarter. The Company will next make a determination
                                            with respect to its foreign private issuer status on 30 June 2024. With the increased focus
                                            on the U.S., it is possible that the Company may lose its foreign private issuer status.
                                            As result, it would become subject to the same rules as would apply to U.S. listed companies,
                                            in addition to the rules to that apply Belgian listed companies, which would lead to a further
                                            substantial increase of compliance costs. The loss of foreign private issuer status may also
                                            be accelerated by the De-Listing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholders
                                            of the Company will be able to trade their Shares on Nasdaq&nbsp;</I>&ndash;&nbsp;As a result
                                            of the De-Listing, the Shares will no longer be traded on Euronext Brussels after the Transition
                                            Period (which is currently expected to be at least three weeks after the completion of the
                                            Share Consolidation). Holders of Shares currently traded on Euronext Brussels will have,
                                            however, the ability to transfer the trading of their Shares to Nasdaq.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
for the termination of the ADS programme</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the completion of the Share Consolidation, the Company&rsquo;s board of directors proposes to proceed with the termination of the
ADS programme, on the basis of the following considerations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            termination of the ADS programme is necessary to transition to a sole listing of the Shares
                                            on Nasdaq &ndash;</I> As described throughout the Special Report, the main purpose of the
                                            Share Consolidation and De-Listing is to transition to a sole listing of Shares on Nasdaq.
                                            In view thereof, a termination of the ADS programme is necessary in order to have only Shares
                                            trading on Nasdaq. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            annual, transaction-specific and other fees payable by ADS holders will no longer apply</I>
                                            &ndash; As disclosed in the Company&rsquo;s securities filings in the U.S., ADS holders incur
                                            annual, transaction-specific and other fees under the ADS programme. By terminating the ADS
                                            programme, which will result in ADS holders receiving Shares in exchange for their ADSs,
                                            these fees will no longer apply.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            Company&rsquo;s cost of compliance with the requirements of the ADS programme will be eliminated
                                            &ndash;</I> The Company incurs certain costs under the ADS programme (e.g., in connection
                                            with soliciting proxies from ADS holders in the context of the Company&rsquo;s general shareholders&rsquo;
                                            meetings) which will be eliminated.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers
to further implement the Share Consolidation and De-Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors will request the powers to further implement the Share Consolidation and De-Listing. Provided that the EGM approves
the proposed Share Consolidation and De-Listing (see also section &ldquo;&mdash;Proposals in relation to the Share Consolidation and
De-Listing&rdquo; above), the Company will further inform the holders of Shares of the timing and practical formalities for the Share
Consolidation and De-Listing, including regarding the formalities for the Market Repositioning of Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this context, it should be noted that the Company intends to withdraw the proposal regarding the De-Listing if the Share Consolidation
has not been approved by the EGM. However, the Company&rsquo;s board of directors reserves the right to nevertheless continue with the
proposed De-Listing to the extent an alternative mechanism can be found so as to allow for the practical implementation of the De-Listing
in an equivalent manner for the Company&rsquo;s shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the Company&rsquo;s board of directors reserves the right to withdraw and not to implement the proposed De-Listing if the ADS programme
has not been terminated, unless to the extent an alternative mechanism can be found so as to allow for the practical implementation of
the De-Listing in an equivalent manner for the Company&rsquo;s shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information regarding the Market Repositioning, see also section &ldquo;&mdash;Practical implementation of the Market Repositioning&rdquo;.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicative
timetable for the Share Consolidation and De-Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided
that the initial EGM approves the proposed Share Consolidation and De-Listing, the main dates and timelines to implement the Share Consolidation
and De-Listing are expected to be as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Action</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcement
    of the contemplated De-Listing and convening of the EGM to approve the Share Consolidation and De-Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    October 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
    of the Share Consolidation and De-Listing by the EGM of the Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    November 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    date for the Share Consolidation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
    to be approximatively 9 trading days after the approval of the Share Consolidation and De-Listing by the EGM (or second EGM)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    of the ADS programme and start of trading of the Shares on Nasdaq</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
    to be approximatively 6 trading day following the effective date of the Share Consolidation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Start
    of the Transition Period</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
    to be upon start of trading of the Shares on Nasdaq</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of the Transition Period and end of trading of the Shares on Euronext Brussels</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
    to be approximatively 3 weeks after the start of the Transition Period, but no later than Friday 29 December 2023, at 5:30 p.m. Brussels
    time</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided
that the initial EGM approves the proposed Share Consolidation and De-Listing, the Company&rsquo;s board of directors will have the power
to further amend the dates, times and periods indicated in the above timetable. If the board of directors decides to amend such dates,
times or periods, it will inform the investors by a press release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the 50% attendance quorum is not reached at the initial EGM, a second EGM, where no attendance quorum applies, will be convened to approve
the proposed Share Consolidation and De-Listing. The convening of such a second EGM will consequently entail the need for the board of
directors to amend the timeline detailed above.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Practical
implementation of the Market Repositioning</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided
that the EGM approves the proposed Share Consolidation and De-Listing, and provided that ADS programme will have been terminated, the
Company will apply for the admission of its Shares to trading on Nasdaq (see also the section &ldquo;&mdash;Certain other Approvals&rdquo;
above). As of the admission of the Shares to trading on Nasdaq, the holders of Shares will be able to request that the Shares be repositioned
from the trading system used for trading of the Shares on Euronext Brussels into the trading system used for trading of the Shares on
Nasdaq. This Market Repositioning will be subject to certain formalities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the Market Repositioning, the Company intends to split its share register into two components (based on article 7:33 of
the Belgian Companies and Associations Code), consisting of a Belgian component, which will reflect the Company&rsquo;s Shares that will
be admitted to trading on Euronext Brussels until the De-Listing becomes effective, and a U.S. component, which will be maintained in
the U.S. and which will be managed by a transfer agent in the U.S. that will be appointed by the Company. Only the Shares that will have
been repositioned onto the U.S. component will be capable of being traded on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will inform the shareholders of the respective formalities for the Market Repositioning through its website, including via, among
other things, a &ldquo;Frequently Asked Questions&rdquo; (FAQ) which will be uploaded on the Company&rsquo;s website on the day of the
convening of the EGM, and which will be kept up-to-date from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that, following the announcement of the final details of the Transition Period and De-Listing, many financial
intermediaries or custodians in Europe will use their discretionary rights (under their terms of service to their clients) to automatically
(at the initiative of the brokers) proceed with a Market Repositioning of the Shares of their clients in such a manner that these Shares
can be traded on Nasdaq. The Company also expects that, after a Market Repositioning at the initiative of the financial intermediaries
or custodians, shareholders will be able to continue to hold such Shares on their current securities account, without having to open
a new securities account or having to take any further action. The Company also expects that many financial intermediaries or custodians
will effect the automatic Market Repositioning either for free or for a nominal administrative fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
should, however, contact their financial intermediary or custodian to enquire whether their Shares will be automatically repositioned
or not, whether they will need to open a new securities account, and whether such repositioning will be subject to costs or expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to support the possibility for shareholders to carry out a Market Repositioning at least for the foreseeable future.
If the Company no longer supports a Market Repositioning, it will announce this subject to a prior notice of at least three months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences
of the Proposed Share Consolidation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes some of the material consequences of the Share Consolidation, and assumes that the proposed Share Consolidation
has been approved by the EGM.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of the Share Consolidation for Holders of Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is proposed that the Share Consolidation be carried out simultaneously for all outstanding Shares of the Company, so that after the completion
of the Share Consolidation each new Share shall represent the same fraction of the Company&rsquo;s share capital. All new shares after
the completion of the Share Consolidation shall have the same rights and benefits, and shall rank <I>pari passu</I> in all respects,
including as to entitlements to dividends and other distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Following
the Share Consolidation, the Company&rsquo;s shareholders will still own the same proportion of the capital of the Company as immediately
prior to the Share Consolidation, subject to any fractions of Shares (see also below under &ldquo;&mdash;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation
and Sale of Fractions of new Shares resulting from the Share Consolidation<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Share Consolidation will not affect the form of the outstanding shares (dematerialized or registered) and the outstanding dematerialized
and registered Shares will be processed separately. Subject to the practical arrangements that will be announced after the Share Consolidation
has been approved, the Share Consolidation will in principle be implemented automatically, without the need for shareholders to take
any steps.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation
and Sale of Fractions of new Shares resulting from the Share Consolidation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Share Consolidation might give rise to the appearance of fractions if prior to the Share Consolidation a shareholder does not hold a
number of Shares which corresponds to a multiple of ten (10). In that case, the number of new shares held by that shareholder will be
rounded down to the lower whole number. For example, the holder of 12 Shares prior the Share Consolidation will be entitled to 1 new
Share and 2/10<SUP>th</SUP> of a Share after the Share Consolidation becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is proposed that the Company&rsquo;s board of directors will have the powers to determine the manner and process to effect the Share
Consolidation with respect to holders of existing Shares of the Company who at the time that the Share Consolidation becomes effective
do not have a sufficient number of existing Shares in order to receive a whole number of new Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is currently intended that no fractions of new Shares will be issued as a result of the Share Consolidation, but that any fractions of
Shares which might give rise as a result of the Share Consolidation shall be aggregated by one or more of the banks or financial institutions
that shall be appointed by the Company for this purpose, and which will be instructed to sell or place the new Shares resulting from
the aggregation of fractions, via an exempt private placement, block trade, market sale, bookbuilding (accelerated or not) or otherwise,
to or with institutional, qualified or professional investors or individuals in and outside of Belgium. The proceeds of such sale or
placement will be distributed on a pro rata basis to the holders of existing Shares that do not have a sufficient number of existing
shares to be converted into whole new shares, provided that the proceeds shall not be less than one euro cent (EUR&nbsp;0.01) per old
Share. The relevant transaction costs and expenses (including commissions, fees and expenses of agents and advisors) and applicable taxes,
all as applicable, will be borne by the Company.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of the Share Consolidation for Holders of Subscription Rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is proposed that the Share Consolidation will be implemented for the outstanding subscription rights of the Company in the manner as
contemplated in the respective terms and conditions of these subscription rights. This will in principle entail that, as a result of
the Share Consolidation, a holder of subscription rights will have to exercise subscription rights with respect to at least 10 Shares
prior the Share Consolidation in order to subscribe for one Share after the Share Consolidation. It is proposed that the holders of subscription
rights will be informed of the consequences of the Share Consolidation after the Share Consolidation has become effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences
of the Proposed De-Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes some of the material consequences of the De-Listing for the governance of the Company, the rights of holders of
Shares, and legal framework that applies to reporting and disclosures by the Company. It assumes that the proposed De-Listing has been
approved by the EGM. It is based on certain provisions of the Company&rsquo;s articles of association, the Belgian Companies and Associations
Code, as well as certain provision of the legal rules and provisions that apply to Belgian and U.S. listed companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
this description is a summary, it does not purport to provide a complete overview of the Company&rsquo;s articles of association or the
relevant provisions of Belgian and U.S. law. The description may therefore not contain all information important to holders of Shares
or ADSs. Neither should it be considered as legal advice regarding these matters.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in Legal Framework</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Euronext
Brussels is a &ldquo;regulated market&rdquo; within the meaning of the Markets in Financial Instruments Directive (Directive 2014/64/EU)
(MiFID II) and the Markets in Financial Instruments Regulation (Regulation (EU) 600/2014) (MiFIR), which came into effect on 3 January
2018. While Nasdaq is a reputed and well-known trading venue for securities, it does not qualify as a regulated market in Belgium or
elsewhere in the European Economic Area (the &ldquo;<B>EEA</B>&rdquo;). Consequently, as a result of the De-Listing, the Company will
no longer qualify as a listed company pursuant to article 1:11 of the Belgian Companies and Associations Code, nor as a public-interest
entity (&ldquo;<B>PIE</B>&rdquo;) pursuant to article 1:12 of the Belgian Companies and Associations Code as from the De-Listing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company no longer qualifies as a listed company or PIE under Belgian law, many of the rules that otherwise apply to Belgian listed
companies will no longer apply to the Company. This is particularly the case for several provisions of the Belgian Companies and Associations
Code that only apply to listed companies and PIEs. This is also the case for several other rules and regulations, such as the rules set
out in the Belgian Royal Decree of 14 November 2007 regarding the obligations of issuers of financial instruments admitted to trading
on a regulated market (the &ldquo;<B>Belgian Transparency Decree</B>&rdquo;), the Belgian Act of 2 May 2007 regarding the disclosure
of important participations in issuers with shares admitted to trading on a regulated market and regarding miscellaneous provisions (the
&ldquo;<B>Belgian Act of 2 May 2007</B>&rdquo;), the Belgian Royal Decree of 14 February 2008 regarding the disclosure of important participations,
and Regulation (EU) No&nbsp;596/2014 of the European Parliament and of the Council of 16&nbsp;April 2014 on market abuse (market abuse
regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC
and 2004/72/EC (the &ldquo;<B>Market Abuse Regulation</B>&rdquo;). Furthermore, the Company will no longer be subject to the 2020 Belgian
Code on Corporate Governance Code (the &ldquo;<B>Belgian Corporate Governance Code</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, as long as the ADSs and Shares are admitted to trading on Nasdaq, the Company will remain subject to the reporting and
disclosure requirements of the U.S.&nbsp;Securities Exchange Act of 1934 (the &ldquo;<B>Exchange Act</B>&rdquo;), the U.S.&nbsp;Sarbanes-Oxley
Act, the U.S.&nbsp;Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq listing requirements and other applicable securities
rules and regulations, as described below.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
and Corporate Governance of the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently relies on a provision in the listing rules of the Nasdaq Stock Market that allows it to follow Belgian corporate law
and practices with respect to certain aspects of corporate governance. This allows the Company to apply certain corporate governance
practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.
In particular, the listing rules of the Nasdaq Stock Market require a majority of the directors of a listed U.S. company to be independent
(Nasdaq Rule 5605), whereas in Belgium, only three directors need to be independent. The listing rules of the Nasdaq Stock Market (Nasdaq
Rule 5605) further require that each of the nominating, compensation and audit committees of a listed U.S. company be comprised entirely
of independent directors (although a foreign private issuer is also required to have an audit committee solely composed of independent
directors, as noted below). However, the Belgian Corporate Governance Code recommends only that a majority of the directors on the nomination
committee meet the technical requirements for independence under Belgian corporate law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a summary of the Company&rsquo;s current management and corporate governance, see also the corporate governance statement included in
the report of the Company&rsquo;s board of directors that has been included in the Company&rsquo;s annual report for the financial year
ended 31 December 2022. A copy of the annual report is available on the Company&rsquo;s website (under the section &ldquo;<I>Financial
Reports</I>&rdquo;) free of charge (see 2022-Annual-Report-ENG.pdf (mdxhealth.com)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the De-Listing, the Company will no longer be subject to some of the rules and requirements of Belgian law that apply to
the management and corporate governance of listed companies. Consequently, unless the Company decides to comply with the listing rules
of the Nasdaq Stock Market, it will be subject to a less strict regime for its corporate governance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the main material changes as a result of the De-Listing can be summarized for information purposes as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
                                            requirement to appoint independent directors</I>&nbsp;&ndash;&nbsp;The Company will no longer
                                            be required to appoint independent directors. Belgian law generally requires listed companies
                                            to have at least three independent directors. On the date of this Special Report the board
                                            has five (5) non-executive directors, which qualify as independent within the meaning of
                                            article 7:87 of the Belgian Companies and Associations Code, provision 3.5 of the Belgian
                                            Corporate Governance Code, and Rule 10A-3(b)(1) under the Exchange Act (subject to the exemptions
                                            provided in Rule 10A-3(c) under such act). The board of directors also intends to maintain
                                            a number of independent directors after the De-Listing, including in order to comply with
                                            the requirements of the Exchange Act that the members of the audit committee are independent
                                            pursuant to Rule 10A-3 under the Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
                                            requirement to have an audit committee or nomination and remuneration committee</I>&nbsp;&ndash;&nbsp;The
                                            Company will no longer be required to have an audit committee or nomination and remuneration
                                            committee within the sense of the Belgian Companies and Associations Code and the Belgian
                                            Corporate Governance Code. The Company will, however, still be required to have an audit
                                            committee under the Nasdaq rules and Rule 10A-3 under the Exchange Act. The requirement to
                                            have an audit committee (and for that audit committee to be fully independent) will apply
                                            to the Company regardless of whether it continues to be treated as a foreign private issuer
                                            for purposes of the SEC rules. The Company&rsquo;s audit committee is currently in compliance
                                            with SEC and Nasdaq requirements. In relation to its nomination and remuneration committee,
                                            the board of directors has no plan to change the committee&rsquo;s terms of reference or
                                            composition (except to comply with the requirements of U.S. law and the Nasdaq rules following
                                            the De-Listing, <I>i.e.</I> in order to ensure compliance with the requirement that all members
                                            of the committee be independent), but this could change.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Specific
                                            process for related party transactions&nbsp;</I>&ndash;&nbsp;Article 7:97 of the Belgian
                                            Companies and Associations Code provides for a particular approval and disclosure process
                                            that applies to certain transactions or decisions by the Company or its subsidiaries with
                                            parties that would qualify as a related party pursuant to International Financial Reporting
                                            Standards (IFRS) as adopted by the European Union. As part of this process, the relevant
                                            transactions or decisions must (amongst other things) first be assessed by an <I>ad hoc</I>
                                            committee of at least three independent directors. The requirements of article 7:97 of the
                                            Belgian Companies and Associations Code will no longer apply following the De-Listing. The
                                            Company will, however, continue to disclose related party transactions to the extent required
                                            by applicable SEC and accounting rules and standards, which are broadly the same as the disclosure
                                            standards for related party transactions under the Prospectus Regulation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gender
                                            diversity</I>&nbsp;&ndash;&nbsp;The Belgian Companies and Associations Code provides that
                                            at least one third of the members of the board of directors of a Belgian listed company should
                                            be of the opposite gender. The Company has met the one third gender diversity requirement
                                            since 1 January 2018 and continues to comply with such requirement at the date of this Special
                                            Report. As a result of the De-Listing, the aforementioned requirement will no longer apply
                                            as from the De-Listing Date. The board of directors, however, currently has no plan the fundamentally
                                            change the composition of the board, including in terms of gender, but this could change.
                                            It should be noted, however, that the Nasdaq rules contain requirements related to diverse
                                            board representation (Nasdaq Rule 5605 and 5606). These rules apply equally to domestic issuers
                                            and foreign private issuers, therefore would apply to the Company regardless of whether it
                                            loses its foreign private issuer status.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Belgian
                                            Corporate Governance Code will no longer apply</I>&nbsp;&ndash;&nbsp;In accordance with the
                                            Belgian Royal Decree of 12 May 2019 designating the corporate governance code to be complied
                                            with by listed companies, the Company designated the Belgian Corporate Governance Code as
                                            reference code within the meaning of article 3:6, &sect;2 of the Belgian Companies and Associations
                                            Code. The Belgian Corporate Governance Code contains several principles and provisions that
                                            need to be complied by listed companies, but companies are able to deviate from the code
                                            on the basis of the &ldquo;comply-or-explain&rdquo; principle of the code. The Company currently
                                            complies to a large extent with the provisions of the Belgian Corporate Governance Code,
                                            except for a limited number of deviations which the Company believe are justified in view
                                            of the Company&rsquo;s specific situation. See also the corporate governance statement included
                                            in the Company&rsquo;s board of directors that has been included in the Company&rsquo;s annual
                                            report for the financial year ended 31 December 2022. As a result of the De-Listing, the
                                            Company no longer needs to designate a corporate governance code, and the Company will no
                                            longer be subject to the Belgian Corporate Governance Code. This will entail that the Company
                                            will have greater freedom in determining its corporate governance practices. The board of
                                            directors currently has no plan to fundamentally change its corporate governance, but this
                                            could change in the future.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
of Directors and Executives</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently relies on a provision in the listing rules of the Nasdaq Stock Market (Nasdaq Rule 5615) that allows it to follow Belgian
corporate law and practices with respect to certain aspects of corporate governance, including regarding the remuneration of the Company&rsquo;s
directors and executive management. For a summary of the Company&rsquo;s current remuneration policy, and the remuneration that was paid
to the members of the board and executive management, see remuneration policy, as well as the remuneration report included in the report
of Company&rsquo;s board of directors that has been included in the Company&rsquo;s annual report for the financial year ended 31 December
2022. A copy of the remuneration policy and annual report are available on the Company&rsquo;s website (under the following respective
sections &ldquo;<I>Corporate Governance</I>&rdquo; and &ldquo;<I>Financial Reports</I>&rdquo;) free of charge (see, respectively, Remuneration-Policy-English.pdf
(mdxhealth.com) and 2022-Annual-Report-ENG.pdf (mdxhealth.com)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the De-Listing, the Company will no longer be subject to some of the rules and requirements of Belgian law that apply to
the remuneration of the members of the board of directors and executive management of listed companies. Consequently, unless the Company
decides to comply with the listing rules of the Nasdaq Stock Market applicable to domestic issuers, it will be subject to a less strict
regime in terms of director and executive compensation. Some of the main material changes as a result of the De-Listing can be summarized
for information purposes as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Remuneration
                                            policy</I>&nbsp;&ndash;&nbsp;In accordance with article 7:89/1 of the Belgian Companies and
                                            Associations Code, Belgian listed companies must establish a remuneration policy with respect
                                            to directors, other officers and delegates for day-to-day management. This article details
                                            the objectives of, as well as the information that needs to be included in, the remuneration
                                            policy. The remuneration policy must be approved by a binding vote of the general shareholders&rsquo;
                                            meeting and must be submitted to the general shareholders&rsquo; meeting for approval whenever
                                            there is a material change and in any case at least every four years. In view hereof, in
                                            accordance with article 7:89/1 of the Belgian Companies and Associations Code, the Company&rsquo;s
                                            shareholders approved a new remuneration policy that the board of directors submitted to
                                            the ordinary general shareholders&rsquo; meeting held on 27 May 2021. Following the De-Listing,
                                            the board shall no longer be required to prepare a remuneration policy as aforementioned,
                                            and to submit it to a vote by the general shareholders&rsquo; meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restrictions
                                            on the remuneration of directors</I>&nbsp;&ndash;&nbsp;Pursuant to the Belgian Companies
                                            and Associations Code, the general shareholders&rsquo; meeting approves the remuneration
                                            of the directors. This applies both to listed companies and non-listed companies. In addition,
                                            Belgian law requires that the general shareholders&rsquo; meeting approves the following
                                            in relation to the remuneration of directors of a listed company:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to the remuneration of executive and non-executive directors, the exemption from
                                            the restriction that share-based awards can only vest after a period of at least three years
                                            as of the grant of the awards;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to the remuneration of executive directors, the exemption from the restrictions
                                            that (unless the variable remuneration is less than a quarter of the annual remuneration)
                                            at least one quarter of the variable remuneration must be based on performance criteria that
                                            have been determined in advance and that can be measured objectively over a period of at
                                            least two years and that at least another quarter of the variable remuneration must be based
                                            on performance criteria that have been determined in advance and that can be measured objectively
                                            over a period of at least three years;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to the remuneration of non-executive directors, any variable part of the remuneration
                                            (provided, however, that no variable remuneration can be granted to independent non-executive
                                            directors); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            service agreements to be entered into with executive directors providing for severance payments
                                            exceeding twelve months&rsquo; remuneration (or, subject to a motivated opinion by the remuneration
                                            and nomination committee, eighteen months&rsquo; remuneration).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned restrictions of Belgian law regarding the remuneration of directors of listed companies will no longer apply as from the
De-Listing. The principle will remain, however, that the general shareholders&rsquo; meeting approves the remuneration of the directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restrictions
                                            on the remuneration of the members of the executive management</I>&nbsp;&ndash;&nbsp;The
                                            remuneration of the executive management is determined by the Company&rsquo;s board of directors.
                                            As an exception to the foregoing rule, Belgian law provides that the general shareholders&rsquo;
                                            meeting must approve, as relevant:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to the remuneration of members of the executive management and other executives,
                                            an exemption from the rule that share-based awards can only vest after a period of at least
                                            three years as of the grant of the awards;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            relation to the remuneration of members of the executive management and other executives,
                                            an exemption from the rule that (unless the variable remuneration is less than a quarter
                                            of the annual remuneration) at least one quarter of the variable remuneration must be based
                                            on performance criteria that have been determined in advance and that can be measured objectively
                                            over a period of at least two years and that at least another quarter of the variable remuneration
                                            must be based on performance criteria that have been determined in advance and that can be
                                            measured objectively over a period of at least three years; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            service agreements to be entered into with members of the executive management and other
                                            executives (as the case may be) providing for severance payments exceeding twelve months&rsquo;
                                            remuneration (or, subject to a motivated opinion by the remuneration and nomination committee,
                                            eighteen months&rsquo; remuneration).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned restrictions of Belgian law regarding the remuneration of the executive management will no longer apply as from the De-Listing,
and the general shareholders&rsquo; meeting shall no longer need to approve the foregoing matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Belgian
                                            Corporate Governance Code will no longer apply</I>&nbsp;&ndash;&nbsp;As set out above under
                                            &ldquo;&mdash;Management and Corporate Governance of the Company&rdquo;, following the De-Listing,
                                            the Company no longer needs to designate a corporate governance code, and the Company will
                                            no longer be subject to the Belgian Corporate Governance Code. The Belgian Corporate Governance
                                            Code contains a number of additional requirements for the remuneration of members of the
                                            board and executive management that go beyond the provisions of Belgian company law, such
                                            as:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provision
                                            7.6 of the Belgian Corporate Governance Code, which provides that no share options should
                                            be granted to Non-Executive Directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provision
                                            7.6 of the Belgian Corporate Governance Code, which provides that non-executive directors
                                            should receive a part of their remuneration in the form of Shares of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provision
                                            7.9 of the Belgian Corporate Governance Code, which provides that the board should set a
                                            minimum threshold of shares to be held by members of the executive management;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provision
                                            7.12 of the Belgian Corporate Governance Code, which provides that the board should include
                                            provisions that would enable the Company to recover variable remuneration paid, or withhold
                                            the payment of variable remuneration, to executive management, and specify the circumstances
                                            in which it would be appropriate to do so, insofar as enforceable by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the board already decided to deviate from the aforementioned provisions of the Belgian Corporate Governance Code, the aforementioned
restrictions will no longer apply as from the De-Listing.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
of Shareholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights attached to the Shares of the Company will not materially change following the completion of the De-Listing, subject to what is
stated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            general shareholders&rsquo; meeting will no longer need to vote on certain corporate governance
                                            and remuneration related matters</I>&nbsp;&ndash;&nbsp;As indicated in the section &ldquo;&mdash;Management
                                            and Corporate Governance of the Company&rdquo; above, certain decisions regarding the remuneration
                                            of directors and executive management no longer need to be submitted to the general shareholders&rsquo;
                                            meeting following the De-Listing. Furthermore, because the Company is no longer a listed
                                            company after the De-Listing, the requirement of article 7:151 of the Belgian Companies and
                                            Associations Code will no longer apply to the Company. This entails that decisions or transactions
                                            that give rights to third parties that have a significant influence on the assets of the
                                            Company or that give rise to significant obligations for the Company when the exercise of
                                            such rights are dependent on the launching of a public tender offer for the Company&rsquo;s
                                            Shares or a change in the control over the Company, no longer need to be approved by the
                                            general shareholders&rsquo; meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shorter
                                            notice period to convene general shareholders&rsquo; meetings&nbsp;</I>&ndash;&nbsp;Until
                                            the De-Listing has been completed, the notice convening the general shareholders&rsquo; meeting
                                            has to be published at least 30 calendar days prior to the general shareholders&rsquo; meeting.
                                            The term of 30 calendar days prior to the general shareholders&rsquo; meeting for the publication
                                            and distribution of the convening notice can be reduced to 17 calendar days for a second
                                            meeting if, as the case may be, the applicable quorum for the meeting is not reached at the
                                            first meeting, the date of the second meeting was mentioned in the notice for the first meeting
                                            and no new item is put on the agenda of the second meeting. When the De-Listing is completed,
                                            the notice convening the general shareholders&rsquo; meeting has to be published at least
                                            15 calendar days prior to the general shareholders&rsquo; meeting. The term of 15 calendar
                                            days prior to the general shareholders&rsquo; meeting for the publication and distribution
                                            of the convening notice can be reduced to 10 calendar days for a second meeting if, as the
                                            case may be, the applicable quorum for the meeting is not reached at the first meeting, the
                                            date of the second meeting was mentioned in the notice for the first meeting and no new item
                                            is put on the agenda of the second meeting. Before as well as after the De-Listing, the notice
                                            convening the general shareholders&rsquo; meeting will be published in the Belgian Official
                                            Gazette (<I>Belgisch Staatsblad/Moniteur Belge</I>), in a newspaper that is published nation-wide
                                            in Belgium, in paper or electronically, and on the Company&rsquo;s website. A publication
                                            in a nation-wide newspaper is not needed for annual general shareholders&rsquo; meetings
                                            taking place on the date, hour and place indicated in the articles of association of the
                                            Company if the agenda is limited to the treatment and approval of the financial statements,
                                            the annual report of the board of directors, the report of the statutory auditor, and the
                                            discharge from liability of the directors and statutory auditor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
                                            right to put items on the agenda of the general shareholders&rsquo; meeting and to table
                                            draft resolutions</I>&nbsp;&ndash;&nbsp;Before and after the De-Listing, shareholders holding,
                                            alone or together, at least 10% of the Company&rsquo;s share capital can request that the
                                            board of directors be convened. Shareholders that do not hold at least 10% of the Company&rsquo;s
                                            share capital do not have the right to have the general shareholders&rsquo; meeting convened.
                                            After the De-Listing, however, shareholders who hold alone or together with other shareholders
                                            at least 3% of the Company&rsquo;s share capital will no longer have the right to put additional
                                            items on the agenda of a general shareholders&rsquo; meeting that has already been convened
                                            and to table draft resolutions in relation to items that have been or are to be included
                                            in the agenda of a meeting that has already been convened.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized
                                            capital&nbsp;</I>&ndash;&nbsp;The general shareholders&rsquo; meeting of the Company may
                                            authorise the board of directors, within certain limits, to increase the Company&rsquo;s
                                            share capital without any further approval of the shareholders. This is the so-called authorized
                                            capital. The authorization needs to be limited in time (<I>i.e.</I>, it can only be granted
                                            for a renewable period of maximum five years) and scope (<I>i.e.</I>, the authorized capital
                                            may not exceed the amount of the registered capital at the time of the authorization). The
                                            limitation regarding the maximum amount for the authorized capital shall no longer apply
                                            after the De-Listing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Formalities
                                            to attend general shareholders&rsquo; meeting&nbsp;&ndash;&nbsp;</I>Some of the formalities
                                            to attend general shareholders&rsquo; meetings will be different, but will still be in line
                                            with Belgian law.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
by the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company no longer qualifies as a listed company or PIE under Belgian law, many of the rules that on the date of this Special Report
apply to the <I>ad hoc</I> and ongoing reporting and disclosures by Belgian listed companies will no longer apply to the Company. This
includes, amongst other things, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
                                            the De-Listing, the Company will no longer be obliged to prepare consolidated annual and
                                            interim financial statements in accordance with International Financial Reporting Standards
                                            (IFRS) as adopted by the European Union. Instead, it can decide to prepare its annual consolidated
                                            financial statements in accordance with Belgian generally accepted accounting principles.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because of the trading of its ADSs or Shares on Nasdaq, the Company will still prepare annual and interim financial statements
in conformity with IFRS as issued by the IASB (or, to the extent it ceases to be a foreign private issuer, U.S. GAAP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
                                            the De-Listing, the Company will no longer need to include a corporate governance statement
                                            and remuneration report in its annual report, although it will be required to include certain
                                            disclosures on corporate governance and remuneration in its Annual Report on Form 20-F (or
                                            on Form 10-K, to the extent it ceases to be a foreign private issuer).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            a result of the De-Listing, the Company will no longer be obliged to comply with the ongoing
                                            disclosure and reporting obligations that are set out in the Belgian Transparency Decree
                                            and the Market Abuse Regulation, which require that certain material, price sensitive and
                                            other information and documentation is made available through the Company&rsquo;s website,
                                            press releases, the communication channels of Euronext Brussels, on STORI (the information
                                            storage mechanism operated by the FSMA), or a combination of these means.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will, however, be subject to Nasdaq Rule 5250 requiring prompt disclosure of any material information that would reasonably be
expected to affect the value of their securities or influence investors&rsquo; decisions. The Company will also be obliged to comply
with the anti-fraud and anti-manipulation rules of the SEC, such as Section 10(b) of and Rule 10b-5 under the Exchange Act. In addition,
to the extent it ceases to be a foreign private issuer, the Company would be required to comply with Regulation&nbsp;FD (Fair Disclosure)
which, generally, is meant to ensure that select groups of investors are not privy to specific information about an issuer before other
investors. All information filed with the SEC can be obtained over the internet on the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
by Shareholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the De-Listing, holders of Shares are subject to the following reporting obligations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to the Belgian Act of 2 May 2007 a notification to the Company and to the FSMA is required
                                            by all natural persons and legal entities (<I>i</I>.<I>e</I>., legal person, enterprise without
                                            legal personality, or trust), in the following circumstances:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            acquisition or disposal of voting securities, voting rights or financial instruments that
                                            are treated as voting securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            reaching of a threshold by persons or legal entities acting in concert;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            conclusion, modification or termination of an agreement to act in concert;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            downward reaching of the lowest threshold;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            passive reaching of a threshold;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            a previous notification concerning the financial instruments treated as equivalent to voting
                                            securities is updated;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            acquisition or disposal of the control of an entity that holds voting securities in the Company;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the Company introduces additional notification thresholds in the articles of association,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
each case where the percentage of voting rights attached to the securities held by such persons reaches, exceeds or falls below the legal
threshold, set at 5% of the total voting rights, and 10%, 15%, 20% and so on in increments of 5% or, as the case may be, the additional
thresholds provided in the articles of association. The Company had provided for an additional threshold of 3% in its articles of association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to the Regulation (EU) No. 236/2012 of the European Parliament and the Council of 14 March
                                            2012 on short selling and certain aspects of credit default swaps, any person that acquires
                                            or disposes of a net short position relating to the Company&rsquo;s issued share capital,
                                            whether by a transaction in Shares or ADSs, or by a transaction creating or relating to any
                                            financial instrument where the effect or one of the effects of the transaction is to confer
                                            a financial advantage on the person entering into that transaction in the event of a decrease
                                            in the price of such Shares or ADSs is required to notify the FSMA if, as a result of which
                                            acquisition or disposal his net short position reaches, exceeds or falls below 0.2% of the
                                            Company&rsquo;s issued share capital and each 0.1% above that. If the net short position
                                            reaches 0.5%, and also at every 0.1% above that, the FSMA will disclose the net short position
                                            to the public.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the De-Listing, the aforementioned disclosure obligations will no longer apply. Notwithstanding the foregoing, the following reporting
obligations continue to apply to holders of Shares (or ADSs):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            accordance with U.S. federal securities laws, holders of Shares (and ADSs) will be required
                                            to comply with disclosure requirements relating to their ownership of the Company&rsquo;s
                                            securities. Any person that, after acquiring beneficial ownership of Shares (or ADSs), is
                                            the beneficial owners of more than 5% of Shares (or Shares underlying ADSs) must file with
                                            the SEC a Schedule 13D or Schedule 13G, as applicable, disclosing the information required
                                            by such schedules, including the number of Shares (or Shares underlying ADSs) that such person
                                            has acquired (whether alone or jointly with one or more other persons). In addition, if any
                                            material change occurs in the facts set forth in the report filed on Schedule 13D (including
                                            a more than 1% increase or decrease in the percentage of the total shares beneficially owned),
                                            the beneficial owner must promptly file an amendment disclosing such change. These requirements
                                            apply equally to domestic and foreign private issuers, and therefore would apply to the Company
                                            regardless of whether it loses its foreign private issuer status.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to article 7:83 of the Belgian Companies and Associations Code, all natural persons and legal
                                            entities directly or indirectly acquiring voting securities in dematerialized form (whether
                                            or not these securities represent the capital of the Company) will be required to notify
                                            the Company of the number of securities owned when the voting rights attached to those securities
                                            exceed 25% of the total number of voting rights at the time of the acquisition. The notice
                                            must be made within five business days following the date of acquisition. The same notification
                                            must be made within the same term of five business days if the voting rights attached to
                                            securities owned by such persons falls below 25% as a result of a disposal of voting securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person that fails to make the aforementioned notification will not be able to participate to the general shareholders&rsquo; meeting
with votes in excess of 25% of the total voting rights on the date of the general shareholders&rsquo; meeting concerned. This restriction
does not apply to securities acquired through the exercise of subscription rights, or that have been acquired on the basis of a universal
transfer or on the basis of a liquidation.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
when the Company no longer is a Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
mentioned above, the listing rules of the Nasdaq Stock Market include certain accommodations in relation to corporate governance requirements
that allow foreign private issuers such as the Company, to follow &ldquo;home country&rdquo; corporate governance practices in lieu of
the otherwise applicable corporate governance standards of the Nasdaq Stock Market. The Company currently follows Belgian corporate governance
practices in lieu of the corporate governance requirements of the Nasdaq Stock Market in respect of the matters set out below. If the
Company no longer qualifies as a foreign private issuer, it will also need to comply with such rules of the Nasdaq Stock Market. Furthermore,
the Exchange Act contains certain exemptions for foreign private issuers. These exemptions will no longer be available if the Company
no longer qualifies as a foreign private issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sections below summarize for information purposes the most material changes that do not currently apply to the Company, but would apply
to the Company once it no longer qualifies as a foreign private issuer, regardless of whether the De-Listing is effected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quorum
                                            at general shareholder meetings&nbsp;</I>&ndash;&nbsp;In general, there is no attendance
                                            quorum requirement for a general shareholders&rsquo; meeting under Belgian law, and decisions
                                            are generally passed with a simple majority of the votes of the Shares present or represented.
                                            However, capital increases (other than those decided by the board of directors pursuant to
                                            the authorized capital), decisions with respect to the Company&rsquo;s dissolution, mergers,
                                            de-mergers and certain other reorganizations of the Company, amendments to the articles of
                                            association (other than an amendment of the corporate purpose), and certain other matters
                                            referred to in the Belgian Companies and Associations Code do not only require the presence
                                            or representation of at least 50% of the share capital of the Company but also a majority
                                            of at least 75% of the votes cast. An amendment of the Company&rsquo;s corporate purpose
                                            requires the approval of at least 80% of the votes cast at a general shareholders&rsquo;
                                            meeting, which can only validly pass such resolution if at least 50% of the share capital
                                            of the Company and at least 50% of the profit certificates, if any, are present or represented.
                                            In the event where the required quorum is not present or represented at the first meeting,
                                            a second meeting needs to be convened through a new notice. The second general shareholders&rsquo;
                                            meeting may validly deliberate and decide regardless of the number of Shares present or represented.
                                            The special majority requirements, however, remain applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Stock Market Listing Rule 5620(c) requires that for any meeting of shareholders, the attendance quorum must be no less than 33.33% of
the outstanding shares of common voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination
                                            and remuneration committee&nbsp;</I>&ndash;&nbsp;Nasdaq Stock Market Listing Rule 5605(d)(2)
                                            requires that compensation of officers must be determined by, or recommended to, the board
                                            of directors for determination, either by a majority of the independent directors, or a compensation
                                            committee comprised solely of independent directors. Nasdaq Stock Market Listing Rule 5605(e)
                                            requires that director nominees be selected, or recommended for selection, either by a majority
                                            of the independent directors or a nominations committee comprised solely of independent directors.
                                            Under Belgian law, the Company is not subject to any such requirements. In particular, the
                                            Company&rsquo;s articles of association provide that our board of directors may form committees
                                            from among its members. Accordingly, the Company&rsquo;s board of directors has set up and
                                            appointed a nomination and remuneration committee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to article 7:100 of the Belgian Companies and Associations Code, only a majority of the members of the remuneration committee should
in principle meet the independence criteria referred to in article 7:87 of the Belgian Companies and Associations Code and set out in
provision 3.5 of the Belgian Corporate Governance Code. Pursuant to provision 4.19 of the Belgian Corporate Governance Code, only a majority
of the members of the remuneration committee must qualify as independent. This requirement of Belgian law will no longer apply following
the De-Listing. See also above under &ldquo;&mdash;Management and Corporate Governance of the Company&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Charters&nbsp;</I>&ndash;&nbsp;Nasdaq
                                            Stock Market Listing Rules 5605(c)(1), (d)(1) and (e)(2) require that each committee of the
                                            board of directors must have a formal written charter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Belgian Corporate Governance Code, the Company&rsquo;s board of directors has drawn up a corporate governance charter including,
amongst others, the internal rules of the committees. The requirements of the Belgian Corporate Governance Code will no longer apply
following the De-Listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Independent
                                            director majority&nbsp;</I>&ndash;&nbsp;Nasdaq Stock Market Listing Rules 5605(b)(1) and
                                            (2) require that a majority of the board of directors must be comprised of independent directors
                                            and that independent directors must have regularly scheduled meetings at which only independent
                                            directors are present.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not required under Belgian law to have a majority of independent directors on its board of directors. However, Company&rsquo;s
articles of association provide that the board of directors must be comprised of at least three directors, of which, pursuant to the
Company&rsquo;s corporate governance charter and provision 3.4 of the Belgian Corporate Governance Code, at least three directors must
be independent directors under Belgian law. Furthermore, in line with the provisions of the Belgian Companies and Associations Code and
the Belgian Corporate Governance Code, the nomination and remuneration committee should consist of a majority of independent directors,
and the audit committee should have at least one independent director among its members. The aforementioned requirements of Belgian law
will no longer apply following the De-Listing. See also above under &ldquo;&mdash;Management and Corporate Governance of the Company&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Meetings
                                            of independent directors&nbsp;</I>&ndash;&nbsp;Nasdaq Stock Market Listing Rule 5605(b)(2)
                                            requires that independent directors must have regularly scheduled meetings at which only
                                            independent directors are present.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently does not intend to require its independent directors to meet separately from the full board of directors on a regular
basis or at all, although the board of directors is supportive of its independent members voluntarily arranging to meet separately from
the other members of the board of directors when and if they wish to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
                                            approval of certain share issuances&nbsp;</I>&ndash;&nbsp;Nasdaq Stock Market Listing Rule
                                            5635(a) requires shareholder approval prior to the issuance of securities in connection with
                                            the acquisition of the stock or assets of another company if (1)(A) the common stock has
                                            or will have upon issuance voting power equal to or in excess of 20% of the voting power
                                            outstanding before the issuance of stock or securities convertible into or exercisable for
                                            common stock or (B) the number of shares of common stock to be issued is or will be equal
                                            to or in excess of 20% of the number of shares of common stock outstanding before the issuance
                                            of the stock or securities; or (2) any director, officer or Substantial Shareholder (as defined
                                            in the Nasdaq rules) has a 5% or greater interest (or all such parties have a 10% or greater
                                            interest in the aggregate) in the Company or assets to be acquired or in the consideration
                                            to be paid in the transaction or series of transactions and the transaction or series of
                                            transactions results in an increase in the outstanding common shares or voting power of 5%
                                            or more.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
law currently requires the prior shareholder approval for issues of shares and other securities convertible or exercisable for shares.
However, such further approval is not required in relation to the issuance of securities pursuant to the powers that are granted to the
board of directors by the general shareholders&rsquo; meeting under the authorized capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
                                            approval of equity compensation arrangements&nbsp;</I>&ndash;&nbsp;Nasdaq Stock Market Listing
                                            Rule 5635(c) requires shareholder approval when a plan or other equity compensation arrangement
                                            is established or materially amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Belgian law the establishment or amendment of equity compensation arrangements does not require a prior approval by the general shareholders&rsquo;
meeting. However, pursuant to Belgian law the shareholders must decide any issuance of new equity, as a general matter. The general shareholders&rsquo;
meeting may authorize the board of directors, within certain limits, to issue new equity (including equity compensation arrangements)
in the framework of the so-called authorized capital. By virtue of a resolution of the extraordinary general shareholders&rsquo; meeting
of 30 June 2023, the Company&rsquo;s board of directors was authorized to issue equity (including equity compensation arrangements) in
the framework of the authorized capital. Furthermore, the compensation of director mandates and certain features of the compensation
of the members of the executive management is subject to an approval by the general shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other&nbsp;</I>&ndash;&nbsp;As
                                            a foreign private issuer, the Company is exempt under the Exchange Act from, among other
                                            things, the rules prescribing the furnishing and content of proxy statements, and the Company&rsquo;s
                                            executive officers, directors and principal shareholders are exempt from the reporting and
                                            short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act.
                                            In addition, the Company is not required under the Exchange Act to file periodic reports
                                            and financial statements with the SEC as frequently or as promptly as U.S. companies whose
                                            securities are registered under the Exchange Act. As a foreign private issuer, the Company
                                            is also exempt from the requirements of Regulation&nbsp;FD (Fair Disclosure) which, generally,
                                            are meant to ensure that select groups of investors are not privy to specific information
                                            about an issuer before other investors. The Company is, however, still subject to the anti-fraud
                                            and anti-manipulation rules of the SEC, such as Rule 10b-5 of the Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will remain a foreign private issuer until such time that more than 50% of its outstanding voting securities are held by U.S.
residents and any of the following three circumstances applies: (i)&nbsp;the majority of the members of the board of directors are U.S.
citizens or residents; (ii)&nbsp;more than 50% of the Company&rsquo;s assets are located in the United&nbsp;States; or (iii)&nbsp;the
Company&rsquo;s business is administered principally in the United States. The determination of foreign private issuer status will be
made annually on the last business day of the Company&rsquo;s most recently completed second fiscal quarter. The Company will next make
a determination with respect to its foreign private issuer status on 30 June 2024. With the increased focus on the U.S., it is possible
that the Company may lose its foreign private issuer status. The loss of foreign private issuer status may be accelerated by the De-Listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
of Nasdaq</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
was founded in 1971 as a wholly-owned subsidiary of Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;), a private U.S.
self-regulatory organization that regulates member brokerage firms and exchange markets. Beginning in 2000, FINRA restructured and broadened
ownership in Nasdaq by selling shares to FINRA members, investment companies and issuers listed on The Nasdaq Stock Market. In connection
with this restructuring, FINRA fully divested its ownership of Nasdaq in 2006, and The Nasdaq Stock Market became an independent registered
national securities exchange in 2007. In February 2008, Nasdaq and OMX AB combined their businesses, and Nasdaq changed its corporate
name to The NASDAQ OMX Group, Inc. This transformational combination resulted in the expansion of its business from a U.S.-based exchange
operator to a global exchange company offering technology that powers its own exchanges and markets as well as many other marketplaces
around the world. Nasdaq operated as the NASDAQ OMX Group until it rebranded its business as Nasdaq, Inc. in 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
operates a variety of listing platforms around the world to provide multiple global capital raising solutions for public companies. Companies
listed on its markets represent a diverse array of industries including, among others, health care, consumer products, telecommunication
services, information technology, financial services, industrials and energy. Nasdaq&rsquo;s main listing markets are The Nasdaq Stock
Market and the Nasdaq Nordic and Nasdaq Baltic exchanges. Companies seeking to list securities on The Nasdaq Stock Market may do so on
one of the three market tiers: The Nasdaq Global Select Market, The Nasdaq Global Market, or The Nasdaq Capital Market. To qualify, companies
must meet minimum listing requirements, including specified financial and corporate governance criteria. Once listed, companies must
maintain rigorous listing and corporate governance standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, a total of 4,230 companies listed securities on The Nasdaq Stock Market, with 1,566 listings on The Nasdaq Global
Select Market, 1,298 on The Nasdaq Global Market and 1,366 on The Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
seeks new listings from companies conducting IPOs, including SPACs, and direct listings as well as companies looking to switch from alternative
exchanges. The 2022 new listings were comprised of 161 IPOs, 14 switches from the NYSE or NYSE American and 145 ETPs and other listings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion below is for general information only and is not, and should not be interpreted to be, tax advice to any holder of Share or
ADSs of the Company. Each holder or prospective holder of Shares or ADSs is urged to consult his, her or its own tax advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the assumption that the owners of ADSs are for purposes of the domestic Belgian tax legislation treated as owners of the Shares represented
by such ADSs, no Belgian income tax consequences are expected to arise from the Share Consolidation and termination of the ADS programme.
Similarly, no Belgian income tax consequences are expected to arise from the De-Listing and Market Repositioning. The aforementioned
has, however, not been confirmed by or verified with the Belgian Tax Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the summary below is to describe the most material Belgian tax consequences with respect to holding Shares listed on Nasdaq
after the Share Consolidation, the termination of the ADS programme, the Delisting and, where relevant, the Market Repositioning.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
paragraphs below present a summary of certain Belgian federal income tax consequences of the ownership and disposal of the Shares by
an investor. The summary is based on laws, treaties and regulatory interpretations in effect in Belgium on the date of this Special Report,
all of which are subject to change, including changes that could have retroactive effect. Belgian tax legislation, as well as the relevant
tax legislation of a prospective investor&rsquo;s country of origin, may have an impact on the income received from the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
should appreciate that, as a result of evolutions in law or practice, the eventual tax consequences may be different from what is stated
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not purport to address all tax consequences of the investment in, ownership in and disposal of the Shares, and does not
take into account the specific circumstances of particular investors, some of which may be subject to special rules, or the tax laws
of any country other than Belgium. This summary does not describe the tax treatment of investors that are subject to special rules, such
as banks, insurance companies, collective investment undertakings, dealers in securities or currencies, persons that hold, or will hold,
Shares as a position in a straddle, Share repurchase transaction, conversion transactions, synthetic security or other integrated financial
transactions. This summary does not address the tax regime applicable to Shares held by Belgian tax residents through a fixed basis or
a permanent establishment situated outside Belgium. This summary does in principle not address the local taxes that may be due in connection
with an investment in the Shares, other than Belgian local surcharges which generally vary from 0 % to 9 % of the investor&rsquo;s income
tax liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this summary, a Belgian resident is an individual subject to Belgian personal income tax (<I>i</I>.<I>e</I>., an individual
who is domiciled in Belgium or has his seat of wealth in Belgium or a person assimilated to a resident for purposes of Belgian tax law),
a company subject to Belgian corporate income tax (<I>i</I>.<I>e</I>., a corporate entity that has its main establishment, its administrative
seat or seat of management in Belgium<SUP>1</SUP>), an Organisation for Financing Pensions (&ldquo;<B>OFP</B>&rdquo;) subject to Belgian
corporate income tax (<I>i</I>.<I>e</I>., a Belgian pension fund incorporated under the form of an OFP), or a legal entity subject to
Belgian income tax on legal entities (<I>i</I>.<I>e</I>., a legal entity other than a company subject to Belgian corporate income tax,
that has its main establishment, its administrative seat or seat of management in Belgium).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-resident is any person that is not a Belgian resident. Investors should consult their own advisers regarding the tax consequences
of an investment in the Shares in the light of their particular circumstances, including the effect of any state, local or other national
laws.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            corporate entity that has its statutory seat in Belgium is presumed, in the absence of evidence
                                            to the contrary, also to have its main establishment, its administrative seat or seat of
                                            management in Belgium. Such evidence to the contrary shall be admissible only if it is also
                                            demonstrated that the tax domicile of the company is established in a State other than Belgium
                                            under the tax legislation of that other State.</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
taxation of dividends on Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Belgian income tax purposes, the gross amount of all benefits paid on or attributed to the Shares is generally treated as a dividend
distribution. By way of exception, the repayment of capital carried out in accordance with the Belgian Companies and Associations Code
is not treated as a dividend distribution to the extent that such repayment is imputed to the fiscal capital. This fiscal capital is,
in principle, the capital that is formed through contributions in cash or in kind, other than labour, and, subject to certain conditions,
the paid-up issuance premiums and the amounts subscribed to, in cash or in kind, other than labour, at the time of the issue of profit
sharing certificates. However, a repayment of capital decided upon by the shareholder&rsquo;s meeting as of 1 January 2018 and which
is carried out in accordance with the Belgian Companies and Associations Code is partly considered to be a dividend distribution, more
specifically with respect to the portion that is deemed to be the distribution of the existing taxed retained earnings (irrespective
of whether they are incorporated into the capital) and/or of the tax-free retained earnings incorporated into the capital. Such portion
is determined on the basis of the ratio of the taxed retained earnings (except for the legal reserve up to the legal minimum and certain
unavailable retained earnings) and the tax-free retained earnings incorporated into the capital (with a few exceptions) over the aggregate
of such retained earnings and the fiscal capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
withholding tax of 30%<SUP>2</SUP> is normally levied on dividends, subject to such relief as may be available under applicable domestic
or tax treaty provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of redemption of the Shares, the redemption gain (<I>i</I>.<I>e</I>., the redemption proceeds after deduction of the portion of
fiscal capital represented by the redeemed Shares) will be treated as a dividend subject to a Belgian withholding tax of 30%, subject
to such relief as may be available under applicable domestic or tax treaty provisions. No withholding tax will be triggered if such redemption
is carried out on Euronext or a similar stock exchange and meets certain conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of liquidation of the Company, the liquidation gain (<I>i</I>.<I>e</I>., the amount distributed in excess of the fiscal capital)
will in principle be subject to Belgian withholding tax at a rate of 30%, subject to such relief as may be available under applicable
domestic or tax treaty provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Belgian
dividend withholding tax, if any, will neither be creditable against any Belgian income tax due nor reimbursable to the extent that it
exceeds Belgian income tax due.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident individuals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Belgian resident individuals who acquire and hold the Shares as a private investment, the Belgian dividend withholding tax fully discharges
their personal income tax liability. They may nevertheless elect to report the dividends in their personal income tax return. Where such
individual opts to report them, dividends will normally be taxable at the lower of the generally applicable 30% withholding tax rate
on dividends or at the progressive personal income tax rates applicable to the taxpayer&rsquo;s overall declared income (local surcharges
will not apply). The first EUR&nbsp;800 (amount applicable for income year 2023) of reported ordinary dividend income will be exempt
from tax. For the avoidance of doubt, all reported dividends (hence, not only dividends distributed on the Shares) are taken into account
to assess whether said maximum amount is reached. In addition, if the dividends are reported, the dividend withholding tax levied at
source may be credited against the personal income tax due and is reimbursable to the extent that it exceeds the personal income tax
due, provided that the dividend distribution does not result in a reduction in value of or a capital loss on the Shares. This condition
is not applicable if the individual can demonstrate that he has held the Shares in full legal ownership for an uninterrupted period of
twelve months prior to the attribution of the dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Belgian resident individuals who acquire and hold the Shares for professional purposes, the Belgian withholding tax does not fully discharge
their personal income tax liability. Dividends received must be reported by the investor and will, in such case, be taxable at the investor&rsquo;s
personal income tax rate increased with local surcharges. Withholding tax levied at source may be credited against the personal income
tax due and is reimbursable to the extent that it exceeds the personal income tax due, subject to two conditions: (1) the taxpayer must
own the Shares in full legal ownership on the day the beneficiary of the dividend is identified and (2) the dividend distribution may
not result in a reduction in value of or a capital loss on the Shares. The latter condition is not applicable if the investor can demonstrate
that he has held the full legal ownership of the Shares for an uninterrupted period of twelve months prior to the attribution of the
dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is possible that certain provisions of the BITC regarding withholding taxes will be modified
                                            in the coming months (e.g., a decrease of the standard withholding tax rate of 30% to 25%
                                            while certain specific beneficial regimes could be deleted) but this is still subject to
                                            political discussions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident companies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Corporate
income tax </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Belgian resident companies, the dividend withholding tax does not fully discharge the corporate income tax liability. For such companies,
the gross dividend income (including the withholding tax) must be declared in the corporate income tax return and will be subject to
a corporate income tax rate of 25%. Subject to certain conditions, a reduced corporate income tax rate may apply.<SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Belgian dividend withholding tax levied at source may be credited against the corporate income tax due and is reimbursable to the extent
that it exceeds the corporate income tax due, subject to two conditions: (1) the taxpayer must own the Shares in full legal ownership
on the day the beneficiary of the dividend is identified; and (2) the dividend distribution may not result in a reduction in value of
or a capital loss on the Shares. The latter condition is not applicable (a)&nbsp;if the company can demonstrate that it has held the
Shares in full legal ownership for an uninterrupted period of twelve months prior to the attribution of the dividends; or (b)&nbsp;if,
during said period, the Shares never belonged to a taxpayer other than a resident company or a non-resident company which has, in an
uninterrupted manner, invested the Shares in a permanent establishment (&ldquo;<B>PE</B>&rdquo;) in Belgium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, Belgian resident companies can (subject to certain limitations) deduct 100% of gross dividends received from their taxable
income (dividend received deduction)<SUP>4</SUP>, provided that at the time of a dividend payment or attribution: (1)&nbsp;the Belgian
resident company holds Shares representing at least 10% of the share capital of the Company or a participation in the Company with an
acquisition value of at least EUR&nbsp;2,500,000; (2)&nbsp;the Shares have been held or will be held in full ownership for an uninterrupted
period of at least one year; and (3)&nbsp;the conditions relating to the taxation of the underlying distributed income, as described
in article 203 of the Belgian Income Tax Code (the &ldquo;<B>article 203 ITC Taxation Condition</B>&rdquo;) are met (together, the &ldquo;<B>Conditions
for the application of the dividend received deduction regime</B>&rdquo;). Under certain circumstances the conditions referred to under
(1)&nbsp;and (2)&nbsp;do not need to be fulfilled in order for the dividend received deduction to apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Conditions for the application of the dividend received deduction regime depend on a factual analysis, upon each distribution, and for
this reason the availability of this regime should be verified upon each distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Withholding
tax </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed to a Belgian resident company will be exempt from Belgian withholding tax provided that the Belgian resident company holds,
upon payment or attribution of the dividends and as beneficial owner thereof, at least 10% of the share capital of the Company and such
minimum participation is held or will be held during an uninterrupted period of at least one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to benefit from this exemption, the Belgian resident company must provide the Company or its paying agent with a certificate confirming
its qualifying status and the fact that it meets the required conditions. If the Belgian resident company holds the required minimum
participation for less than one year, at the time the dividends are paid on or attributed to the Shares, the Company will levy the withholding
tax but will not transfer it to the Belgian Treasury provided that the Belgian resident company certifies its qualifying status, the
date from which it has held such minimum participation, and its commitment to hold the minimum participation for an uninterrupted period
of at least one year. The Belgian resident company must also inform the Company or its paying agent if the one-year period has expired
or if its shareholding will drop below 10% of the share capital of the Company before the end of the one-year holding period. Upon satisfying
the one-year shareholding requirement, the dividend withholding tax which was temporarily withheld, will be refunded to the Belgian resident
company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to certain conditions, a reduced corporate income tax rate of 20% applies for Small and Medium
                                            Sized Enterprises (as defined by article 1:24 &sect;1 to &sect;6 of the Belgian Companies
                                            and Associations Code) on the first EUR&nbsp;100,000 of taxable profits.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is possible that certain provisions of the BITC regarding the dividends received deduction
                                            will be modified in the coming months but this is still subject to political discussions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
note that the above described dividend received deduction and withholding tax exemption will not be applicable to dividends which are
connected to an arrangement or a series of arrangements (&ldquo;<I>rechtshandeling of geheel van rechtshandelingen</I>&rdquo;/&ldquo;<I>acte
juridique ou un ensemble d&rsquo;actes juridiques</I>&rdquo;) for which the Belgian tax administration, taking into account all relevant
facts and circumstances, has proven, unless evidence to the contrary, that this arrangement or this series of arrangements is not genuine
(&ldquo;<I>kunstmatig</I>&rdquo;/&ldquo;<I>non authentique&rdquo;)</I> and has been put in place for the main purpose or one of the main
purposes of obtaining the dividend received deduction, the above dividend withholding tax exemption or one of the advantages of the EU
Parent-Subsidiary Directive of 30 November 2011 (2011/96/EU) (&ldquo;<B>Parent-Subsidiary Directive</B>&rdquo;) in another EU Member
State. An arrangement or a series of arrangements is regarded as not genuine to the extent that they are not put into place for valid
commercial reasons which reflect economic reality.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident organisations for financing pensions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
OFPs, <I>i</I>.<I>e</I>., Belgian pension funds incorporated under the form of an OFP (&ldquo;<I>organismen voor de financiering van
pensioenen</I>&rdquo;/&ldquo;<I>organismes de financement de pensions</I>&rdquo;) within the meaning of article 8 of the Belgian Act
of 27 October 2006, the dividend income is generally tax exempt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations, any Belgian dividend withholding tax levied at source may be credited against the corporate income tax due and
is reimbursable to the extent that it exceeds the corporate income tax due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
(or foreign) OFPs not holding the Shares - which give rise to dividends - for an uninterrupted period of 60 days in full ownership amounts
to a rebuttable presumption that the arrangement or series of arrangements (&ldquo;<I>rechtshandeling of geheel van rechtshandelingen</I>&rdquo;/&ldquo;<I>acte
juridique ou un ensemble d&rsquo;actes juridiques</I>&rdquo;) which are connected to the dividend distributions, are not genuine (&ldquo;<I>kunstmatig</I>&rdquo;/&ldquo;<I>non
authentique</I>&rdquo;). The withholding tax exemption will in such case not apply and/or any Belgian dividend withholding tax levied
at source on the dividends will in such case not be credited against the corporate income tax, unless counterproof is provided by the
OFP that the arrangement or series of arrangements are genuine.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Belgian resident legal entities subject to Belgian legal entities tax</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
taxpayers subject to the Belgian income tax on legal entities, the Belgian dividend withholding tax in principle fully discharges their
income tax liability.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-resident
individuals or non-resident companies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-resident
income tax </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
non-resident individuals and companies, the dividend withholding tax will be the only tax on dividends in Belgium, unless the non-resident
holds the Shares in connection with a business conducted in Belgium through a fixed base in Belgium or a Belgian PE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Shares are acquired by a non-resident in connection with a business in Belgium, the investor must report any dividends received,
which will be taxable at the applicable non-resident personal or corporate income tax rate, as appropriate. Belgian withholding tax levied
at source may be credited against non-resident personal or corporate income tax and is reimbursable to the extent that it exceeds the
income tax due, subject to two conditions: (1) the taxpayer must own the Shares in full legal ownership on the day the beneficiary of
the dividend is identified and (2) the dividend distribution may not result in a reduction in value of or a capital loss on the Shares.
The latter condition is not applicable if (a)&nbsp;the non-resident individual or the non-resident company can demonstrate that the Shares
were held in full legal ownership for an uninterrupted period of twelve months prior to the attribution of the dividends or (b)&nbsp;with
regard to non-resident companies only, if, during said period, the Shares have not belonged to a taxpayer other than a resident company
or a non-resident company which has, in an uninterrupted manner, invested the Shares in a Belgian PE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-resident
companies whose Shares are invested in a Belgian PE may deduct 100% of the gross dividends received from their taxable income if, at
the date the dividends are paid or attributed, the Conditions for the application of the dividend received deduction regime are met.
See also subsection &ldquo;<I>Belgian resident companies</I>&rdquo; under section &ldquo;<I>Belgian taxation of capital gains and losses
on Shares</I>&rdquo; below. Application of the dividend received deduction regime depends, however, on a factual analysis to be made
upon each distribution and its availability should be verified upon each distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Belgian
dividend withholding tax relief for non-residents </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed to non-resident individuals who do not use the Shares in the exercise of a professional activity, may be eligible for the
tax exemption with respect to ordinary dividends in an amount of up to EUR&nbsp;800 (amount applicable for income year 2022) per year.
For the avoidance of doubt, all dividends paid or attributed to such non-resident individual (and hence not only dividends paid or attributed
on the Shares) are taken into account to assess whether said maximum amount is reached. Consequently, if Belgian withholding tax has
been levied on dividends paid or attributed to the Shares, such non-resident individual may request in its Belgian non-resident income
tax return that any Belgian withholding tax levied up to such an amount be credited and, as the case may be, reimbursed. However, if
no Belgian non-resident income tax return has to be filed by the non-resident individual, any Belgian withholding tax levied up to such
an amount could in principle be reclaimed by filing a request thereto addressed to the tax official (&ldquo;<I>Adviseur-generaal Centrum
Buitenland</I>&rdquo;/&ldquo;<I>Conseiller-g&eacute;n&eacute;ral du Centre &Eacute;tranger</I>&rdquo;) appointed by the Belgian Royal
Decree of 28 April 2019. Such a request has to be made at the latest on 31 December of the calendar year following the calendar year
in which the relevant dividend(s) have been received, together with an affidavit confirming the non-resident individual status and certain
other formalities determined in the Royal Decree.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Belgian tax law, withholding tax is not due on dividends paid to a foreign pension fund which satisfies the following conditions: (i)&nbsp;it
is a non-resident saver within the meaning of article 227, 3&deg; of the Belgian Income Tax Code which implies that it has separate legal
personality and has its tax residence outside of Belgium; (ii)&nbsp;whose corporate purpose consists solely in managing and investing
funds collected in order to pay legal or complementary pensions; (iii)&nbsp;whose activity is limited to the investment of funds collected
in the exercise of its corporate purpose, without any profit making aim; (iv)&nbsp;which is exempt from income tax in its country of
residence; and (v)&nbsp;provided that it is not contractually obliged to redistribute the dividends to any ultimate beneficiary of such
dividends for whom it would manage the Shares, nor obliged to pay a manufactured dividend with respect to the Shares under a securities
borrowing transaction. The exemption will only apply if the foreign pension fund provides a certificate confirming that it is the full
legal owner or usufruct holder of the Shares and that the above conditions are satisfied. The organisation must then forward that certificate
to the Company or its paying agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
pension fund not holding the Shares - which give rise to dividends - for an uninterrupted period of 60 days in full ownership amounts
to a rebuttable presumption that the arrangement or series of arrangements (&ldquo;<I>rechtshandeling of geheel van rechtshandelingen</I>&rdquo;/&ldquo;<I>acte
juridique ou un ensemble d&rsquo;actes juridiques</I>&rdquo;) which are connected to the dividend distributions, are not genuine (&ldquo;<I>kunstmatig</I>&rdquo;/&ldquo;<I>non
authentique</I>&rdquo;). The withholding tax exemption will in such case be rejected, unless counterproof is provided by the OFP that
the arrangement or series of arrangements are genuine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed to non-resident qualifying parent companies established in a Member State of the EU or in a country with which Belgium has
concluded a double tax treaty that includes a qualifying exchange of information clause, will, under certain conditions, be exempt from
Belgian withholding tax provided that the Shares held by the non-resident company, upon payment or attribution of the dividends, amount
to at least 10% of the share capital of the Company and such minimum participation is held or will be held during an uninterrupted period
of at least one year. A non-resident company qualifies as a parent company provided that (i)&nbsp;for companies established in a Member
State of the EU, it has a legal form as listed in the annex to the EU Parent-Subsidiary Directive, as amended from time to time, or,
for companies established in a country with which Belgium has concluded a qualifying double tax treaty, it has a legal form similar to
the ones listed in such annex; (ii)&nbsp;it is considered to be a tax resident according to the tax laws of the country where it is established
and the double tax treaties concluded between such country and third countries; and (iii)&nbsp;it is subject to corporate income tax
or a similar tax without benefiting from a tax regime that derogates from the ordinary tax regime. In order to benefit from this exemption,
the non-resident company must provide the Company or its paying agent with a certificate confirming its qualifying status and the fact
that it meets the required conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the non-resident company holds a minimum participation for less than one year at the time the dividends are attributed to the Shares,
the Company must levy the withholding tax but does not need to transfer it to the Belgian Treasury provided that the non-resident company
provides the Company or its paying agent with a certificate confirming, in addition to its qualifying status, the date as of which it
has held the minimum participation, and its commitment to hold the minimum participation for an uninterrupted period of at least one
year. The non-resident company must also inform the Company or its paying agent when the one-year period has expired or if its shareholding
drops below 10% of the Company&rsquo;s share capital before the end of the one-year holding period. Upon satisfying the one-year holding
requirement, the dividend withholding tax which was temporarily withheld, will be refunded to the non-resident company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
note that the above withholding tax exemption will not be applicable to dividends which are connected to an arrangement or a series of
arrangements (&ldquo;<I>rechtshandeling of geheel van rechtshandelingen</I>&rdquo;/&ldquo;<I>acte juridique ou un ensemble d&rsquo;actes
juridiques</I>&rdquo;) for which the tax Belgian tax administration, taking into account all relevant facts and circumstances, has proven,
unless evidence to the contrary, that this arrangement or this series of arrangements is not genuine (&ldquo;<I>kunstmatig</I>&rdquo;/&ldquo;<I>non
authentique</I>&rdquo;) and has been put in place for the main purpose or one of the main purposes of obtaining the dividend received
deduction, the above dividend withholding tax exemption or one of the advantages of the Parent-Subsidiary Directive in another EU Member
State. An arrangement or a series of arrangements is regarded as not genuine to the extent that they are not put into place for valid
commercial reasons which reflect economic reality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed by a Belgian company to non-resident companies on a share participation of less than 10% will under certain conditions be
subject to an exemption from withholding tax, provided that the non-resident companies (i)&nbsp;are either established in another Member
State of the EEA or in a country with which Belgium has concluded a double tax treaty, where that treaty, or any other treaty concluded
between Belgium and that jurisdiction, includes a qualifying exchange of information clause; (ii)&nbsp;have a legal form as listed in
Annex I, Part A to the Parent-Subsidiary Directive as amended from time to time, or a legal form similar to the legal forms listed in
the aforementioned annex and which is governed by the laws of another Member State of the EEA or a similar legal form in a country with
which Belgium has concluded a double tax treaty; (iii)&nbsp;hold a share participation in the Belgian dividend distributing company,
upon payment or attribution of the dividends, of less than 10% of the Company&rsquo;s share capital but with an acquisition value of
at least EUR&nbsp;2,500,000; (iv)&nbsp;hold or will hold the Shares which give rise to the dividends in full legal ownership during an
uninterrupted period of at least one year; and (v)&nbsp;are subject to the corporate income tax or a tax regime similar to the corporate
income tax without benefiting from a tax regime which deviates from the ordinary regime. The exemption from withholding tax is only applied
to the extent that the Belgian withholding tax, which would be applicable absent the exemption, could not be credited nor reimbursed
at the level of the qualifying, dividend receiving, company. The non-resident company must provide the Company or its paying agent with
a certificate confirming, in addition to its full name, legal form, address and fiscal identification number (if applicable), its qualifying
status and the fact that it meets the required conditions mentioned under (i)&nbsp;to (v)&nbsp;above, and indicating to which extent
the withholding tax, which would be applicable absent the exemption, is in principle creditable or reimbursable on the basis of the law
as applicable on 31 December of the year preceding the year during which the dividend is paid or attributed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
dividend withholding tax is also subject to a relief as may be available under applicable tax treaty provisions. Belgium has concluded
tax treaties with more than 95 countries, reducing the dividend withholding tax rate to 20%, 15%, 10%, 5% or 0% for residents of those
countries, depending on conditions, among others, related to the size of the shareholding and certain identification formalities. Such
reduction may be obtained either directly at source or through a refund of taxes withheld in excess of the applicable treaty rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
holders of Shares should consult their own tax advisers to determine whether they qualify for a reduction in withholding tax upon payment
or attribution of dividends, and, if so, to understand the procedural requirements for obtaining a reduced withholding tax upon the payment
of dividends or for making claims for reimbursement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
taxation of capital gains and losses on Shares</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident individuals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
principle, Belgian resident individuals acquiring the Shares as a private investment should not be subject to Belgian capital gains tax
on the disposal of the Shares and capital losses will not be tax deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
capital gains realized by a Belgian resident individual are taxable at 33% (plus local surcharges) if the capital gain on the Shares
is deemed to be realized outside the scope of the normal management of the individual&rsquo;s private estate (e.g. in case of speculation).
Capital losses are, however, not tax deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
capital gains realized by Belgian resident individuals on the disposal of the Shares, outside the exercise of a professional activity,
to a non-resident company (or body constituted in a similar legal form), to a foreign State (or one of its political subdivisions or
local authorities) or to a non-resident legal entity, each time established outside the EEA, are in principle taxable at a rate of 16.5%
(plus local surcharges) if, at any time during the five years preceding the sale, the Belgian resident individual has owned, directly
or indirectly, alone or with his/her spouse or with certain relatives, a substantial shareholding in the Company (<I>i</I>.<I>e</I>.,
a shareholding of more than 25% in the Company). Capital losses are, however, not tax deductible in such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized by Belgian resident individuals upon redemption of the Shares or upon liquidation of the Company will generally be taxable
as a dividend. See also subsection &ldquo;&mdash;<I>Belgian resident individuals</I>&rdquo; under section &ldquo;&mdash;<I>Belgian taxation
of dividends on Shares</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident individuals who hold the Shares for professional purposes are taxable at the ordinary progressive personal income tax rates
(plus local surcharges) on any capital gains realized upon the disposal of the Shares, except for the Shares held for more than five
years, which are taxable at a separate rate of 10% (capital gains realized in the framework of the cessation of activities under certain
circumstances) or 16.5% (other), plus local surcharges. Capital losses on the Shares incurred by Belgian resident individuals who hold
the Shares for professional purposes are in principle tax deductible.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident companies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident companies are normally not subject to Belgian capital gains taxation on gains realized upon the disposal of the Shares provided
that the Conditions for the application of the dividend received deduction regime are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
one or more of the Conditions for the application of the dividend received deduction regime are not met, any capital gain realized would
be taxable at the standard corporate income tax rate of 25%, unless the reduced corporate income tax rate of 20% applies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
losses on the Shares incurred by Belgian resident companies are as a general rule not tax deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
held in the trading portfolios of Belgian qualifying credit institutions, investment enterprises and management companies of collective
investment undertakings are subject to a different regime. The capital gains on such Shares are taxable at the ordinary corporate income
tax rate of 25%, unless the reduced corporate income tax rate of 20% applies, and the capital losses on such Shares are tax deductible.
Internal transfers to and from the trading portfolio are assimilated to a realization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized by Belgian resident companies upon redemption of the Shares or upon liquidation of the Company will, in principle, be
subject to the same taxation regime as dividends.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
resident organisations for financing pensions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains on the Shares realized by OFPs within the meaning of article 8 of the Belgian Act of 27 October 2006 are in principle exempt from
corporate income tax and capital losses are not tax deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized by Belgian OFPs upon the redemption of ordinary shares or upon the liquidation of the Company will in principle be taxed
as dividends.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Belgian resident legal entities subject to Belgian legal entities tax</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized upon disposal of the Shares by Belgian resident legal entities are in principle not subject to Belgian income tax and
capital losses are not tax deductible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized upon disposal of (part of) a substantial participation in a Belgian company (<I>i</I>.<I>e</I>., a participation representing
more than 25% of the share capital of the Company at any time during the last five years prior to the disposal) may, however, under certain
circumstances be subject to income tax in Belgium at a rate of 16.5%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized by Belgian resident legal entities upon redemption of the Shares or upon liquidation of the Company will, in principle,
be subject to the same taxation regime as dividends.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-resident
individuals, non-resident companies or non-resident entities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-resident
individuals, companies or entities are, in principle, not subject to Belgian income tax on capital gains realized upon disposal of the
Shares, unless the Shares are held as part of a business conducted in Belgium through a fixed base in Belgium or a PE. In such a case,
the same principles apply as described with regard to Belgian individuals (holding the Shares for professional purposes), Belgian companies,
Belgian resident organisations for financing pensions or other Belgian resident legal entities subject to Belgian legal entities tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-resident
individuals who do not use the Shares for professional purposes and who have their fiscal residence in a country with which Belgium has
not concluded a tax treaty or with which Belgium has concluded a tax treaty that confers the authority to tax capital gains on the Shares
to Belgium, might<SUP>5</SUP> be subject to tax in Belgium if the capital gains are obtained or received in Belgium and arise from transactions
which are to be considered speculative or beyond the normal management of one&rsquo;s private estate or in case of disposal of a substantial
participation in a Belgian company as mentioned in the tax treatment of the disposal of the shares by Belgian individuals. See subsection
(a)&nbsp;(Belgian resident individuals) above. Such non-resident individuals might therefore be obliged to file a tax return and should
consult their own tax adviser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized by non-resident individuals or non-resident companies upon redemption of the Shares or upon liquidation of the Company
will, in principle, be subject to the same taxation regime as dividends.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
tax on stock exchange transactions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase and the sale and any other acquisition or transfer for consideration of existing Shares (secondary market transactions) is subject
to the Belgian tax on stock exchange transactions (&ldquo;<I>taks op de beursverrichtingen</I>&rdquo;/&ldquo;<I>taxe sur les op&eacute;rations
de bourse</I>&rdquo;) if (i)&nbsp;it is entered into or carried out in Belgium through a professional intermediary, or (ii)&nbsp;deemed
to be entered into or carried out in Belgium, which is the case if the order is directly or indirectly made to a professional intermediary
established outside of Belgium, either by private individuals with habitual residence in Belgium, or legal entities for the account of
their seat or establishment in Belgium (both referred to as a &ldquo;<B>Belgian Investor</B>&rdquo;). The tax on stock exchange transactions
is not due upon the listing of new Shares (primary market transactions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax on stock exchange transactions is levied at a rate of 0.35% of the purchase price, capped at EUR&nbsp;1,600 per transaction and per
party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgium
                                            has concluded tax treaties with more than 95 countries which generally provide for a full
                                            exemption from Belgian capital gains taxation on such gains realized by residents of those
                                            countries. Capital losses are generally not tax deductible.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
tax is separately due by each party to the transaction and is collected by the professional intermediary. However, if the order is made
directly or indirectly to a professional intermediary established outside of Belgium, the tax will in principle be due by the Belgian
Investor, unless that Belgian Investor can demonstrate that the tax has already been paid. In the latter case, the foreign professional
intermediary also has to provide each client (which gives such intermediary an order) with a qualifying order statement (&ldquo;<I>bordereau</I>&rdquo;/&ldquo;<I>borderel</I>&rdquo;),
at the latest on the business day after the day the transaction concerned was realized. The qualifying order statements must be numbered
in series and a duplicate must be retained by the financial intermediary. The duplicate can be replaced by a qualifying day-today listing,
numbered in series. Alternatively, professional intermediaries established outside of Belgium can, subject to certain conditions and
formalities, appoint a Belgian stock exchange tax representative (&ldquo;<B>Stock Exchange Tax Representative</B>&rdquo;), which will
be liable for the tax on stock exchange transactions in respect of the transactions executed through the professional intermediary and
for complying with the reporting obligations and the obligations relating to the order statement in that respect. If such a Stock Exchange
Tax Representative has paid the tax on stock exchange transactions due, the Belgian Investor will, as per the above, no longer be the
debtor of the tax on stock exchange transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
tax on stock exchange transactions is due on transactions entered into by the following parties, provided they are acting for their own
account: (i)&nbsp;professional intermediaries described in article 2, 9&deg; and 10&deg; of the Belgian Act of 2 August&nbsp;2002 on
the supervision of the financial sector and financial services; (ii)&nbsp;insurance companies described in article 2, &sect;1 of the
Belgian Act of 9 July 1975 on the supervision of insurance companies; (iii)&nbsp;pension institutions referred to in article 2,1&deg;
of the Belgian Act of 27 October 2006 concerning the supervision of pension institutions; (iv)&nbsp;undertakings for collective investment;
(v)&nbsp;regulated real estate companies; and (vi)&nbsp;Belgian non-residents provided they deliver a certificate to their financial
intermediary in Belgium confirming their non-resident status.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Belgian
annual tax on securities accounts</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Belgian Act of 17 February 2021 has introduced an annual tax on securities accounts which entered into force on 26 February 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual tax on securities accounts is a subscription tax, levied on securities accounts and not on the holders thereof. A securities account
is defined as an account on which financial instruments can be credited and debited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax applies to securities accounts held both in Belgium and abroad when the account holder is a Belgian resident or when the account
forms part of the assets of a Belgian establishment of a non-Belgian resident. The tax applies to securities accounts held by natural
persons residing in Belgium, as well as to companies and legal entities subject to the tax for legal entities that are established in
Belgium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax is also applicable to securities accounts held by non-Belgian residents (both natural persons and legal persons), if the securities
account is held in Belgium. If the applicable double tax treaty however allocates the right to tax capital to the jurisdiction of residence,
Belgium would be prevented from applying the annual tax on securities accounts to the Belgian securities accounts held by non-Belgian
residents. As described above, the tax applies whether or not the account is held in Belgium if the account forms part of the assets
of a Belgian establishment of a non-Belgian resident.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual tax on securities accounts is applicable to securities accounts of which the average value of the assets amounts to more than
EUR&nbsp;1,000,000 during the reference period. In principle, this reference period starts on 1 October and ends on 30 September of the
following year, except for the first reference period which starts on 26 February 2021 and ends on 30 September 2021. The aforementioned
threshold is assessed on the average value of the assets in the securities account at reference points within the reference period (in
principle 31 December, 31 March, 30 June and 30 September). The threshold is assessed per securities account and not per account holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable tax rate is 0.15%, which is levied on the average value of the assets held in the securities account that exceeds the EUR&nbsp;1,000,000
threshold. All securities held on a securities account are targeted, such as shares, bonds, participations in investment funds and investment
companies, but also derived products, such as index trackers, turbos, real estate certificates and cash. It is however limited to 10%
of the difference between the average value and the threshold of EUR&nbsp;1,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual tax on securities accounts is in principle withheld, reported and paid by the Belgian intermediary. If the intermediary is established
outside of Belgium, the tax must in principle be reported and paid by the account holder, unless the account holder can demonstrate that
the tax has already been reported and paid by an intermediary. Intermediaries established outside of Belgium can appoint a representative
in Belgium (the &ldquo;<B>Annual Tax on Securities Accounts Representative</B>&rdquo;), which will be liable for reporting and paying
the tax in respect of securities accounts in scope of the tax that are managed by such intermediaries. If the Annual Tax on Securities
Accounts Representative would have reported and paid the tax, the relevant account holder will, as per the above, no longer be the debtor
of the tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual tax on securities accounts is however not applicable on securities accounts held by certain categories of account holders active
in the financial or fund sector, as listed in the law (e.g. credit institutions, insurance companies, investment companies, and certain
collective investment undertakings). These exemptions do however not apply if a non-qualifying third party has a direct or indirect claim
on the value of the securities account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
law provides for both a general anti-abuse provision, as well as specific anti-abuse provisions targeting (i)&nbsp;the splitting of a
securities account in multiple securities accounts held at the same intermediary and (ii)&nbsp;the conversion of taxable financial instruments,
included in a securities account, into registered financial instruments. These anti-abuse provisions have a retroactive effect as from
30 October 2020. However, in its judgment of 27 October 2022, the Constitutional Court annulled the specific anti-abuse provisions as
well as the retroactive effect up to 30 October 2020 of the general anti-abuse provision. As a result, only the general anti-abuse provision
can still be validly applied and, moreover, only as of 26 February 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors are strongly advised to seek their own professional advice in relation to the possible impact of the new annual tax on securities
accounts on their own personal tax position</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Reporting Standard</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
recent international developments, the exchange of information is governed by the Common Reporting Standard (&ldquo;<B>CRS</B>&rdquo;).
More than 100 jurisdictions have signed the multilateral competent authority agreement (&ldquo;<B>MCAA</B>&rdquo;). The MCAA is a multilateral
framework agreement to automatically exchange financial and personal information, with the subsequent bilateral exchanges coming into
effect between those signatories that file the subsequent notifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than 45 jurisdictions, including Belgium, have committed to a specific and ambitious timetable leading to the first automatic information
exchanges in 2017, relating to income year 2016 (&ldquo;<B>Early Adopters</B>&rdquo;). More than 50 jurisdictions have committed to exchange
information as from 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
CRS, financial institutions resident in a CRS country are required to report, according to a due diligence standard, financial information
with respect to reportable accounts, which includes interest, dividends, account balance or value, income from certain insurance products,
sales proceeds from financial assets and other income generated with respect to assets held in the account or payments made with respect
to the account. Reportable accounts include accounts held by individuals and entities (which includes trusts and foundations) with fiscal
residence in another CRS country. The standard includes a requirement to look through passive entities to report on the relevant controlling
persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
9 December 2014, EU Member States adopted Directive 2014/107/EU on administrative cooperation in direct taxation (&ldquo;<B>DAC2</B>&rdquo;),
which provides for mandatory automatic exchange of financial information as foreseen in CRS. DAC2 amends the previous Directive on administrative
cooperation in direct taxation, Directive 2011/16/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mandatory automatic exchange of financial information by EU Member States as foreseen in DAC2 started as of 30 September 2017 (as of
30 September 2018 for Austria).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Belgian government has implemented said Directive 2014/107/EU, respectively the Common Reporting Standard, per the Belgian Act of 16
December 2015 regarding the exchange of information on financial accounts by Belgian financial institutions and by the Belgian tax administration,
in the context of an automatic exchange of information on an international level and for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Belgian Act of 16 December 2015, the mandatory automatic exchange of information applies in Belgium (i)&nbsp;as of income
year 2016 (first information exchange in 2017) towards the EU Member States, (ii)&nbsp;as of income year 2014 (first information exchange
in 2016) towards the US and (iii), with respect to any other non-EU States that have signed the MCAA, as of the respective date as determined
by the Belgian Royal Decree of 14 June 2017. The Belgian Royal Decree provides that (i)&nbsp;for a first list of 18 countries, the mandatory
exchange of information applies as of income year 2016 (first information exchange in 2017) and (ii)&nbsp;for a second list of 44 countries,
the mandatory automatic exchange of information applies as of income year 2017 (first information exchange in 2018), (iii)&nbsp;as from
2019 (for the 2018 financial year) for another single jurisdiction and (iv)&nbsp;as from 2020 (for the 2019 financial year) for a third
list of 6 jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
who are in any doubt as to their position should consult their professional advisers.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed Financial Transaction Tax (FTT)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
14 February 2013 the EU Commission adopted the Draft Directive on a common Financial Transaction Tax. Earlier negotiations for a common
transaction tax among all 28 EU Member States had failed. The current negotiations between the Participating Member States (<I>i</I>.<I>e</I>.,
Austria, Belgium, France, Germany, Greece, Italy, Portugal, Slovakia, Slovenia and Spain) are seeking a compromise under &ldquo;enhanced
cooperation&rdquo; rules, which require consensus from at least nine nations. Estonia already left the negotiations by declaring it would
not introduce the FTT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Draft Directive currently stipulates that once the FTT enters into force, the Participating Member States shall not maintain or introduce
taxes on financial transactions other than the FTT (or VAT as provided in the Council Directive 2006/112/EC of 28 November 2006 on the
common system of value added tax). For Belgium, the tax on stock exchange transactions should thus be abolished once the FTT enters into
force.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Draft Directive, the FTT would be payable on financial transactions provided at least one party to the financial transaction is
established or deemed established in a Participating Member State and there is a financial institution established or deemed established
in a Participating Member State which is a party to the financial transaction, or is acting in the name of a party to the transaction.
The FTT would, however, not apply to (inter alia) primary market transactions referred to in article 5(c) of Regulation (EC) No 1287/2006,
including the activity of underwriting and subsequent allocation of financial instruments in the framework of their issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rates of the FTT would be fixed by each Participating Member State but for transactions involving financial instruments other than derivatives
shall amount to at least 0.1% of the taxable amount. The taxable amount for such transactions would in general be determined by reference
to the consideration paid or owed in return for the transfer or the market price (whichever is higher). The FTT should be payable by
each financial institution established or deemed established in a Participating Member State which is either a party to the financial
transaction, or acting in the name of a party to the transaction or where the transaction has been carried out on its account. Where
the FTT due has not been paid within the applicable time limits, each party to a financial transaction, including persons other than
financial institutions, would become jointly and severally liable for the payment of the FTT due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of implementation any sale, purchase or exchange of Shares would become subject to the FTT at a minimum rate of 0.1% provided the
above mentioned prerequisites are met. The issuance of new Shares would not be subject to the FTT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019 Germany and France proposed that a French-style FTT be levied on the acquisition of shares of listed companies whose head
office is in a Member State of the European Union and whose market capitalization exceeds EUR&nbsp;1 billion on 1 December of the preceding
year. The tax should be levied on the transfer of ownership when shares of listed public limited companies are acquired. Initial public
offerings, market making and intraday trading should not be taxable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax rate should be no less than 0.2 per cent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
11 March 2019 the finance ministers of the Participating Member States met in the margins of the Ecofin meeting. There is consensus among
the ministers that the FTT should continue to be negotiated according to the Franco-German proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
the introduction of the FTT remains subject to negotiations between the Participating Member States. It may therefore be altered prior
to any implementation, of which the eventual timing and fate remains unclear. Additional EU Member States may decide to participate or
drop out of the negotiations. The project will be terminated if the number of Participating Member States falls below nine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the framework of the Multiannual Financial Framework (MFF)/Own Resources negotiations, the European Parliament supported the introduction
of the FTT as an Own Resource. The Commission agreed to issue a declaration as part of the overall political agreement. The Commission
has recently clarified that &ldquo;should there be an agreement on this Financial Transaction Tax, the Commission will make a proposal
in order to transfer revenues from this Financial Transaction Tax to the EU budget as an own resource. If there is no agreement by end
of 2022, the Commission will, based on impact assessments, propose a new own resource, based on a new Financial Transaction Tax. The
Commission shall endeavor to make these proposals by June 2024 in view of its introduction by 1 January 2026&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2021, EU Member States have been consulted on their current position regarding the FTT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
18 May 2021, the Commission again mentioned in a Communication that it will propose additional new own resources, which could include
a Financial Transaction Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors should consult their own professional advisors in relation to the FTT.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda
and Proposals Submitted to the EGM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agenda and proposed resolutions that are submitted to the EGM, which, as the case may be, can be amended at the meeting on behalf of
the Company&rsquo;s board of directors, are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Submission
                                            of special report</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
of and discussion on, the special report, prepared by the board of directors, in connection with the Share Consolidation and De-Listing
(as defined below in points 2 and 3 of the agenda).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
                                            Consolidation (1-for-10 reverse stock split)</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proposed
resolution:</I> In accordance with article 7:49 of the Belgian Companies and Associations Code, the extraordinary general shareholders&rsquo;
meeting decides to effect a share consolidation with respect to all outstanding shares of the Company by means of a 1-for-10 reverse
stock split (the &ldquo;Share Consolidation&rdquo;), and to grant the board of directors of the Company the authority for a six-month
period following the date of this extraordinary general shareholders&rsquo; meeting to further implement the Share Consolidation. If
the board of directors does not initiate the process for implementing the Share Consolidation within a six-month period following the
date of this extraordinary general shareholders&rsquo; meeting, the board of director&rsquo;s authority to effect the Share Consolidation
shall expire, unless renewed. The board of director&rsquo;s authority to implement the Share Consolidation is subject to the following
terms and conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Share
                                            Consolidation</U>: All of the outstanding shares of the Company shall be consolidated into
                                            a new and reduced number of shares pursuant to the ratio of one (1) new share for ten (10)
                                            existing shares (the &ldquo;Ratio&rdquo;). Subject to the terms and conditions set out below,
                                            the Share Consolidation will be carried out simultaneously for all outstanding shares of
                                            the Company in accordance with the Ratio, so that after the completion of the Share Consolidation
                                            each new share shall represent the same fraction of the Company&rsquo;s share capital. The
                                            Share Consolidation will not result in a reduction or increase of the Company&rsquo;s share
                                            capital.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
                                            and nature of the new shares</U>: <FONT STYLE="font-weight: normal">The Share Consolidation
                                            will not affect the form of the outstanding shares (dematerialized or registered) and the
                                            outstanding dematerialized and registered shares will be processed separately within the
                                            framework of the Share Consolidation. All new shares after the completion of the Share Consolidation
                                            shall have the same rights and benefits and shall rank <I>pari passu</I> in all respects,
                                            including as to entitlements to dividends and other distributions, in application of the
                                            Ratio.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            fractions of new shares</U>: <FONT STYLE="font-weight: normal">Within the framework of the
                                            Share Consolidation, the existing shares can only be consolidated, in accordance with the
                                            Ratio, into a whole number of new shares. No fractions of new shares can be issued. Subject
                                            to applicable company, financial and securities law rules, and subject to the provisions
                                            of the foregoing paragraphs, the board of directors shall be authorized to determine the
                                            manner and process to effect the Share Consolidation with respect to holders of existing
                                            shares of the Company who at the time of the Share Consolidation do not have a sufficient
                                            number of existing shares in order to receive a whole number of new shares in accordance
                                            with the Ratio. Within this context, the board of directors shall have the authority to determine
                                            that (i)&nbsp;the positions of old shares that cannot be consolidated into a whole number
                                            of new shares in accordance with the Ratio can be aggregated for consolidation into new shares,
                                            (ii)&nbsp;such new shares can be sold or placed, via an exempt private placement, block trade,
                                            market sale, bookbuilding (accelerated or not) or otherwise, to or with institutional, qualified
                                            or professional investors or individuals in and outside of Belgium, and (iii)&nbsp;the proceeds
                                            of such sale or placement will be distributed on a pro rata basis to the holders of existing
                                            shares that do not have a sufficient number of existing shares to be converted into whole
                                            new shares in accordance with the Ratio, provided that the proceeds shall not be less than
                                            one euro cent (EUR&nbsp;0.01) per existing share. If proceeds are less or cannot be distributed
                                            on a pro rata basis as aforementioned, these shall accrue to the Company. The relevant transaction
                                            costs and expenses (including commissions, fees and expenses of agents and advisors) and
                                            applicable taxes, all as applicable, will be borne by the Company. Subject to applicable
                                            provisions of company, financial and securities law, the board of directors shall also have
                                            the authority to determine that the positions of existing shares that cannot be consolidated
                                            in accordance with the Ratio into a whole number of new shares, can be acquired by the Company
                                            or one of its subsidiaries and that the proceeds of such sale will be distributed on a pro
                                            rata basis as aforementioned.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cancellation
                                            of existing shares</U>: <FONT STYLE="font-weight: normal">Following the completion of the
                                            Share Consolidation, the existing shares of the Company shall be cancelled and will no longer
                                            remain outstanding.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Timing
                                            of the Share Consolidation:</U> <FONT STYLE="font-weight: normal">The board of directors shall
                                            be authorized to determine the effective date of the Share Consolidation, provided however,
                                            that the Share Consolidation is to be implemented within a six-month period following the
                                            date of this extraordinary general shareholders&rsquo; meeting at the latest. The board of
                                            directors shall have the authority not to proceed with the implementation of the Share Consolidation,
                                            or, in case the implementation of the Share Consolidation has already started, to suspend
                                            or cancel the completion of the Share Consolidation if the board of directors determines
                                            that the market circumstances do not allow for the completion of the Share Consolidation
                                            in circumstances deemed satisfactory to it.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Agents</U>:
                                            <FONT STYLE="font-weight: normal">One or more banks or financial institutions shall or may
                                            be appointed by the Company for the purpose of the further organization and implementation
                                            of the Share Consolidation, including (but not limited to) the consolidation of positions
                                            of existing shares that cannot be consolidated into a whole number of new shares in accordance
                                            with the Ratio, and the sale of new shares as permitted by paragraph (c).</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustment
                                            of the subscription price of the Subscription Rights</U>: <FONT STYLE="font-weight: normal">At
                                            completion of the Share Consolidation, the Share Consolidation shall be effected </FONT>in
                                            relation to the outstanding subscription rights of the Company in the manner as contemplated
                                            in the respective terms and conditions of these subscription rights, so that a holder of
                                            subscription rights will have to exercise subscription rights with respect to at least 10
                                            Shares prior the Share Consolidation in order to subscribe for one Share after the Share
                                            Consolidation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment
                                            of the articles of association</U>: <FONT STYLE="font-weight: normal">At completion of the
                                            Share Consolidation, Article 5 of the Company&rsquo;s articles of association shall be amended
                                            and restated to take into account the resulting number of outstanding and existing shares.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
                                            implementation of the Share Consolidation</U>: <FONT STYLE="font-weight: normal">Subject
                                            to applicable company, financial and securities law rules, and subject to the provisions
                                            of the foregoing paragraphs, the board of directors shall have the authority to further implement
                                            and effect the Share Consolidation, including (without being limited to) the authority to
                                            (i)&nbsp;determine the practical implementation of the Share Consolidation, (ii)&nbsp;determine
                                            the timing and the effective date of the Share Consolidation as contemplated by paragraph
                                            (e), (iii)&nbsp;determine the manner and process to deal with positions of existing shares
                                            that cannot be consolidated into a whole number of new shares in accordance with the Ratio
                                            as contemplated by paragraph (c), (iv)&nbsp;appoint one or more banks or financial institutions
                                            for the further organization and implementation of the Share Consolidation as contemplated
                                            by paragraph (f), (v)&nbsp;proceed with the recording of the amendment and the restatement
                                            of the articles of association as contemplated by paragraph (h) before a notary public, (vi)&nbsp;take
                                            all useful or necessary steps with Euronext, Euroclear, any other competent settlement agency,
                                            and any regulatory or listing authority in connection with the implementation of the Share
                                            Consolidation, (vii)&nbsp;make all changes in the relevant securities register books of the
                                            Company reflecting the Share Consolidation, and (viii)&nbsp;do such other things as shall
                                            be useful, appropriate or necessary in connection with the foregoing. The board of directors
                                            shall have the authority to delegate the further implementation and execution of the Share
                                            Consolidation (including the powers referred to in sub-sections (i) to (viii)), in whole
                                            or in part, to one or more members of the Company&rsquo;s executive management or personnel.
                                            Any director, any member of the executive management, and any other persons that shall be
                                            expressly appointed for such purpose by the board of directors shall be authorized to record
                                            the amendment and the restatement of the articles of association as contemplated by paragraph
                                            (h) before a notary public.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>De-Listing
                                            from Euronext Brussels</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proposed
resolution:</I> The extraordinary general shareholders&rsquo; meeting decides to approve a de-listing of the Company&rsquo;s shares from
the regulated market of Euronext Brussels (the &ldquo;De-Listing&rdquo;), to amend the Company&rsquo;s articles of association for the
purpose of such De-Listing, and to grant the board of directors of the Company the authority to further implement the De-Listing, subject
to the following terms and conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>De-Listing</U>:
                                            The general shareholders&rsquo; meeting approves and agrees that the admission of the Company&rsquo;s
                                            shares to listing and trading shall be terminated and, consequently, the Company&rsquo;s
                                            shares shall no longer be able to list and trade on the regulated market of Euronext Brussels
                                            (&ldquo;Euronext Brussels&rdquo;), provided that the Company&rsquo;s shares (or, as the case
                                            may be, American Depositary Shares or American Depositary Receipts in relation to such shares)
                                            shall be admitted to trading on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effective
                                            date</U>: The board of directors shall have the power to determine the effective date of
                                            the De-Listing subject to a prior transition period of at least three weeks prior to the
                                            effective date of the De-Listing Date (the &ldquo;Transition Period&rdquo;) during which
                                            the Company&rsquo;s shares shall remain admitted to trading on Euronext Brussels. If and
                                            to the extent the Share Consolidation has been effected, the Transition Period shall at least
                                            be three weeks after the Share Consolidation has become effective.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendments
                                            to the articles of association</U>: Upon the effective date of the De-Listing, the following
                                            provisions of the Company&rsquo;s articles of association of the Company shall be amended
                                            and restated as follows (except that the amendment in paragraph (i) is effective immediately
                                            upon approval of the amendment by the extraordinary general shareholders&rsquo; meeting):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            article 9 (&ldquo;Nature of the securities&rdquo;), the three last paragraphs shall be amended
                                            and restated as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;A
share register is kept at the registered office of the company and may be split by decision of the board of directors in accordance with
the provisions of the applicable law. The board of directors can appoint a third party of its choice to keep any part of the split share
register. Subject to applicable provisions of companies, financial and securities laws, and unless decided otherwise by the board directors
in accordance with article 43 of the articles of association, dividends and other distributions (as the case may be) by the company on
shares can be made in euro (EUR) or United States dollars (USD) depending on the component of the (split) share register on which the
shares are reflected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
(split) register of registered shares and the registers of other registered securities, as the case may be, can be kept electronically.
Each holder of securities can consult the (split) register with respect to his/her/its securities. The board of directors can appoint
a third party of its choice to keep this (split) electronic register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
recordings in the (split) share register and the registers of other registered securities, including transfers and conversions, can be
validly made on the basis of documents or instructions submitted electronically or via any other means by the transferor, the transferee
and/or the holder of the securities, as applicable.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            text of article 14 (&ldquo;Transparency obligation&rdquo;) shall be amended and restated
                                            as follows: &ldquo;Each natural or legal person acquiring or transferring voting securities
                                            of the company, whether or not representing the share capital of the company, must comply
                                            with the relevant notification and information obligations that are imposed by applicable
                                            law.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            text of article 15 (&ldquo;Voting rights&rdquo;) shall be amended and restated as follows:
                                            &rdquo; Non-compliance with the relevant notification and information obligations that are
                                            imposed by applicable law in relation to the acquisition or transfer of voting securities
                                            of the company, whether or not representing the share capital of the company, may result,
                                            in accordance with applicable law, a suspension of the voting rights attached to the relevant
                                            voting securities or such other consequence as provided for by applicable law.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            article 32 (&ldquo;Admission &ndash; Prior formalities&rdquo;), the following paragraphs
                                            shall be added after the first paragraph of article 32:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
board of directors shall have the ability to determine that the right to attend the general shareholders&rsquo; meetings and to exercise
the voting right at such meetings (as the case may be) is determined by the registration of the ownership of the securities concerned
in the name of the holder of such securities on the third (3rd) business day prior to the date of the relevant general shareholders&rsquo;
meeting (or such other date as shall be set out in the notice convening the general shareholders&rsquo; meeting, but which cannot be
earlier than the 15th calendar date before the relevant general shareholders&rsquo; meeting), at midnight at the end of such day (Brussels
time) (such date and hour being the relevant registration date), by means of the registration of such securities in the relevant (portion
of the split) register book for such securities, or in the accounts of a certified account holder or relevant settlement institution
for the securities concerned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may make participation to the general shareholders&rsquo; meetings dependent on a requirement of notification by the
securities holders concerned to the company, or to the person appointed for this purpose by the company, on a date to be determined by
the board of directors before the date of the scheduled meeting, that such securities holder intends to attend the meeting, stating the
number of securities with which such securities holder wishes to participate. The manner in which such notification must be made (as
the case may be) must be set out in the notice convening the general shareholders&rsquo; meeting.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            article 33 (&ldquo;Representation of shareholders&rdquo;), the second paragraph shall be
                                            amended and restated as follows: &ldquo;Such proxies must be granted and submitted to the
                                            company in accordance with the applicable law and/or as set out (in accordance with the applicable
                                            law) in the convening notice, as the case may be.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            article 35 (&ldquo;Adjournment of the meeting&rdquo;), the reference in the first and second
                                            paragraph to &ldquo;five (5) weeks&rdquo; shall be replaced by &ldquo;three (3) weeks&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            text of article 36 (&ldquo;Decisions on matters not on the agenda - Amendments&rdquo;) shall
                                            be amended and restated as follows: &ldquo;The general shareholders&rsquo; meeting cannot
                                            validly deliberate or decide on the items that are not included or implicitly contained in
                                            the agenda, unless all shareholders are present or represented at the meeting and unanimously
                                            agree and if, in the case of a vote by mail, the form authorises a proxy to make such a decision.
                                            The required consent is assumed to exist, if no objection is recorded in the minutes of the
                                            meeting.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            article 39 (&ldquo;Remote voting or participation&rdquo;) the reference to &ldquo;sixth calendar
                                            day&rdquo; shall be replaced by &ldquo;third business day&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            heading of article 51 shall be amended and restated as &ldquo;Certain defined terms&rdquo;,
                                            and the text of article 51 shall be amended and restated as follows: &ldquo;Unless the context
                                            requires otherwise or unless otherwise defined in these articles of association, for the
                                            purposes of these articles of association, (a)&nbsp;&ldquo;personnel&rdquo; shall have the
                                            meaning defined in Article 1:27 of the Belgian Companies and Associations Code, and (b)&nbsp;&ldquo;business
                                            day&rdquo; shall have the meaning defined in Article 1:32 of the Belgian Companies and Associations
                                            Code.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
                                            implementation of the De-Listing</U>: <FONT STYLE="font-weight: normal">Subject to applicable
                                            company, financial and securities law rules, and subject to the provisions of the foregoing
                                            paragraphs, the board of directors shall have the authority to further implement and effect
                                            the De-Listing, including (without being limited to) the authority to (i)&nbsp;determine
                                            the practical implementation of the De-Listing, (ii)&nbsp;determine the timing and the effective
                                            date of the De-Listing and the duration of the Transition Period, (iii)&nbsp;determine the
                                            manner and process for the </FONT>shares (or, as the case may be, American Depositary Shares
                                            or American Depositary Receipts in relation to such shares) <FONT STYLE="font-weight: normal">to
                                            be traded on Nasdaq, (iv)&nbsp;appoint one or more banks or financial institutions for the
                                            further organization and implementation of the De-Listing, (v)&nbsp;proceed with the recording
                                            of the amendment and the restatement of the articles of association as contemplated by paragraph
                                            (c) before a notary public, (vi)&nbsp;take all useful or necessary steps with Euronext, Euroclear,
                                            any other competent settlement agency, and any regulatory or listing authority in connection
                                            with the implementation of the De-Listing, and (vii)&nbsp;do such other things as shall be
                                            useful, appropriate or necessary in connection with the foregoing. The board of directors
                                            shall have the authority to delegate the further implementation and execution of the De-Listing
                                            (including the powers referred to in sub-sections (i) to (vii)), in whole or in part, to
                                            one or more members of the Company&rsquo;s executive management or personnel. Any director,
                                            any member of the executive management, and any other persons that shall be expressly appointed
                                            for such purpose by the board of directors shall be authorized to record the amendment and
                                            the restatement of the articles of association as contemplated by paragraph (c) before a
                                            notary public</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glossary
of Selected Terms</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following definitions apply throughout this Special Report unless the context requires otherwise:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ADS</B>&rdquo;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    American Depositary Share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Belgian
    Act of 2 May 2007</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the Belgian Act of 2 May 2007 regarding the disclosure of important participations in issuers with shares admitted to trading on
    a regulated market and regarding miscellaneous provisions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Belgian
    Corporate Governance Code</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the 2020 Belgian Code on Corporate Governance Code.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Belgian
    Markets for Financial Instruments Act</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the Belgian Act of 21 November 2017 relating to the infrastructures for markets for financial instruments and regarding the transposition
    of Directive 2014/65/EU.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Belgian
    Transparency Decree</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the Belgian Royal Decree of 14 November 2007 regarding the obligations of issuers of financial instruments admitted to trading on
    a regulated market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    MDxHealth SA.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>De-Listing</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the proposed de-listing of the Shares from listing and trading on the regulated market of Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>EEA</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the European Economic Area.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>EGM</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    an extraordinary general shareholders&rsquo; meeting of the Company to be held on 3 November 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Euronext
    Brussels</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the regulated market of Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FINRA</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the Financial Industry Regulatory Authority.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FSMA</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the Belgian Financial Services and Markets Authority.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Special
    Report</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the special report regarding the proposed share consolidation and de-listing of shares from the regulated market of Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Market
    Abuse Regulation</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Market
    Repositioning</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the repositioning of the Shares from the trading system used for trading the Shares on Euronext Brussels into the trading system
    used for trading the Shares on Nasdaq, which shall be subject to certain formalities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>MDxHealth</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the Company, together with its consolidated subsidiaries from time to time.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Nasdaq</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    Nasdaq Capital Market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>PIE</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    public-interest entity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the U.S. Securities and Exchange Commission.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Share</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    any outstanding share of the Company, representing the Company&rsquo;s share capital from time to time.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Share
    Consolidation</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the proposed consolidation of Shares by means of a 1-for-10 reverse stock split.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transition
    Period</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the period as from the approval of the De-Listing until the last day of trading of the Company&rsquo;s Shares on Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>U.S.</B>&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ea186179ex99-4_mdxhealth.htm
<DESCRIPTION>LETTER FROM THE CHAIRPERSON
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 99.4</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex99-5_001.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LETTER FROM THE CHAIRPERSON</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MDXHEALTH SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<FONT STYLE="background-color: white">a company
with limited liability (<I>naamloze vennootschap/soci&eacute;t&eacute; anonyme</I>) incorporated and operating under the laws of Belgium,
with enterprise number 0479.292.440</FONT>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October 2, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>To the Holders of Shares </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Proposed share consolidation, termination
of the ADS program <BR>
and Euronext de-listing for repositioning on Nasdaq</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">On October 2, 2023, MDxHealth SA (the &ldquo;Company&rdquo;)
announced that the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) has determined it is in the best interest of the Company, its
investors and other stakeholders to consolidate all trading of the Company&rsquo;s securities on one exchange in the United States. The process
for implementing this transition (the &ldquo;Transaction&rdquo;) from a dual listing of the Company&rsquo;s American Depositary Shares (the &ldquo;ADSs&rdquo;)
on Nasdaq and ordinary shares (the &ldquo;Shares&rdquo;) on Euronext Brussels to a sole listing of Shares on Nasdaq broadly involves (1)
a share consolidation with respect to all outstanding Shares by means of a 1-for-10 reverse stock split (the &ldquo;Share Consolidation&rdquo;),
after which then existing Shares will be represented by one new Share, and each ADS will represent one new Share, (2) listing the Shares
on Nasdaq, (3) a mandatory exchange under the Company&rsquo;s ADS Facility as a result of which ADS holders will receive Shares in exchange
for their ADSs on the basis of a ratio of one ADS for one Share (the &ldquo;Mandatory ADS Exchange&rdquo;), (4) subject to certain formalities,
a repositioning of the Shares from the trading system used for trading the Shares on Euronext Brussels into the trading system used for
trading the Shares on Nasdaq (the &ldquo;Market Repositioning&rdquo;), and (5), following a transition period of at least three weeks after
the Mandatory ADS Exchange (the &ldquo;Transition Period&rdquo;), the de-listing of the Shares from listing and trading on Euronext Brussels
(the &ldquo;De-Listing&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In order to implement the
Transaction, the Company&rsquo;s Shareholders must approve the Share Consolidation and the De-Listing. The proposal regarding the
De-Listing also contains a number of technical amendments to the Company&rsquo;s articles of association that allow for the
De-Listing. The Board has convened an extraordinary general shareholders&rsquo; meeting of the Company to be held on 3 November 2023
to seek approval of these matters (the &ldquo;EGM&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">This letter highlights selected
information contained in the Special Report and does not contain all of the information you should take into consideration. The Special
Report is available on the Company&rsquo;s <I>website</I>.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reasons for the Sole Listing</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The Board believes that a sole listing of Shares
on Nasdaq (the &ldquo;Sole Listing&rdquo;) will yield a number of benefits for the Company its investors and other stakeholders, as summarized
below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify"><B><I>A listing on Nasdaq is in line with the Company&rsquo;s focus
on the United States (the &ldquo;U.S.&rdquo;).</I></B> The Company is domiciled and listed as a public company in Belgium, but the Company&rsquo;s
primary commercial focus is in the U.S., where over 95% of its tests are performed and revenues are generated. The Company&rsquo;s entire executive
management team and over 95% of staff are based in or report to the Company&rsquo;s U.S. headquarters in Irvine, California, or one of the
Company&rsquo;s laboratories in Irvine, California or Plano, Texas. The Company carried out a U.S. IPO of ADSs in 2021, and its ADSs have been
trading on Nasdaq since November 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Trading on one single market may simplify trading for investors, and could lead to greater liquidity and more efficient pricing
and trading activity</I>.</B> By bringing all trading to Nasdaq, the Board believes that this could simplify the trading process for investors
and increase liquidity, potentially narrow trading spreads, and improve the overall efficiency of price discovery between buyers and sellers,
all of which could further improve the attractiveness of the Shares, and hence lead to improved trading activity of the Shares. Since
its February 2023 public offering of ADSs in the U.S., average daily liquidity of the Company&rsquo;s ADSs on Nasdaq has exceeded by over
3-times the average daily liquidity of Shares on Euronext Brussels.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Nasdaq has become a more important source for equity fund raising than Euronext Brussels</I>.</B> Since the U.S. IPO&nbsp;in
2021, the focus on the U.S. as a source for equity funding has only increased in importance, including through the Company&rsquo;s August 2022
acquisition of the GPS (formerly Oncotype DX GPS) prostate cancer business from Genomic Health, Inc., a subsidiary of Exact Sciences Corporation,
a portion of the consideration for which was paid with ADSs, and the Company&rsquo;s February 2023 public offering of ADSs in the U.S.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The legal regime in terms of investor protection will remain similar</I></B>.&nbsp;Following completion of the Transaction,
the legal regime that will apply in terms of transparency and investor protection will remain similar to the regime that applies currently.
This particularly applies to the rules regarding the publication of annual and interim financial information, the disclosure of material
non-public information, and the disclosure of trading by significant shareholders.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The dual listing on Euronext Brussels and Nasdaq has not led to increased liquidity or trading</I>.</B> The trading on Nasdaq
and Euronext Brussels takes place in different currencies (U.S. dollars on Nasdaq and EUR on Euronext Brussels), and at different times
(resulting from different time zones, different trading days and different public holidays in the U.S. and Belgium). The Company believes
that, at times, this has negatively affected the trading prices of the Shares and ADSs on these two markets and that this may have reduced
the interest of potential investors to invest in the Company&rsquo;s Shares or ADSs.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Company incurs substantial compliance costs due to the listing on Euronext Brussels and Nasdaq as well as additional uncertainty
due to compliance with both sets of rules</I>.</B> As a result of the listing on both Euronext Brussels and Nasdaq, the Company not only
needs to comply with the Belgian legal framework for listed companies, but also with the U.S. listing rules. This entails significant
legal, accounting, and other expenses. From time to time, this also may result in uncertainty regarding compliance matters and result
in additional costs necessitated by legal analysis of dual legal regimes.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Company may lose its &ldquo;foreign private issuer&rdquo; status under U.S. securities laws in the future, which would lead
to a further substantial compliance cost increase</I>.</B> On the date hereof, the Company is considered a &ldquo;foreign private issuer&rdquo;
under U.S. securities laws. In its capacity as a foreign private issuer, the Company is exempt from certain rules under U.S. securities
law rules that impose certain disclosure obligations and procedural requirements for proxy solicitations, and for reporting and disclosure
requirements for members of the board of directors and important Shareholders with respect to their purchases and sales of the Company&rsquo;s
securities. With the increased focus on the U.S., it is possible that the Company may lose its foreign private issuer status. As result,
it would become subject to the same rules as would apply to U.S. listed companies, in addition to the rules to that apply Belgian listed
companies, which would lead to a further substantial increase of compliance costs. The loss of foreign private issuer status may also
be accelerated by the De-Listing.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Shareholders of the Company will be able to trade their Shares on Nasdaq</I>.</B> As a result of the De-Listing, the Shares
will no longer be traded on Euronext Brussels after the Transition Period. Holders of Shares currently traded on Euronext Brussels will
have, however, the ability, during and after the Transition Period, to reposition their Shares so that they can be traded on Nasdaq. The
Company expects that many financial intermediaries will use their discretionary rights (under their terms of service to their clients)
to automatically reposition their clients&rsquo; shares on their behalf.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-size: 10pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD><TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">For the sake of completeness,
the corporate structure and governing company law (Belgian law) of the Company will not change as a result of the proposed Transaction.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reasons for the Share Consolidation</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company&rsquo;s ADSs, which are trading on Nasdaq,
currently represent outstanding Shares on a 1-for-10 basis, whereby each ADS represents 10 outstanding Shares. As a result of the Share
Consolidation, the ADSs will represent Shares of the Company on a 1-for-1 basis. This will simplify an exchange of the ADSs for Shares
upon termination of the ADS program and a Market Repositioning of the Shares to Nasdaq.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">Following the Share Consolidation, the Company&rsquo;s
Shareholders will still own the same proportion of the capital of the Company as immediately prior to the Share Consolidation, subject
to any fractions of Shares. As set out in the FAQs, a process will be put in place so that any fractional interest resulting from such
Share Consolidation would entitle the holder of such fractional interest to a cash payment in lieu thereof.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reasons for the Mandatory ADS Exchange</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Board believes that the Mandatory ADS Exchange
will yield a number of benefits for the Company and ADS holders, as outlined below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Mandatory ADS Exchange is necessary to transition to a Sole Listing of Shares on Nasdaq.</I></B> As described above, the
main purpose of the Transaction is to transition to a Sole Listing of Shares on Nasdaq. In view thereof, the Mandatory ADS Exchange is
necessary to complete this process.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The annual, transaction-specific and other fees payable by ADS holders will no longer apply.</I></B> As disclosed in the Company&rsquo;s
securities filings in the U.S., ADS holders incur annual, transaction-specific and other fees under the ADS Facility. By implementing
the Mandatory ADS Exchange, which will result in ADS holders receiving Shares in exchange for their ADSs, these fees will no longer apply.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Company&rsquo;s cost of compliance with the requirements of the ADS Facility will be eliminated.</I></B> The Company incurs certain
costs under the ADS Facility (<I>e.g.,</I> in connection with soliciting proxies from ADS holders in the context of Company&rsquo;s general
shareholders&rsquo; meeting) which will be eliminated.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effect of the Transaction on Shareholders</P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Effects of the Share Consolidation</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">As a result of the Share Consolidation, all outstanding Shares will be consolidated at the ratio of one new Share for ten existing
Shares, and a process will be put in place so that any fractional interests resulting from such Share Consolidation would entitle the
holder of such fractional interest to a cash payment in lieu thereof.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The Share Consolidation will not affect the proportionate ownership of Shareholders, subject to any fractions of new Shares being
consolidated and sold, but is necessary to ensure that each ADS represents one Share, which will simplify an exchange of the ADSs for
Shares upon termination of the ADS program and a Market Repositioning of the Shares to Nasdaq.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">In principle, the Share Consolidation will be implemented automatically, without the need for Shareholders to take any action and
will not affect the form of the outstanding Shares (dematerialized or registered) prior to the De-Listing.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">No Belgian income tax consequences are expected to arise as a result of the Share Consolidation.</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-size: 10pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD><TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Effects of the De-Listing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">During the Transition Period, Shareholders will continue to be able to trade Shares on Euronext Brussels until their Shares are repositioned
from the Belgian component of the Company&rsquo;s share register maintained by Euroclear Belgium in Belgium to the U.S. component of the Company&rsquo;s
share register that will be set up by the Company and maintained in the U.S by the transfer agent that will be appointed for such purpose
in the U.S. (the &ldquo;U.S. Transfer Agent&rdquo;). Thereafter the Shares will no longer be listed on Euronext Brussels and Shareholders
will no longer be able to trade the Shares on Euronext Brussels.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">During and after the Transition Period or thereafter, by completing a simple procedure through their financial intermediary, holders
of Shares currently trading on Euronext Brussels will have the ability to reposition their Shares so that they can be traded on Nasdaq.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">As a result of the De-Listing the Company will no longer qualify as a listed company pursuant to article 1:11 of the Belgian Companies
and Associations Code, nor as a PIE pursuant to article 1:12 of the Belgian Companies and Associations Code as from the De-Listing Date
and many of the rules that otherwise apply to Belgian listed companies will no longer apply to the Company.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The rights attached to the Shares will not materially change as a result of the Transaction. However, Shareholders will no longer
need to vote on certain corporate governance and remuneration related matters. Furthermore, a shorter notice period will apply to convene
Shareholders&rsquo; meeting and formalities to convene and attend such Shareholders&rsquo; meetings will also be different, albeit still in line with
Belgian law.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The Company will be required to continue to comply will all regulatory requirements applicable to a Nasdaq listed company, including
all applicable rules and regulations of the SEC.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">No Belgian income tax consequences are expected to arise as a result of the De-Listing.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Holders of Shares currently trading on Euronext Brussels should contact their financial intermediary about possible handling fees
associated with repositioning their Shares as well as costs associated with holding and trading Shares listed on Nasdaq.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effect of the Transaction on ADS Holders</P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Effects of the Share Consolidation and De-listing</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Other than causing each ADS to represent one Share, the Share Consolidation is not expected to have any impact on ADS holders.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The De-Listing is not expected to have any direct impact on ADS holders, as the ADS program will be terminated before the De-Listing.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Prior to the termination of the ADS program, following the Share Consolidation, the Company will proceed with the Mandatory ADS Exchange
pursuant to which holders of ADSs will receive the underlying new Shares in the context of the Share Consolidation, which will have a
CUSIP and will be listed on Nasdaq.</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-size: 10pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD><TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Effects of the Mandatory ADS Exchange</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">As a result of the Mandatory ADS Exchange, each of the Company&rsquo;s outstanding ADSs will be canceled and exchanged for one U.S. Share
(as defined below) it represents as follows:</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">ADSs held in brokerage accounts as well as ADSs in book-entry form on the books of The Bank of New York Mellon (the &ldquo;Depositary&rdquo;)
will be automatically exchanged for Shares without holders having to take any action.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">If there are any holders of certificated ADSs, the Exchange Agent will send such holders a letter of transmittal calling for surrender
of their ADS certificate(s) in exchange for U.S. Shares.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The Shares received in exchange for ADSs will be listed on Nasdaq and the Nasdaq ADS listing will be terminated.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The Transaction is not expected to have any tax consequences for ADS holders.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The Company has arranged with the Depositary to cover, on behalf of the ADS holders, the USD 0.05 per ADS termination fee due to the
Depositary under the Deposit Agreement in connection with the termination of the ADS program.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white"><B>Board Recommendation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-weight: normal">The
Board considers the Transaction to be in the best interests of the Company, its Shareholders and other stakeholders, considered individually
and as a whole. Accordingly, the Board unanimously recommends that you vote &ldquo;FOR&rdquo; the proposals as the directors of the Company
each intend to do so in respect of their own beneficial holdings of Shares. </FONT>Your vote is very important<FONT STYLE="font-weight: normal">.
Whether or not you plan to attend the EGM, please take appropriate action to make sure your Shares are represented and voted at the EGM.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-size: 10pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD><TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Expected Timeline</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.25in">Provided that the EGM approves the proposed Share
Consolidation and De-Listing, the main dates and timelines to implement the Transaction are expected to be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 69%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Action</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 29%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcement of the contemplated De-Listing and convening of the EGM to approve the Share Consolidation and De-Listing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">2 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval of the Share Consolidation and De-Listing by the EGM of the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">3 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective date for the Share Consolidation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated to be approximately 9 trading days after the approval of the Share Consolidation and De-Listing by the EGM (or second EGM)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination of the ADS program and start of trading of the Shares on Nasdaq</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated to be approximately 6 trading days following the effective date of the Share Consolidation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Start of the Transition Period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated to be upon start of trading of the Shares on Nasdaq</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End of the Transition Period and end of trading of the Shares on Euronext Brussels</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
    to be approximately 3 weeks after the start of the Transition Period, but no later than Friday 29 December 2023, at 5:30 p.m.
    Brussels time</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Provided that the EGM approves the proposed Share
Consolidation and De-Listing, the Board will have the power to further amend the dates, times and periods indicated in the above timetable.
If the board of directors decides to amend such dates, times or periods, it will inform the investors by a press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If the 50% attendance quorum is not reached at the EGM, a Second EGM,
where no attendance quorum applies, will be convened to approve the proposed Share Consolidation and De-Listing. The convening of such
a Second EGM will consequently entail the need for the Board to amend the timeline detailed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-size: 10pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD><TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Glossary</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Glossary of Selected Terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following definitions apply throughout this
Letter unless the context requires otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 35%; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&ldquo;<B>ADS</B>&rdquo;</P></TD>
    <TD STYLE="text-align: justify; width: 65%; text-indent: 0in">means American Depositary Shares, each representing ten Shares (prior to the Share Consolidation).</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>ADS Facility</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the deposit agreement between the Company and the Depositary.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>ADS holder</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means a holder of ADSs.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Company</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means MDxHealth SA.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>De-Listing</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the proposed de-listing of the Shares from listing and trading on the regulated market of Euronext Brussels.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Depositary</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means The Bank of New York Mellon.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>EGM</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means an extraordinary general shareholders&rsquo; meeting of the Company to be
    held on 3 November 2023.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Euronext Brussels</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the regulated market of Euronext Brussels.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>European Shares</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means Shares reflected in the Belgian component of the Company&rsquo;s share register.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top"><FONT STYLE="font-size: 10pt">&ldquo;<B>Exchange Agent</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the Bank of New York Mellon, the Depositary of the Company&rsquo;s ADSs, or another party appointed by the Company to serve as exchange agent for purposes of the Mandatory ADS Exchange.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>FAQs</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the Frequently Asked Questions uploaded on the Company&rsquo;s website.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>FSMA</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the Belgian Financial Services and Markets Authority.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Mandatory ADS Exchange</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means a mandatory exchange under the Company&rsquo;s ADS facility as a result of which ADS holders will receive Shares in exchange for their ADSs.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Market Repositioning</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the repositioning of the Shares from the trading system used for trading the Shares on Euronext Brussels into the trading system used for trading the Shares on Nasdaq, which shall be subject to certain formalities.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Nasdaq</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the Nasdaq Stock Market.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>PIE</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means public-interest entity.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-size: 10pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD><TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; vertical-align: top; width: 35%">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 65%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>SEC</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the U.S. Securities and Exchange Commission.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Second EGM</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the means an extraordinary general shareholders&rsquo; meeting of the
    Company to be held on 23 November 2023, if needed.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Share</B>&rdquo; or &ldquo;<B>Ordinary Share&rdquo;</B></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means any outstanding share of the Company, representing the Company&rsquo;s share capital from time to time.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Share Consolidation</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the proposed share consolidation of the outstanding Shares by means of a 1-for-10 reverse stock split.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Shareholder</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means a holder of Shares.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Sole Listing</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means proposed transition from a dual listing of the Company&rsquo;s ADSs on Nasdaq and Ordinary Shares on Euronext Brussels to a sole listing of Ordinary Shares on Nasdaq.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Special Report</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the special report regarding the proposed share consolidation and de-listing of shares from the regulated market of Euronext Brussels. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Transaction</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the Share Consolidation, the De-Listing and the Mandatory ADS Exchange, together.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>Transition Period</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the period as from the approval of the De-Listing until the last day of trading of the Shares on Euronext Brussels.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>U.S.</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the United States.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; vertical-align: top">&ldquo;<B>U.S. Transfer Agent</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">means the transfer agent that will be appointed to maintain the Company&rsquo;s share register in the U.S.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 47%">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; width: 6%">8</TD>
    <TD STYLE="text-align: right; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter from the Chairperson - MDxHealth</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>6
<FILENAME>ea186179ex99-5_mdxhealth.htm
<DESCRIPTION>FREQUENTLY ASKED QUESTIONS REGARDING SHARE CONSOLIDATION, TERMINATION OF ADS PROGRAM AND EURONEXT DE-LISTING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt"><B>Exhibit 99.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt"><IMG SRC="ex99-5_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt">Published 2 Oct 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FAQs REGARDING THE SHARE CONSOLIDATION, TERMINATION
OF THE <BR>
ADS PROGRAM AND EURONEXT DE-LISTING FOR REPOSITIONING ON <BR>
NASDAQ</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Set forth below are
frequently asked questions (FAQs) relating to the proposed share consolidation, the termination of the ADS program, the Euronext
de-listing and (subject to the approval of the proposed share consolidation and de-listing) the potential process to reposition your
shares so that they may be traded on Nasdaq. If you have additional questions relating to the process to reposition your shares,
please contact your financial intermediary or custodian. The repositioning shall only become relevant provided the proposed share
consolidation and de-listing have been approved by the Company&rsquo;s extraordinary general shareholders&rsquo; meeting.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>General</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>What is the proposed Transaction?</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The board of directors (the &ldquo;Board&rdquo;) of MDxHealth SA (the
&ldquo;Company&rdquo;) has determined it is in the best interest of the Company, its investors and other stakeholders to consolidate all
trading of the Company&rsquo;s securities on one exchange in the United States. The process for implementing this transition (the &ldquo;Transaction&rdquo;)
from a dual listing of the Company&rsquo;s American Depositary Shares (the &ldquo;ADSs&rdquo;) on Nasdaq and ordinary shares (the &ldquo;Shares&rdquo;)
on Euronext Brussels to a sole listing of Shares on Nasdaq broadly involves (1) a share consolidation with respect to all outstanding
Shares by means of a 1-for-10 reverse stock split (the &ldquo;Share Consolidation&rdquo;), after which ten existing Shares will be represented
by one new Share, and each ADS will represent one new Share, (2) listing the Shares on Nasdaq, (3) a mandatory exchange under the Company&rsquo;s
ADS Facility as a result of which ADS holders will receive Shares in exchange for their ADSs on the basis of a ratio of one ADS for one
Share (the &ldquo;Mandatory ADS Exchange&rdquo;), (4) subject to certain formalities, a repositioning of the Shares from the trading system
used for trading the Shares on Euronext Brussels into the trading system used for trading the Shares on Nasdaq (the &ldquo;Market Repositioning&rdquo;),
and (5), following a transition period of at least three weeks after the Mandatory ADS Exchange (the &ldquo;Transition Period&rdquo;), the
de-listing of the Shares from listing and trading on Euronext Brussels (the &ldquo;De-Listing&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to implement the Transaction, the Company&rsquo;s Shareholders must
approve the Share Consolidation and the De-Listing. The proposal regarding the De-Listing also contains a number of technical amendments
to the Company&rsquo;s articles of association that allow for the De-Listing. The Board has convened an extraordinary general shareholders&rsquo;
meeting of the Company to be held on 3 November 2023 to seek approval of these matters (the &ldquo;EGM&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>What are the reasons for the Transaction?</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Reasons for the proposed transition from a dual listing
of the Company&rsquo;s ADSs on Nasdaq and Ordinary Shares on Euronext Brussels to a sole listing of Ordinary Shares on Nasdaq (the &ldquo;Sole
Listing&rdquo;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes that the Sole Listing will
yield a number of benefits for the Company, its investors and other stakeholders, as summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>A listing on Nasdaq is in line with the Company&rsquo;s focus on the United States (the &ldquo;U.S.&rdquo;).</I></B> The Company is
domiciled and listed as a public company in Belgium, but the Company&rsquo;s primary commercial focus is in the U.S., where over 95% of its
tests are performed and revenues are generated. The Company&rsquo;s entire executive management team and over 95% of staff are based in or report
to the Company&rsquo;s U.S. headquarters in Irvine, California, or one of the Company&rsquo;s laboratories in Irvine, California or Plano, Texas.
The Company carried out a U.S. IPO of ADSs in 2021, and its ADSs have been trading on Nasdaq since November 2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Trading on one single market may simplify trading for investors, and could lead to greater liquidity and more efficient pricing
and trading activity</I>.</B> By bringing all trading to Nasdaq, the Board believes that this could simplify the trading process for investors
and increase liquidity, potentially narrow trading spreads, and improve the overall efficiency of price discovery between buyers and sellers,
all of which could further improve the attractiveness of the Shares, and hence lead to improved trading activity of the Shares. Since
its February 2023 public offering of ADSs in the U.S., average daily liquidity of the Company&rsquo;s ADSs on Nasdaq has exceeded by over
3-times the average daily liquidity of Shares on Euronext Brussels.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Nasdaq has become a more important source for equity fund raising than Euronext Brussels</I>.</B> Since the U.S. IPO&nbsp;in
2021, the focus on the U.S. as a source for equity funding has only increased in importance, including through the Company&rsquo;s August 2022
acquisition of the GPS (formerly Oncotype DX GPS) prostate cancer business from Genomic Health, Inc., a subsidiary of Exact Sciences Corporation,
a portion of the consideration for which was paid with ADSs, and the Company&rsquo;s February 2023 public offering of ADSs in the U.S.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The legal regime in terms of investor protection will remain similar</I></B>.&nbsp;Following completion of the Transaction,
the legal regime that will apply in terms of transparency and investor protection will remain similar to the regime that applies currently.
This particularly applies to the rules regarding the publication of annual and interim financial information, the disclosure of material
non-public information, and the disclosure of trading by significant shareholders.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The dual listing on Euronext Brussels and Nasdaq has not led to increased liquidity or trading</I>.</B> The trading on Nasdaq
and Euronext Brussels takes place in different currencies (U.S. dollars on Nasdaq and EUR on Euronext Brussels), and at different times
(resulting from different time zones, different trading days and different public holidays in the U.S. and Belgium). The Company believes
that, at times, this has negatively affected the trading prices of the Shares and ADSs on these two markets and that this may have reduced
the interest of potential investors to invest in the Company&rsquo;s Shares or ADSs.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Company incurs substantial compliance costs due to the listing on Euronext Brussels and Nasdaq as well as additional uncertainty
due to compliance with both sets of rules</I>.</B> As a result of the listing on both Euronext Brussels and Nasdaq, the Company not only
needs to comply with the Belgian legal framework for listed companies, but also with the U.S. listing rules. This entails significant
legal, accounting, and other expenses. From time to time, this also may result in uncertainty regarding compliance matters and result
in additional costs necessitated by legal analysis of dual legal regimes.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Company may lose its &ldquo;foreign private issuer&rdquo; status under U.S. securities laws in the future, which would lead
to a further substantial compliance cost increase</I>.</B> On the date hereof, the Company is considered a &ldquo;foreign private issuer&rdquo;
under U.S. securities laws. In its capacity as a foreign private issuer, the Company is exempt from certain rules under U.S. securities
law rules that impose certain disclosure obligations and procedural requirements for proxy solicitations, and for reporting and disclosure
requirements for members of the board of directors and important Shareholders with respect to their purchases and sales of the Company&rsquo;s
securities. With the increased focus on the U.S., it is possible that the Company may lose its foreign private issuer status. As result,
it would become subject to the same rules as would apply to U.S. listed companies, in addition to the rules to that apply Belgian listed
companies, which would lead to a further substantial increase of compliance costs. The loss of foreign private issuer status may also
be accelerated by the De-Listing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Shareholders of the Company will be able to trade their Shares on Nasdaq</I>.</B> As a result of the De-Listing, the Shares
will no longer be traded on Euronext Brussels after the Transition Period. Holders of Shares currently traded on Euronext Brussels will
have, however, the ability, during and after the Transition Period, to reposition their Shares so that they can be traded on Nasdaq. The
Company expects that many financial intermediaries will use their discretionary rights (under their terms of service to their clients)
to automatically reposition their clients&rsquo; shares on their behalf.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white">For the sake of completeness,
the corporate structure and governing company law (Belgian law) of the Company will not change as a result of the proposed Transaction,
as set out in the answer to Question 20 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Reasons for the Share Consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s ADSs, which are trading on Nasdaq,
currently represent outstanding Shares on a 1-for-10 basis, whereby each ADS represents 10 outstanding Shares. As a result of the Share
Consolidation, the ADSs will represent Shares of the Company on a 1-for-1 basis. This will simplify an exchange of the ADSs for Shares
upon termination of the ADS program and a Market Repositioning of the Shares to Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Share Consolidation, the Company&rsquo;s
Shareholders will still own the same proportion of the capital of the Company as immediately prior to the Share Consolidation, subject
to any fractions of Shares. As set out in the answer to Question 7 below, a process will be put in place so that any fractional interest
resulting from such Share Consolidation would entitle the holder of such fractional interest to a cash payment in lieu thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Reasons for the Mandatory ADS Exchange</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes that the Mandatory ADS Exchange
will yield a number of benefits for the Company and ADS holders, as outlined below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Mandatory ADS Exchange is necessary to transition to a Sole Listing of Shares on Nasdaq.</I></B> As described above, the
main purpose of the Transaction is to transition to a Sole Listing of Shares on Nasdaq. In view thereof, the Mandatory ADS Exchange is
necessary to complete this process.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The annual, transaction-specific and other fees payable by ADS holders will no longer apply.</I></B> As disclosed in the Company&rsquo;s
securities filings in the U.S., ADS holders incur annual, transaction-specific and other fees under the ADS Facility. By implementing
the Mandatory ADS Exchange, which will result in ADS holders receiving Shares in exchange for their ADSs, these fees will no longer apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>The Company&rsquo;s cost of compliance with the requirements of the ADS Facility will be eliminated.</I></B> The Company incurs certain
costs under the ADS Facility (<I>e.g.,</I> in connection with soliciting proxies from ADS holders in the context of Company&rsquo;s general
shareholders&rsquo; meeting) which will be eliminated.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>What am I being asked to vote on at the EGM?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board has convened the EGM to be held on 3 November 2023 to seek
the approvals necessary to complete the Transaction. At the EGM, you are being asked to vote on and approve the Share Consolidation and
the De-Listing, which proposals also contains a number of technical amendments to the Company&rsquo;s articles of association that allow for
the De-Listing. The agenda and proposed resolutions that are submitted to the EGM can be found on the Company&rsquo;s website at mdxhealth.com/investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholder approval is not required for the Mandatory ADS Exchange
and the listing of the Company&rsquo;s Shares on Nasdaq. However, the Company does not intend to take these actions if its Shareholders do not
approve all of the proposals presented at the EGM.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information on the proposals that will be submitted to the
EGM, see the Special Report, which can be found on the Company&rsquo;s website at mdxhealth.com/investors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>What is the Board&rsquo;s recommendation?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white">The Board considers the
Transaction to be in the best interests of the Company, its Shareholders and other stakeholders, considered individually and as a whole.
Accordingly, the Board unanimously recommends that you vote &ldquo;FOR&rdquo; the proposals as the directors of the Company each intend
to do so in respect of their own beneficial holdings of Shares. <B>Your vote is very important</B>. Whether or not you plan to attend
the EGM, please take appropriate action to make sure your Shares are represented and voted at the EGM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>How do I attend the EGM and vote?</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Further
information on date, hour and venue of the EGM, the manner in which the holders of securities issued by the Company can participate in
the EGM and vote their Shares is available in the convening notice which can be found on the Company&rsquo;s website at </FONT>mdxhealth.com/investors<FONT STYLE="font-size: 10pt">.
</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>When is the expected timeline for the completion of the Transaction?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board has convened the EGM to approve the Transaction on 3 November
2023. If the attendance quorum is not met at the EGM on 3 November 2023, the Board will convene a second extraordinary general shareholders&rsquo;
meeting of the Company to be held on 23 November 2023 (the &ldquo;Second EGM&rdquo;), if needed to approve the Transaction. If the Transaction
is approved by the Company&rsquo;s Shareholders at either EGM, it is anticipated that the Company will implement the Share Consolidation approximately
9 trading days following such approval. Shortly following the effective date of Share Consolidation, the Company will effect the Mandatory
ADS Exchange and the listing of the Company&rsquo;s Shares on Nasdaq. Once the Share Consolidation is effective and the Mandatory ADS Exchange
has been completed, a Transition Period of at least three weeks will begin, during which the Company&rsquo;s Shares will be listed and traded
on both Nasdaq and Euronext Brussels. At the end of the Transition Period, the De-Listing of the Shares from Euronext Brussels will occur,
and the Shares will be solely listed and tradeable on Nasdaq. The expected timeline is tentative, and the Board reserves the right to
adjust the timeline as it deems necessary and may decide in its sole discretion not to undertake the Transaction at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please see the Expected Timeline at the end of these FAQs for a more
detailed expected timeline of the Transaction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>The Effects of the Transaction if Approved and Implemented</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>What are the effects of the Share Consolidation on Shareholders?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Share Consolidation, all outstanding Shares will
be consolidated at the ratio of one new Share for ten existing Shares, and a process will be put in place so that any fractional interests
resulting from such Share Consolidation would entitle the holder of such fractional interest to a cash payment in lieu thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Share Consolidation will not affect the proportionate ownership
of Shareholders, subject to any fractions of new Shares being consolidated and sold, but is necessary to ensure that each ADS represents
one Share, which will simplify an exchange of the ADSs for Shares upon termination of the ADS program and a Market Repositioning of the
Shares to Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In principle, the Share Consolidation will be implemented automatically,
without the need for Shareholders to take any action and will not affect the form of the outstanding Shares (dematerialized or registered)
prior to the De-Listing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Belgian income tax consequences are expected to arise as a result
of the Share Consolidation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further details on the Share Consolidation and process to deal
with fractions of new Shares resulting from the Share Consolidation, please see section &ldquo;<I>Consequences of the proposed Share Consolidation</I>&rdquo;
of the Special Report, which can be found on the Company&rsquo;s website at mdxhealth.com/investors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>What are the effects of the De-Listing on Shareholders?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the Transition Period, Shareholders will continue to be able
to trade Shares on Euronext Brussels until their Shares are repositioned from the Belgian component of the Company&rsquo;s share register maintained
by Euroclear Belgium in Belgium to the U.S. component of the Company&rsquo;s share register that will be set up by the Company and maintained
in the U.S by the transfer agent that will be appointed for such purpose in the U.S. (the &ldquo;<B>U.S. Transfer Agent</B>&rdquo;). Thereafter
the Shares will no longer be listed on Euronext Brussels and Shareholders will no longer be able to trade the Shares on Euronext Brussels.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the De-Listing the Company will no longer qualify as
a listed company pursuant to article 1:11 of the Belgian Companies and Associations Code, nor as a PIE pursuant to article 1:12 of the
Belgian Companies and Associations Code as from the De-Listing Date and many of the rules that otherwise apply to Belgian listed companies
will no longer apply to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights attached to the Shares will not materially change as a result
of the Transaction. However, Shareholders will no longer need to vote on certain corporate governance and remuneration related matters.
Furthermore, a shorter notice period will apply to convene Shareholders&rsquo; meeting and formalities to convene and attend such Shareholders&rsquo;
meetings will also be different, albeit still in line with Belgian law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will be required to continue to comply will all regulatory
requirements applicable to a Nasdaq listed company, including all applicable rules and regulations of the SEC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Belgian income tax consequences are expected to arise as a result
of the De-Listing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of European Shares (as defined below) should contact their
financial intermediary about possible handling fees associated with repositioning their Shares as well as costs associated with holding
and trading Shares listed on Nasdaq.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further details on the effects of the proposed De-Listing, please
see section &ldquo;<I>Consequences of the proposed De-Listing</I>&rdquo; of the Special Report, which can be found on the Company&rsquo;s website
at mdxhealth.com/investors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>The Effects of the Transaction if Approved and Implemented on
Holders of ADSs</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>What are the effects of the Share Consolidation and De-Listing
on ADS Holders?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other than causing each ADS to represent one Share, the Share Consolidation
is not expected to have any impact on ADS holders.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The De-Listing is not expected to have any direct impact on ADS holders,
as the ADS program will be terminated before the De-Listing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the termination of the ADS program, following the Share Consolidation,
the Company will proceed with the Mandatory ADS Exchange pursuant to which holders of ADSs will receive the underlying new Shares in the
context of the Share Consolidation, which will have a CUSIP and will be listed on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><B>What are the effects of the Mandatory ADS Exchange on ADS
Holders?</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Mandatory ADS Exchange, each of the Company&rsquo;s outstanding
ADSs will be canceled and exchanged for one U.S. Share (as defined below) it represents as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">ADSs held in brokerage accounts as well as ADSs in book-entry form on the books of The Bank of New York Mellon (the &ldquo;Depositary&rdquo;)
will be automatically exchanged for U.S. Shares without holders having to take any action.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">If there are any holders of certificated ADSs, the Exchange Agent will send such holders a letter of transmittal calling for surrender
of their ADS certificate(s) in exchange for U.S. Shares.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The U.S. Shares received in exchange for ADSs will be listed on Nasdaq
and the Nasdaq ADS listing will be terminated.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Transaction is not expected to have any tax consequences for ADS
holders.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has arranged with the Depositary to cover on behalf of
the ADS holders the $0.05 per ADS termination fee due to the Depositary under the Deposit Agreement in connection with the termination
of the ADS program.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Action Items if the Transaction is Approved and Implemented</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><B>What do you need to do if you hold ADSs?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Exchange Date (as defined below), each of the Company&rsquo;s existing
ADSs will be canceled and exchanged for the right to receive delivery of one new U.S. Share it represents, listed on the Nasdaq. <U>No
action is required on the part of the holders of ADSs unless such ADSs are certificated</U>. Holders of certificated ADSs will be
required to execute a letter of transmittal and deliver their ADSs to the Exchange Agent for these U.S. Shares to be delivered to them
following the Exchange Date. Beginning on the Exchange Date and in advance of receipt of such letter of transmittal and delivery of the
ADSs to the Exchange Agent, the Exchange Agent will hold the U.S. Shares on behalf of the previous holders of the relevant certificated
ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>12.</B></TD><TD STYLE="text-align: justify"><B>What do you need to do if you hold Shares trading on Euronext
Brussels?</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.35pt"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.35pt"><I>The sections below summarize, for information purposes,
    the Company&rsquo;s current expectations in relation to the process to be followed by shareholders to reposition their Shares from the trading
    system used for trading the Shares on Euronext Brussels into the trading system used for trading the Shares on Nasdaq. This summary is
    subject to change and will be updated by the Company as and when needed and appropriate in connection with the implementation of the Transaction.
    As at today, no repositioning is possible.</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.35pt"><I>&nbsp;</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>12.1. Repositioning of
Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Mandatory ADS Exchange and De-Listing, the Company will
create a U.S. component of its share register in the U.S. that will be maintained by the U.S. Transfer Agent. Only shares that will be
reflected in the U.S. component of the Company&rsquo;s share register (the &ldquo;U.S. Shares&rdquo;) will be capable of settling trades placed
on Nasdaq, with such settlement needing to take place through DTC following the admission of the Company&rsquo;s shares to trading on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Shares that are trading on Euronext Brussels are reflected in the
Belgian component of the Company&rsquo;s share register in Belgium that is maintained by Euroclear Belgium (the &ldquo;European Shares&rdquo;).
The European Shares will remain tradable on Euronext Brussels with settlement through Euroclear until the end of the Transition Period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order for the European Shares to be tradable on Nasdaq, holders
of European Shares will need to reposition their Shares from the Belgian component of the Company&rsquo;s share register to the U.S. component
of the Company&rsquo;s share register so that the European Shares become U.S. Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>12.2. How will the U.S.
Shares and European Shares be distinguished?</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The European Shares and U.S. Shares will have the same ISIN number.
However, the U.S. Shares will also have a DTC-eligible CUSIP number.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of both U.S. Shares and European Shares will be treated equally
and will be entitled to identical voting and economic rights. Hence, the U.S. Shares and the European Shares will have the same dividend
entitlement and be fully fungible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trading currency of the U.S. Shares on Nasdaq will be USD and such
U.S. Shares will be eligible to receive dividends and other distributions in USD, as opposed to the European Shares, of which the trading
currency will be in EUR as long as they trade on Euronext Brussels (until the De-Listing) and be eligible to receive dividends and other
distributions in EUR.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>12.3. Holders of European
Shares in dematerialized form will have the following options</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>(a) Automatic repositioning of European Shares
to U.S. Shares at the initiative of the brokers</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects that following the announcement of the completion
of the Share Consolidation, Mandatory ADS Exchange and approval of the De-Listing by the EGM, many financial intermediaries or custodians
in Europe will use their discretionary rights (under their terms of service to their clients) to automatically (at the initiative of the
brokers) reposition their clients&rsquo; European Shares into U.S. Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company also expects that in the event of such automatic repositioning,
Shareholders that hold European Shares in dematerialized form with a financial intermediary or custodian will automatically receive U.S.
Shares in lieu of their European Shares on their securities account, without having to open a new securities account or having to take
any further action. The Company also expects that many financial intermediaries or custodians will effect the automatic repositioning
either for free or for a nominal administrative fee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders should contact their financial intermediary or custodian
to enquire whether their European Shares will automatically be repositioned, without the need for their direct instruction, or not, whether
they will need to open a new securities account, and whether such repositioning will be subject to costs or expenses.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>(b) If there is not automatic repositioning,
you may request the repositioning of your European Shares to U.S. Shares</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event the European Shares are not automatically repositioned
into U.S. Shares as described in paragraph (a), holders of European Shares may request their financial intermediary or custodian to reposition
their European Shares into U.S. Shares. This request will be possible at any time after the Shares are listed on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders should contact their financial intermediary or custodian
to enquire the steps and timing that are required for the repositioning, and the costs and expenses associated with such repositioning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects that the procedure for repositioning from European
Shares into U.S. Shares should normally be completed within three trading days, but this timing cannot be guaranteed by the Company. As
the Company will not be able to guarantee how long it will take to complete the repositioning or settlement process, it recommends that
Shareholders allow sufficient time for such processes to be completed before trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>(c) You may continue to hold your European
Shares</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the Transaction, European Shares will continue to be valid
Shares with full voting rights, rights to future dividends and other distributions, etc., as currently enjoyed by holders of Shares. However,
following the completion of the Transition Period and De-Listing, there will be no public market in Belgium on which the European Shares
can be traded.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders can decide to keep their European Shares, but if they
would like to sell their Shares on Nasdaq they will be required to reposition their European Shares into U.S. Shares, as described in
paragraph (b) above.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the shares are automatically repositioned into U.S. Shares as described
in paragraph (a) above, Shareholders will still be able to reposition their U.S. Shares back into European Shares. Shareholders who wish
to reposition their U.S. Shares into European Shares will need to contact their financial intermediary or custodian.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects that the procedure for repositioning from U.S.
Shares into European Shares should normally be completed within three trading days, but this timing cannot be guaranteed by the Company.
As the Company will not be able to guarantee how long it will take to complete the repositioning or settlement process, it recommends
that Shareholders allow sufficient time for such processes to be completed before trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders should contact their financial intermediary or custodian
to enquire the steps and timings that are required for the repositioning, and the costs and expenses associated with such repositioning.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -67.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>(d) You may choose to sell your European Shares prior
to the De-Listing.</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">While the Company encourages you to continue to support the Company
with your participation in the capital, in the event the European Shares are not automatically repositioned into U.S. Shares, holders
of European Shares (see paragraph (a) above) can still sell their European Shares on Euronext Brussels at any time during the Transition
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">After the Transition Period, the European Shares will remain transferable,
but the European Shares will not be tradable on Euronext Brussels. Holders of European Shares will, however, be able to reposition their
European Shares into U.S. Shares (see paragraph (b) above).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>12.4. Holders of European
Shares in registered form will have the following options</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares that are held in registered form in the Belgian component of
the Company&rsquo;s share register in Belgium at the time of the announcement of the completion of the Share Consolidation, Mandatory ADS Exchange
and approval of the De-Listing will be European Shares. These Shares cannot be traded on (i) Euronext Brussels, unless they are converted
into European Shares in dematerialized form, and then trading on Euronext Brussels is only possible during the Transition Period, or (ii)
Nasdaq.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Shareholders would like to trade these Shares on Euronext Brussels
or Nasdaq, they will need to contact their financial intermediary or custodian. As relevant, the Shares concerned could be repositioned
directly into U.S. Shares (for trading on Nasdaq), or converted into European Shares in dematerialized form (for trading on Euronext Brussels,
whilst possible until the expiry of the Transition Period).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders should also contact their financial intermediary or custodian
to enquire the steps and timings that will be required for this process, and the costs and expenses associated with this process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>12.5. Repositioning can
be suspended</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the framework of corporate events (including Shareholders&rsquo;
meetings, and in case of payments of dividends or other distributions, or broader corporate action events, as the case may be), the Company
will need to be able to suspend the repositioning of shares for a period of time. In such case, the Company will inform its Shareholders
about such event on its website.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As mentioned above, the Company cannot guarantee how long it will take
to complete the repositioning or settlement process and recommends that Shareholders allow sufficient time for such processes to be completed
before trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>12.6 Duration of the possibility to reposition Shares</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is currently proposed that the Company will continue to support
the repositioning of Shares (from European Shares into U.S. Shares, or <I>vice versa</I>) for the foreseeable future, and that any termination
of such support will need to be announced by the Company subject to a prior notice of three months.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"><B>13.</B></TD><TD STYLE="text-align: justify"><B>You do not have a U.S. securities account. Do you have to open a U.S. securities account to reposition your European Shares into
U.S. Shares?</B></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In order to reposition your European Shares into U.S. Shares, you will
need to be able to take delivery of your U.S. Shares. This means that you either need a U.S. securities account (operated by a DTC participant)
or the ability to hold a direct registration system (&ldquo;<B>DRS</B>&rdquo;) position on the U.S. component of the share register as managed
by the U.S. Transfer Agent. Please contact your financial intermediary to make the necessary arrangements to enable you to reposition
your European Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects that Shareholders that hold European Shares in
dematerialized form with a financial intermediary or custodian will be able to reposition their European Shares into U.S. Shares without
having to open a new securities account. Shareholders should contact their financial intermediary or custodian to enquire whether they
will need to open a new securities account.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"><B>14.</B></TD><TD STYLE="text-align: justify"><B>You do not have a European securities account. Do you have to open a European securities account to reposition your U.S. Shares
into European Shares?</B></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As indicated in Question 12 above, holders of U.S. Shares will be able
to reposition their U.S. Shares into European Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To reposition your U.S. Shares into European Shares, you will need
to be able to take delivery of your European Shares. This means that you either need a European securities account or an account with
a financial institution that has an account, either directly or indirectly through one or more financial intermediaries, with Euroclear
Belgium. Please contact your financial intermediary to make the necessary arrangements to enable you to reposition your European Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders should note that after the Transition Period the European
Shares can no longer be traded on Euronext Brussels, and that the European Shares cannot be traded on Nasdaq at any time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>16.</B></TD><TD STYLE="text-align: justify"><B>What are the costs associated with the repositioning of Shares?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors must ask their financial intermediary about possible handling
fees associated with the repositioning of Shares and possible additional costs associated with holding and trading Shares listed on the
Nasdaq.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects that there will be no substantial differences in
brokerage fees and custody fees in relation to U.S. Shares as compared to European Shares prior to the De-Listing, but each Shareholder
should enquire its financial intermediary or custodian as to the costs for repositioning Shares, trading Shares and holding Shares on
a securities account.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"><B>17.</B></TD><TD STYLE="text-align: justify"><B>What, if any, are the tax consequences under Belgian law of the Transaction, including the repositioning of Shares?</B></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Belgian tax consequences of the Transaction, including the repositioning
of European Shares, are discussed in detail in section &ldquo;<I>Taxation</I>&rdquo; of the Special Report, which can be found on the Company&rsquo;s
website at mdxhealth.com/investors. Shareholders are encouraged to consult their tax advisor regarding the tax treatment of their investment
in European Shares before repositioning such Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>18.</B></TD><TD STYLE="text-align: justify"><B>When will the Shares be available to be sold on Nasdaq after
the Transaction?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">European Shares may be traded and sold on Nasdaq only after completing
the procedure for repositioning. To complete such a repositioning, please see Question 12 above. Please see also the timing for the completion
of a repositioning transaction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company expects that the U.S. Shares to be delivered to ADS Holders
as a result of the Mandatory ADS Exchange will be available to be sold on Nasdaq shortly after the effective time of the Mandatory ADS
Exchange unless the ADSs are in certificated form. ADS holders will receive a notice from the Exchange Agent in advance of the Mandatory
ADS Exchange. Such notice will provide the date of the Mandatory ADS Exchange (the &ldquo;Exchange Date&rdquo;). The Exchange Agent will
cause the U.S. Shares to be delivered to the DTC participant accounts of the financial intermediaries holding ADSs on behalf of their
clients on the Exchange Date. Processing times of each financial intermediary may vary, but the Company expects that most U.S. Shares
automatically issued to ADS holders on the Exchange Date will be available to be sold on Nasdaq on or about such date unless such ADS
are held in certificated form. Holders of certificated ADSs will need to follow the process described in question 10 above before such
U.S. Shares are available to be sold on Nasdaq.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>18.</B></TD><TD STYLE="text-align: justify"><B>Can you trade your European Shares between the date of these
FAQs and the De-Listing?</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes. European Shares will continue to trade as normal on Euronext Brussels
during this period until the end of the Transition Period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"><B>19.</B></TD><TD STYLE="text-align: justify"><B>Can you trade your ADSs between the date of these FAQs and the Mandatory ADS Exchange?</B></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes. ADSs will continue to trade as normal on Nasdaq during this period.
It is expected that trading of the ADSs on Nasdaq will cease at 4:00 pm Eastern Time on the trading day immediately preceding the Exchange
Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Administrative matters relating to Shares</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"><B>20.</B></TD><TD STYLE="text-align: justify"><B>Will there be any changes to the corporate or governance structure of the Company in connection with the proposed Transaction?</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporate structure and governing company law (Belgian law) of
the Company will not change as a result of the proposed Transaction. However, there will be changes to the corporate governance requirements,
securities laws and company law applicable to the Company as set out in detail in section &ldquo;<I>Consequences of the proposed De-Listing</I>&rdquo;
of the Special Report, which can be found on the Company&rsquo;s website at mdxhealth.com/investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>21.</B></TD><TD><B>You have further questions that are not dealt with sufficiently here &ndash; where can you find further information?</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Special Report, which can be found on the Company&rsquo;s website at
mdxhealth.com/investors, contains additional details regarding the Transaction and the Company encourages all Shareholders to read it
carefully. If you hold Shares and the Special Report does not sufficiently answer your questions, please discuss with your financial intermediary
or custodian in the first instance. If you hold ADSs, you may contact the Exchange Agent at 1-800-564-6253. The Company has also established
a helpline for retail investors available in multiple languages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt"><FONT STYLE="background-color: white"><B><I>Retail Investor
Helpline:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><FONT STYLE="background-color: white"><I>Europe: 0800
78 647 &ndash; English (09:00 &ndash; 17:00 CET)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in"><FONT STYLE="background-color: white"><I> 0 805 98 54
87 &ndash; Fran&ccedil;ais (09:00 &ndash; 17:00 CET)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in"><FONT STYLE="background-color: white"><I> 0800 0234038 &ndash;
Nederlands (09:00 &ndash; 17:00 CET)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><FONT STYLE="background-color: white"><I>United States:
844-858-7385 &ndash; English (9am &ndash; 5pm ET)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><I>&nbsp;</I></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Expected Timeline</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that the EGM approves the proposed
Share Consolidation and De-Listing, the main dates and timelines to implement the Transaction are expected to be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; width: 60%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Action</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 38%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date</B></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">Announcement of the contemplated De-Listing and convening of the EGM to approve the Share Consolidation and De-Listing </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-size: 10pt">2 October 2023</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">Approval of the Share Consolidation and De-Listing by the EGM of the Company </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-size: 10pt">3 November 2023</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">Effective date for the Share Consolidation </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">Anticipated to be approximately 9 trading days after the approval of the Share Consolidation and De-Listing by the EGM (or second EGM)</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">Termination of the ADS program and start of trading of the Shares on Nasdaq </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">Anticipated to be approximately 6 trading days following the effective date of the Share Consolidation</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">Start of the Transition Period </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">Anticipated to be upon start of trading of the Shares on Nasdaq</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left; font-size: 10pt">End of the Transition Period and end of trading of the Shares on Euronext Brussels </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt">Anticipated to be approximately 3 weeks after the start of the Transition Period, but no later than Friday 29 December 2023, at 5:30 p.m. Brussels time</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that the EGM approves the proposed Share
Consolidation and De-Listing, the Board will have the power to further amend the dates, times and periods indicated in the above timetable.
If the board of directors decides to amend such dates, times or periods, it will inform the investors by a press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the 50% attendance quorum is not reached at the
EGM, a Second EGM, where no attendance quorum applies, will be convened to approve the proposed Share Consolidation and De-Listing. The
convening of such a Second EGM will consequently entail the need for the Board to amend the timeline detailed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Glossary</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Glossary of Selected Terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The following definitions
apply throughout these FAQs unless the context requires otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 38%; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&ldquo;<B>ADS</B>&rdquo;</P></TD>
    <TD STYLE="width: 62%; text-align: justify"><FONT STYLE="font-size: 10pt">means American Depositary Shares, each representing ten Shares (prior to the Share Consolidation).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&ldquo;<B>ADS Facility</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the deposit agreement between the Company and the Depositary.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&ldquo;<B>Mandatory ADS Exchange</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means a mandatory exchange under the Company&rsquo;s ADS facility as a result of which ADS holders will receive Shares in exchange for their ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>ADS holder</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means a holder of ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Board</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the Board of Directors of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means MDxHealth SA.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>De-Listing</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the proposed de-listing of the Shares from listing and trading on the regulated market of Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Depositary</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means The Bank of New York Mellon.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>DTC</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means The Depository Trust Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>EGM</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means an extraordinary general shareholders&rsquo; meeting of the Company to be held on 3 November 2023.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Euroclear Belgium</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means Euroclear Bank S.A./N.V., an international CSD based in Belgium and part of the Euroclear Group (or any successor or assignee of it in such capacity from time to time).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Euronext Brussels</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the regulated market of Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>European Shares</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means Shares reflected in the Belgian component of the Company&rsquo;s share register.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Exchange Agent</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the Bank of New York Mellon, the Depositary of the Company&rsquo;s ADSs, or another party appointed by the Company to serve as exchange agent for purposes of the Mandatory ADS Exchange.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Exchange Date</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the date of the Mandatory ADS Exchange.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>FAQs</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means these Frequently Asked Questions, dated 2 October, 2023.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>FSMA</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the Belgian Financial Services and Markets Authority.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 45%">&nbsp;</TD><TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></TD><TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 38%"><FONT STYLE="font-size: 10pt">&ldquo;<B>U.S. IPO</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify; width: 62%"><FONT STYLE="font-size: 10pt">means the Company&rsquo;s 2021 initial public offering of ADSs in the U.S.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>ISIN</B>&rdquo; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">means the <FONT STYLE="font-family: Times New Roman, Times, Serif">International
    Securities Identification Number.</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Market Repositioning</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the repositioning of the Shares from the trading system used for trading the Shares on Euronext Brussels into the trading system used for trading the Shares on Nasdaq, which shall be subject to certain formalities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Nasdaq</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the Nasdaq Stock Market.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>PIE</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means public-interest entity.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>SEC</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the U.S. Securities and Exchange Commission.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Second EGM</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the means an extraordinary general shareholders&rsquo; meeting of the Company to be held on 23 November 2023, if needed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Share</B>&rdquo; or &ldquo;<B>Ordinary Share&rdquo;</B> </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means any outstanding share of the Company, representing the Company&rsquo;s share capital from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Share Consolidation</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the proposed share consolidation of the outstanding Shares by means of a 1-for-10 reverse stock split.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Shareholder</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means a holder of Shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Sole Listing</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means proposed transition from a dual listing of the Company&rsquo;s ADSs on Nasdaq and Ordinary Shares on Euronext Brussels to a sole listing of Ordinary Shares on Nasdaq.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Special Report</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the special report regarding the proposed share consolidation and de-listing of shares from the regulated market of Euronext Brussels. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Transaction</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the Share Consolidation, the De-Listing and the Mandatory ADS Exchange, together.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Transition Period</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the period as from the approval of the De-Listing until the last day of trading of the Shares on Euronext Brussels.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>U.S.</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the United States.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>U.S. Transfer Agent</B>&rdquo; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">means the transfer agent that will be appointed to maintain the Company&rsquo;s share register in the U.S.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD STYLE="width: 49%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Frequently Asked Questions - MDxHealth (2 Oct 2023)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>7
<FILENAME>ea186179ex99-6_mdxhealth.htm
<DESCRIPTION>CONVENING NOTICE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MDxHealth SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Limited Liability Company<BR>
(<I>soci&eacute;t&eacute; anonyme)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CAP Business Center<BR>
Zone Industrielle des Hauts-Sarts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rue d&rsquo;Abhooz 31<BR>
4040 Herstal, Belgium<BR>
VAT BE 0479.292.440 (RLP Li&egrave;ge, division Li&egrave;ge)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<DIV STYLE="padding: 1pt; border: Black 1pt solid">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INVITATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>extraordinary
G</B></FONT><B>ENERAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">to be held on Friday, 3 November 2023, at 3:00
p.m.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of securities issued by MDxHealth
SA (the &ldquo;<B>Company</B>&rdquo;) are invited to the extraordinary general shareholders&rsquo; meeting of the Company before a notary public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date, hour and venue:</B> The extraordinary
general shareholders&rsquo; meeting will be held on Friday, 3 November 2023 at 3:00 p.m. at the offices of the notary public Stijn Raes, at
Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is an attendance
quorum requirement for the items on the agenda of the extraordinary general shareholders&rsquo; meeting (see also below under &ldquo;&mdash;Extraordinary
general meeting&rdquo;). If the attendance quorum for the items on the agenda of the extraordinary general shareholders&rsquo; meeting were not
to be reached, a second extraordinary general shareholders&rsquo; meeting will be held for these items on Thursday, 23 November 2023, unless,
as the case may be, decided otherwise on behalf of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opening of the doors:</B> In order to facilitate
the keeping of the attendance list on the day of the extraordinary general shareholders&rsquo; meeting, holders of securities and their representatives
are invited to register as of 2:15 p.m.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>extraordinary</B></FONT><B>
GENERAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Agenda and proposed resolutions: </B>The agenda
and proposed resolutions of the extraordinary general shareholders&rsquo; meeting of the Company which, as the case may be, can be amended at
the meeting on behalf of the board of directors, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Submission of special report</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Submission of and discussion on, the
special report, prepared by the board of directors, in connection with the Share Consolidation and De-Listing (as defined below in points
2 and 3 of the agenda).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Share Consolidation (1-for-10 reverse stock split)</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Proposed resolution:</I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with article 7:49 of the Belgian Companies and Associations Code, the extraordinary general shareholders&rsquo; meeting decides to
effect a share consolidation with respect to all outstanding shares of the Company by means of a 1-for-10 reverse stock split (the &ldquo;<B>Share
Consolidation</B>&rdquo;), and to grant the board of directors of the Company the authority for a six-month period following the date of
this extraordinary general shareholders&rsquo; meeting to further implement the Share Consolidation. If the board of directors does not initiate
the process for implementing the Share Consolidation within a six-month period following the date of this extraordinary general shareholders&rsquo;
meeting, the board of director&rsquo;s authority to effect the Share Consolidation shall expire, unless renewed. The board of director&rsquo;s authority
to implement the Share Consolidation is subject to the following terms and conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Share Consolidation</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the outstanding shares of the Company shall be consolidated into a new and reduced number of shares pursuant to the ratio of one (1)
new share for ten (10) existing shares (the &ldquo;<B>Ratio</B>&rdquo;). Subject to the terms and conditions set out below, the Share Consolidation
will be carried out simultaneously for all outstanding shares of the Company in accordance with the Ratio, so that after the completion
of the Share Consolidation each new share shall represent the same fraction of the Company&rsquo;s share capital. The Share Consolidation will
not result in a reduction or increase of the Company&rsquo;s share capital</FONT><I>.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Form and nature of the new shares</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Share Consolidation will not affect the form of the outstanding shares (dematerialized or registered) and the outstanding dematerialized
and registered shares will be processed separately within the framework of the Share Consolidation. All new shares after the completion
of the Share Consolidation shall have the same rights and benefits and shall rank <I>pari passu</I> in all respects, including as to entitlements
to dividends and other distributions, in application of the Ratio.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>No fractions of new shares</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
the framework of the Share Consolidation, the existing shares can only be consolidated, in accordance with the Ratio, into a whole number
of new shares. No fractions of new shares can be issued. Subject to applicable company, financial and securities law rules, and subject
to the provisions of the foregoing paragraphs, the board of directors shall be authorized to determine the manner and process to effect
the Share Consolidation with respect to holders of existing shares of the Company who at the time of the Share Consolidation do not have
a sufficient number of existing shares in order to receive a whole number of new shares in accordance with the Ratio. Within this context,
the board of directors shall have the authority to determine that (i) the positions of old shares that cannot be consolidated into a whole
number of new shares in accordance with the Ratio can be aggregated for consolidation into new shares, (ii) such new shares can be sold
or placed, via an exempt private placement, block trade, market sale, bookbuilding (accelerated or not) or otherwise, to or with institutional,
qualified or professional investors or individuals in and outside of Belgium, and (iii) the proceeds of such sale or placement will be
distributed on a pro rata basis to the holders of existing shares that do not have a sufficient number of existing shares to be converted
into whole new shares in accordance with the Ratio, provided that the proceeds shall not be less than one euro cent (EUR 0.01) per existing
share. If proceeds are less or cannot be distributed on a pro rata basis as aforementioned, these shall accrue to the Company. The relevant
transaction costs and expenses (including commissions, fees and expenses of agents and advisors) and applicable taxes, all as applicable,
will be borne by the Company. Subject to applicable provisions of company, financial and securities law, the board of directors shall
also have the authority to determine that the positions of existing shares that cannot be consolidated in accordance with the Ratio into
a whole number of new shares, can be acquired by the Company or one of its subsidiaries and that the proceeds of such sale will be distributed
on a pro rata basis as aforementioned.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Cancellation of existing shares</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of the Share Consolidation, the existing shares of the Company shall be cancelled and will no longer remain outstanding<I>.
</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Timing of the Share Consolidation:</U> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors shall be authorized to determine the effective date of the Share Consolidation, provided however, that the Share Consolidation
is to be implemented within a six-month period following the date of this extraordinary general shareholders&rsquo; meeting at the latest.
The board of directors shall have the authority not to proceed with the implementation of the Share Consolidation, or, in case the implementation
of the Share Consolidation has already started, to suspend or cancel the completion of the Share Consolidation if the board of directors
determines that the market circumstances do not allow for the completion of the Share Consolidation in circumstances deemed satisfactory
to it.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Agents</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One or more banks
or financial institutions shall or may be appointed by the Company for the purpose of the further organization and implementation of the
Share Consolidation, including (but not limited to) the consolidation of positions of existing shares that cannot be consolidated into
a whole number of new shares in accordance with the Ratio, and the sale of new shares as permitted by paragraph (c).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Adjustment of the subscription price of the Subscription Rights</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
completion of the Share Consolidation, the Share Consolidation shall be effected in relation to the outstanding subscription rights of
the Company in the manner as contemplated in the respective terms and conditions of these subscription rights, so that a holder of subscription
rights will have to exercise subscription rights with respect to at least 10 Shares prior the Share Consolidation in order to subscribe
for one Share after the Share Consolidation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><U>Amendment of the articles of association</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
completion of the Share Consolidation, Article 5 of the Company&rsquo;s articles of association shall be amended and restated to take
into account the resulting number of outstanding and existing shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><U>Further implementation of the Share Consolidation:</U> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors
shall have the authority to further implement and effect the Share Consolidation, including (without being limited to) the authority to
(i) determine the practical implementation of the Share Consolidation, (ii) determine the timing and the effective date of the Share Consolidation
as contemplated by paragraph (e), (iii) determine the manner and process to deal with positions of existing shares that cannot be consolidated
into a whole number of new shares in accordance with the Ratio as contemplated by paragraph (c), (iv) appoint one or more banks or financial
institutions for the further organization and implementation of the Share Consolidation as contemplated by paragraph (f), (v) proceed
with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary
public, (vi) take all useful or necessary steps with Euronext, Euroclear, any other competent settlement agency, and any regulatory or
listing authority in connection with the implementation of the Share Consolidation, (vii) make all changes in the relevant securities
register books of the Company reflecting the Share Consolidation, and (viii) do such other things as shall be useful, appropriate or necessary
in connection with the foregoing. The board of directors shall have the authority to delegate the further implementation and execution
of the Share Consolidation (including the powers referred to in sub-sections (i) to (viii)), in whole or in part, to one or more members
of the Company&rsquo;s executive management or personnel. Any director, any member of the executive management, and any other persons that shall
be expressly appointed for such purpose by the board of directors shall be authorized to record the amendment and the restatement of the
articles of association as contemplated by paragraph (h) before a notary public.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>De-Listing from Euronext Brussels</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Proposed resolution: </I>The extraordinary
general shareholders&rsquo; meeting decides to approve a de-listing of the Company&rsquo;s shares from the regulated market of Euronext Brussels
(the &ldquo;<B>De-Listing</B>&rdquo;), to amend the Company&rsquo;s articles of association for the purpose of such De-Listing, and to grant the
board of directors of the Company the authority to further implement the De-Listing, subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>De-Listing</U>: The general shareholders&rsquo; meeting approves and agrees that the admission of the Company&rsquo;s
shares to listing and trading shall be terminated and, consequently, the Company&rsquo;s shares shall no longer be able to list and trade on
the regulated market of Euronext Brussels (&ldquo;<B>Euronext Brussels</B>&rdquo;), provided that the Company&rsquo;s shares (or, as the case
may be, American Depositary Shares or American Depositary Receipts in relation to such shares) shall be admitted to trading on the Nasdaq
Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Effective date</U>: The board of directors shall have the power to determine the effective date of
the De-Listing subject to a prior transition period of at least three weeks prior to the effective date of the De-Listing Date (the &ldquo;<B>Transition
Period</B>&rdquo;) during which the Company&rsquo;s shares shall remain admitted to trading on Euronext Brussels. If and to the extent the Share
Consolidation has been effected, the Transition Period shall at least be three weeks after the Share Consolidation has become effective.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Amendments to the articles of association</U>: Upon the effective date of the De-Listing, the following
provisions of the Company&rsquo;s articles of association of the Company shall be amended and restated as follows (except that the amendment
in paragraph (i) is effective immediately upon approval of the amendment by the extraordinary general shareholders&rsquo; meeting):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">In article 9 (&ldquo;Nature of the securities&rdquo;), the three last paragraphs shall be amended and restated
as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<I>A share register is kept at
the registered office of the company and may be split by decision of the board of directors in accordance with the provisions of the applicable
law. The board of directors can appoint a third party of its choice to keep any part of the split share register. Subject to applicable
provisions of companies, financial and securities laws, and unless decided otherwise by the board directors in accordance with article
43 of the articles of association, dividends and other distributions (as the case may be) by the company on shares can be made in euro
(EUR) or United States dollars (USD) depending on the component of the (split) share register on which the shares are reflected.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>The (split) register of registered
shares and the registers of other registered securities, as the case may be, can be kept electronically. Each holder of securities can
consult the (split) register with respect to his/her/its securities. The board of directors can appoint a third party of its choice to
keep this (split) electronic register.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>All recordings in the (split) share
register and the registers of other registered securities, including transfers and conversions, can be validly made on the basis of documents
or instructions submitted electronically or via any other means by the transferor, the transferee and/or the holder of the securities,
as applicable.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The text of article 14 (&ldquo;Transparency obligation&rdquo;) shall be amended and restated as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<I>Each natural or legal person
acquiring or transferring voting securities of the company, whether or not representing the share capital of the company, must comply
with the relevant notification and information obligations that are imposed by applicable law.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">The text of article 15 (&ldquo;Voting rights&rdquo;) shall be amended and restated as follows: &ldquo;<I>Non-compliance
with the relevant notification and information obligations that are imposed by applicable law in relation to the acquisition or transfer
of voting securities of the company, whether or not representing the share capital of the company, may result, in accordance with applicable
law, a suspension of the voting rights attached to the relevant voting securities or such other consequence as provided for by applicable
law.</I>&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">In article 32 (&ldquo;Admission &ndash; Prior formalities&rdquo;), the following paragraphs shall be added
after the first paragraph of article 32:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<I>The board of directors shall
have the ability to determine that the right to attend the general shareholders&rsquo; meetings and to exercise the voting right at such meetings
(as the case may be) is determined by the registration of the ownership of the securities concerned in the name of the holder of such
securities on the third (3rd) business day prior to the date of the relevant general shareholders&rsquo; meeting (or such other date as shall
be set out in the notice convening the general shareholders&rsquo; meeting, but which cannot be earlier than the 15th calendar date before the
relevant general shareholders&rsquo; meeting), at midnight at the end of such day (Brussels time) (such date and hour being the relevant registration
date), by means of the registration of such securities in the relevant (portion of the split) register book for such securities, or in
the accounts of a certified account holder or relevant settlement institution for the securities concerned.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt"><I>The
board of directors may make participation to the general shareholders&rsquo; meetings dependent on a requirement of notification by the securities
holders concerned to the company, or to the person appointed for this purpose by the company, on a date to be determined by the board
of directors before the date of the scheduled meeting, that such securities holder intends to attend the meeting, stating the number of
securities with which such securities holder wishes to participate. The manner in which such notification must be made (as the case may
be) must be set out in the notice convening the general shareholders&rsquo; meeting.</I></FONT>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">In article 33 (&ldquo;Representation of shareholders&rdquo;), the second paragraph shall be amended and
restated as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<I>Such proxies must be granted
and submitted to the company in accordance with the applicable law and/or as set out (in accordance with the applicable law) in the convening
notice, as the case may be.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">In article 35 (&ldquo;Adjournment of the meeting&rdquo;), the reference in the first and second paragraph
to &ldquo;<I>five (5) weeks</I>&rdquo; shall be replaced by &ldquo;<I>three (3) weeks</I>&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">The text of article 36 (&ldquo;Decisions on matters not on the agenda - Amendments&rdquo;) shall be amended
and restated as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<I>The general shareholders&rsquo; meeting
cannot validly deliberate or decide on the items that are not included or implicitly contained in the agenda, unless all shareholders
are present or represented at the meeting and unanimously agree and if, in the case of a vote by mail, the form authorises a proxy to
make such a decision. The required consent is assumed to exist, if no objection is recorded in the minutes of the meeting.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">In article 39 (&ldquo;Remote voting or participation&rdquo;) the reference to &ldquo;<I>sixth calendar day</I>&rdquo;
shall be replaced by &ldquo;<I>third business day</I>&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ix)</TD><TD STYLE="text-align: justify">The heading of article 51 shall be amended and restated as &ldquo;<I>Certain defined terms</I>&rdquo;, and
the text of article 51 shall be amended and restated as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<I>Unless the context requires
otherwise or unless otherwise defined in these articles of association, for the purposes of these articles of association, (a)&nbsp;&ldquo;personnel&rdquo;
shall have the meaning defined in Article 1:27 of the Belgian Companies and Associations Code, and (b)&nbsp;&ldquo;business day&rdquo; shall
have the meaning defined in Article 1:32 of the Belgian Companies and Associations Code.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Further implementation of the De-Listing</U>: Subject to applicable company, financial and securities
law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall have the authority to further implement
and effect the De-Listing, including (without being limited to) the authority to (i) determine the practical implementation of the De-Listing,
(ii) determine the timing and the effective date of the De-Listing and the duration of the Transition Period, (iii) determine the manner
and process for the shares (or, as the case may be, American Depositary Shares or American Depositary Receipts in relation to such shares)
to be traded on Nasdaq, (iv) appoint one or more banks or financial institutions for the further organization and implementation of the
De-Listing, (v) proceed with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph
(c) before a notary public, (vi) take all useful or necessary steps with Euronext, Euroclear, any other competent settlement agency, and
any regulatory or listing authority in connection with the implementation of the De-Listing, and (vii) do such other things as shall be
useful, appropriate or necessary in connection with the foregoing. The board of directors shall have the authority to delegate the further
implementation and execution of the De-Listing (including the powers referred to in sub-sections (i) to (vii)), in whole or in part, to
one or more members of the Company&rsquo;s executive management or personnel. Any director, any member of the executive management, and any
other persons that shall be expressly appointed for such purpose by the board of directors shall be authorized to record the amendment
and the restatement of the articles of association as contemplated by paragraph (c) before a notary public.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Attendance quorum:</B> According to the Belgian
Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the
extraordinary general shareholders&rsquo; meeting for the deliberation and voting on the items of the aforementioned agenda of the extraordinary
general shareholders&rsquo; meeting. If such attendance quorum is not reached, a second extraordinary general shareholders&rsquo; meeting will be
convened for these agenda items, unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance
quorum requirement will not apply to such second meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting and majority:</B> Subject to applicable
legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned
agenda of the extraordinary general shareholders&rsquo; meeting shall be passed if they are approved by a majority of 75% of the votes validly
cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights
have the right to participate to the extraordinary general shareholders&rsquo; meeting, but only with an advisory vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Participation
to the meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Introduction: </B>Holders of securities issued
by the Company who wish to participate to the extraordinary general shareholders&rsquo; meeting of the Company should take into account the
formalities and procedures described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration date</B>: The registration date
for the extraordinary general shareholders&rsquo; meeting shall be Friday, 20 October 2023, at midnight (12:00 a.m., Belgian time). Only persons
owning securities issued by the Company on Friday, 20 October 2023, at midnight (12:00 a.m., Belgian time) shall be entitled to participate
to, and, as the case may be, vote at the extraordinary general shareholders&rsquo; meeting. Only shareholders are entitled to vote. The holders
of subscription rights can participate to the extraordinary general shareholders&rsquo; meeting but only with an advisory vote. Shareholders,
as well as holders of subscription rights must satisfy the formalities that are described under &ldquo;&mdash;Participation to the meeting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participation to the meeting</B>: In order
to be able to participate to the extraordinary general meeting, a holder of securities issued by the Company must satisfy two conditions:
(a)&nbsp;be registered as holder of such securities on the registration date, and (b)&nbsp;notify the Company, as described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><I>Registration</I>: Firstly, the right for a holder of securities issued by the Company to participate
to and, as applicable, to vote at the extraordinary general shareholders&rsquo; meeting is only granted on the basis of the registration of
the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the
securities concerned (for registered securities) or in the accounts of a certified account holder or relevant settlement institution for
the securities concerned (for dematerialised shares).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><I>(b)</I></TD><TD STYLE="text-align: justify"><I>Notification</I>: Secondly, in order to participate to the extraordinary general shareholders&rsquo; meeting,
the holders of securities issued by the Company must notify the Company whether they want to participate to the meeting and must do so
prior to or at the latest on Saturday, 28 October 2023. The holders of securities who wish to make such notification can make use of the
attendance form that can be obtained at the Company&rsquo;s registered office and on the Company&rsquo;s website (http://www.mdxhealth.com). The notice
must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz
31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior
to the extraordinary general shareholders&rsquo; meeting, i.e., on or before Saturday, 28 October 2023 at the latest. For the holders of dematerialised
securities, the notification should include a certificate confirming the number of securities that have been registered in their name
on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder,
the applicable settlement institution, or the relevant financial intermediary for the securities concerned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting by mail: </B>The shareholders can vote
by mail in accordance with article 39 of the Company&rsquo;s articles of association. Votes by mail must be cast by means of the form prepared
by the Company. The voting by mail form can be obtained on the Company&rsquo;s website (http://www.mdxhealth.com). The voting by mail form must
be signed in writing or electronically. The electronic signature must be a qualified electronic signature in the sense of Regulation (EU)
No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic
transactions in the internal market and repealing Directive 1999/93/EC, as amended. Signed voting by mail forms must reach the Company
by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal,
Belgium, Attention: Mr. Ron Kalfus), or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the extraordinary
general shareholders&rsquo; meeting, i.e., on or before Saturday, 28 October 2023 at the latest. Holders of securities who wish to vote by mail
must in any case comply with the formalities to participate to the meeting as explained under &ldquo;&mdash;Participation to the meeting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Representation by proxy:</B> The holders of
securities can participate to the meeting and vote, as applicable, through a written proxy, as the case may be, to the chair of the board
of directors. Written proxy must contain specific voting instructions for each proposed resolution. Proxy forms can be obtained on the
Company&rsquo;s website (http://www.mdxhealth.com). The proxy must be signed in writing or electronically. The electronic signature must meet
the same requirements as the electronic signature for the voting by mail form (see also &ldquo;&mdash;Voting by mail&rdquo;). Signed proxies
must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz
31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior
to the extraordinary general shareholders&rsquo; meeting, i.e., on or before Saturday, 28 October 2023 at the latest. The appointment of a proxy
holder must be made in accordance with the applicable rules of Belgian law, including in relation to conflicts of interests and the keeping
of a register. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities to participate
to the meeting, as explained under &ldquo;&mdash;Participation to the meeting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendments to the agenda and additional proposed
resolutions</B>: Shareholders who alone or together with other shareholders hold at least 3% of the share capital of the Company have
the right to put additional items on the agenda of the extraordinary general shareholders&rsquo; meeting and to table draft resolutions in relation
to items that have been or are to be included in the agenda. If the required attendance quorum for the items on the agenda of the extraordinary
general shareholders&rsquo; meeting is not reached and a second extraordinary general shareholders&rsquo; meeting is convened to deliberate and vote
on such items, this right will not apply in relation to the agenda of the second extraordinary general shareholders&rsquo; meeting. Shareholders
that wish to exercise this right must prove on the date of their request that they own at least 3% of the outstanding shares. The ownership
must be based, for dematerialised shares, on a certificate issued by the applicable settlement institution for the securities concerned,
or by a certified account holder, confirming the number of securities that have been registered in the name of the relevant shareholders,
and, for registered shares, on a certificate of registration of the relevant shares in the share register book of the Company. In addition,
the shareholders concerned must, in any case, comply with the formalities to participate to the meeting, as explained under &ldquo;&mdash;Participation
to the meeting&rdquo;, with at least 3% of the outstanding shares. A request to put additional items on the agenda and/or to table draft
resolutions must be submitted in writing, and must contain, in the event of an additional agenda item, the text of the agenda item concerned
and, in the event of a draft resolution, the text of the draft resolution. The request must also mention the mail or e-mail address to
which the Company will send the confirmation of receipt of the request. The request must reach the Company by mail at its registered office
(CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail
at agsm@mdxhealth.com at the latest on the twenty-second calendar day prior to the extraordinary general shareholders&rsquo; meeting, i.e.,
on or before Thursday, 12 October&nbsp;2023 at the latest. In case of amendments to the agenda and proposed additional resolutions as
aforementioned, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions
no later than on the fifteenth calendar day prior to the extraordinary general shareholders&rsquo; meeting, i.e., on or before Thursday, 19
October 2023 at the latest. In addition, the Company shall make amended forms available for votes by proxy. Proxies that reach the Company
prior to the publication of an amended agenda remain valid for the agenda items to which the proxies apply, subject, however, to applicable
law and the further clarifications set out on the proxy forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right to ask questions</B>: Each holder of
securities issued by the Company has the right to ask questions to the directors and the statutory auditor related to items on the agenda
of a general shareholders&rsquo; meeting. Questions can be asked during the meeting or can be submitted in writing prior to the meeting. Written
questions must reach the Company by mail at its registered office (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz
31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com at the latest on the sixth calendar day prior
to the extraordinary general shareholders&rsquo; meeting, i.e., on or before Saturday, 28 October 2023 at the latest. Answers to written questions
will be provided in writing and will be published on the Company&rsquo;s website (http://www.mdxhealth.com) on or before Friday, 3 November
2023 at the latest, but before the vote on items on the agenda of the meeting concerned in accordance with applicable law. Oral questions
will be answered during the meeting concerned in accordance with applicable law. In addition, in order for written questions to be considered,
the holders of securities issued by the Company who submitted the written questions concerned must comply with the formalities to participate
to the meeting, as explained under &ldquo;&mdash;Participation to the meeting&rdquo; and/or under &ldquo;&mdash;Voting by mail&rdquo; or &ldquo;&mdash;Representation
by proxy&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to the meeting room</B>: The natural
persons who attend the extraordinary general shareholders&rsquo; meeting in their capacity as owner of securities, holder of proxies or representative
of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what
is shared above under &ldquo;&mdash;General information&rdquo;). In addition, the representatives of legal entities must hand over the documents
establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start
of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation &ndash; For
informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recommendation to use e-mail:</B> The Company
recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders&rsquo; meeting.
The Company&rsquo;s e-mail address for such communication is: agsm@mdxhealth.com. The Company also points at that, in addition to be physically
available at the Company&rsquo;s registered office and distributed by mail, all forms and other documentation in relation to the general shareholders&rsquo;
meeting will be available on the Company&rsquo;s website (http://www.mdxhealth.com). See also &ldquo;&mdash;Available documentation&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Data
Protection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Th</FONT>e Company
is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and
proxy holders in the context of general shareholders&rsquo; meeting. The processing of such data will be carried out for the purposes of the
organisation and conduct of the relevant general shareholders&rsquo; meeting, including the convening notices, registrations, participation
and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base
of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued
by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or
services to the Company in connection with the foregoing. The processing of such data will be carried out, <I>mutatis mutandis</I>, in
accordance with the Company&rsquo;s Privacy Policy, available on the Company&rsquo;s website (https://mdxhealth.com/privacy-policy). The Company draws
the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data
subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in
the aforementioned Privacy Policy. All this does not affect the rules that apply in connection with the registration and participation
to the general shareholders&rsquo; meeting. To exercise rights as a data subject and for all other information regarding the processing of personal
data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>available
documentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documentation is available on the
Company&rsquo;s website (http://www.mdxhealth.com): the notice convening the extraordinary general shareholders&rsquo; meeting, updates of the agenda
and proposed resolutions, in case of amendments to the agenda and proposed resolutions, the documents to be submitted to the extraordinary
general shareholders&rsquo; meeting as referred to in the agenda of the meeting, the attendance form, the voting by mail form, and the proxy
form. Prior to the extraordinary general shareholders&rsquo; meeting, holders of securities of the Company can also obtain at the registered
office of the Company (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium), free of cost,
a copy of this documentation. The aforementioned website also mentions the total number of outstanding shares and voting rights of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please address any correspondence on this matter
to MDxHealth SA, Mr. Ron Kalfus CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium. The facsimile
number is +32&nbsp;(0)4&nbsp;259 78 75 and the e-mail address is agsm@mdxhealth.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of the board of directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">This document
is not an offer to sell or a solicitation of an offer to buy shares or other securities of mdxhealth sa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>8
<FILENAME>ea186179ex99-7_mdxhealth.htm
<DESCRIPTION>ATTENDANCE FORM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MDxHealth SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Limited Liability Company<BR>
(<I>soci&eacute;t&eacute; anonyme</I>)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CAP Business Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Zone Industrielle des Hauts-Sarts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rue d&rsquo;Abhooz 31<BR>
4040 Herstal, Belgium<BR>
VAT BE 0479.292.440 (RLP Li&egrave;ge, division Li&egrave;ge)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ATTENDANCE FORM FOR SECURITY HOLDERS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Extraordinary
    General Meeting</B></FONT><B><BR>
    </B>to be held on Friday, 3 November 2023, at 3:00 p.m. (Belgian time)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; border: Black 1pt solid; width: 100%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This attendance form should be used by holders
    of securities of MDxHealth SA (the &ldquo;<B>Company</B>&rdquo;) who want to attend the extraordinary general shareholders&rsquo; meeting in person.
    More information regarding the requirements for, and the modalities of, participation in the meeting can be found in the convening notice
    of the extraordinary general shareholders&rsquo; meeting.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The signed and completed form must reach the Company
    at the latest on the sixth calendar day prior to the extraordinary general shareholders&rsquo; meeting, <I>i</I>.e., <B><U>on or before Saturday,
    28&nbsp;October&nbsp;2023</U></B> at the latest, by mail to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">MDxHealth SA<BR>
    Attention Mr. Ron Kalfus<BR>
    Company Secretary</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CAP Business Center</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Zone Industrielle des Hauts-Sarts<BR>
    Rue d&rsquo;Abhooz, 31<BR>
    4040 Herstal,<BR>
    Belgium</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">or by e-mail to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">agsm@mdxhealth.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The deadline
    for the submission of this notification to attend the meeting is on a Saturday, during which there is usually no ordinary postal service.
    Therefore, the use of e-mail is strongly encouraged.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Holders of dematerialised
    securities must attach to the present form a certificate issued by the certified account holder, the applicable settlement institution,
    or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in
    their name on the registration date (i.e., Friday, 20&nbsp;October&nbsp;2023, at midnight (12:00 a.m., Belgian time)), with which they
    want to participate to the extraordinary general shareholders&rsquo; meeting.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Extraordinary General Shareholders&rsquo; Meeting of MDxHealth SA - Attendance
form for security holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First Name:</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 58%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family Name:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate name:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate form:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered office:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Represented by (first name, family name and capacity):</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">owner of the following number of securities issued
by MDxHealth SA, with registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0in auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Number of shares)</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0in auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Number of subscription rights)<SUP>(1)</SUP></I></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Note:</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders&rsquo; meeting, but only with an advisory vote.</I></FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hereby notifies his/her/its intent to attend the
extraordinary general shareholders&rsquo; meeting of MDxhealth&nbsp;SA to be held on Friday, 3 November 2023, at 3:00 p.m. (Belgian time) at
the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place indicated at that
place at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned agrees that the English translation
of the present attendance form is a free translation and for information purposes only, and that the French version shall prevail over
the English translation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby confirms that the Company
can send all confirmations and information required for participation in the extraordinary general shareholders&rsquo; meeting to the
following e-mail address of the undersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0in auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(E-mail address of security holder)</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">Done at ________________________,
on____________________2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 5%">Signature&nbsp;&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Extraordinary General Shareholders&rsquo; Meeting of MDxHealth SA - Attendance
form for security holders</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>9
<FILENAME>ea186179ex99-8_mdxhealth.htm
<DESCRIPTION>PROXY FORM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 99.8</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E6E6E6">

    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; vertical-align: top; text-align: justify; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Assembl&Eacute;e
                                            g&Eacute;n&Eacute;rale extraordinaire des Actionnaires</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3
    novembre 2023</B></FONT></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; vertical-align: top; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>extraordinary
    general shareholders&rsquo; meeting <BR>
    3 NOVEMBER 2023</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; vertical-align: top; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Procuration</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; vertical-align: top; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Proxy</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cette
    procuration doit &ecirc;tre utilis&eacute;e par les titulaires de titres de MDxHealth&nbsp;SA (la &ldquo;<B>Soci&eacute;t&eacute;</B>&rdquo;)
    qui d&eacute;sirent &ecirc;tre repr&eacute;sent&eacute;s par un mandataire sp&eacute;cial &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
    extraordinaire des actionnaires de la Soci&eacute;t&eacute; &agrave; tenir le vendredi 3 novembre 2023 &agrave; 15h00 (heure belge).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    proxy should be used by holders of securities of MDxHealth SA (the &ldquo;<B>Company</B>&rdquo;) who want to be represented by a proxy
    holder at the extraordinary general shareholders&rsquo; meeting of the Company to be held on Friday, 3 November 2023, at 3:00 p.m. (Belgian
    time).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cette
    procuration ne constitue pas une demande de procuration au sens des articles 7:144 et 7:145 du Code des soci&eacute;t&eacute;s et
    des associations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    proxy does not constitute a proxy solicitation in the sense of articles 7:144 and 7:145 of the Belgian Companies and Associations
    Code.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">La
    procuration doit &ecirc;tre sign&eacute;e de fa&ccedil;on &eacute;crite ou &eacute;lectroniquement. Si une signature &eacute;lectronique
    est utilis&eacute;e, elle doit &ecirc;tre une signature &eacute;lectronique qualifi&eacute;e au sens du R&egrave;glement (UE) n&deg;
    910/2014 du Parlement europ&eacute;en et du Conseil du 23 juillet 2014 sur l&rsquo;identification &eacute;lectronique et les services de
    confiance pour les transactions &eacute;lectroniques au sein du march&eacute; int&eacute;rieur et abrogeant la directive 1999/93/CE,
    tel que modifi&eacute;.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proxy must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic
    signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic
    identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">La
    procuration sign&eacute;e et compl&eacute;t&eacute;e doit parvenir &agrave; la Soci&eacute;t&eacute; au plus tard le sixi&egrave;me
    jour calendrier qui pr&eacute;c&egrave;de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, soit <B><U>le,
    ou avant le, samedi 28 octobre 2023</U></B> au plus tard. Jusqu&rsquo;&agrave; cette date, les procurations peuvent &ecirc;tre envoy&eacute;es
    &agrave; l&rsquo;adresse suivante&nbsp;:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    signed and completed proxy must reach the Company at the latest on the sixth calendar day prior to the extraordinary general shareholders&rsquo;
    meeting, i.e. <B><U>on or before Saturday, 28 October 2023</U></B> at the latest. Until this date, proxies can be sent to the following
    address:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDxHealth
    SA<BR>
    A l&rsquo;attention de M. Ron Kalfus<BR>
    Secr&eacute;taire de la Soci&eacute;t&eacute;<BR>
    CAP Business Center <BR>
    Zone Industrielle des Hauts-Sarts<BR>
    Rue d&rsquo;Abhooz 31,<BR>
    4040 Herstal <BR>
Belgiqu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 4pt; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDxHealth
                                            SA<BR>
                                            Attention Mr. Ron Kalfus<BR>
                                            Company Secretary <BR>
                                            CAP Business Center <BR>
                                            Zone Industrielle des Hauts-Sarts<BR>
                                            Rue d&rsquo;Abhooz, 31<BR>
                                            4040 Herstal,<BR>
                                            Belgium&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ou
    par courrier &eacute;lectronique &agrave;&nbsp;:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
    by e-mail to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agsm@mdxhealth.com</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agsm@mdxhealth.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Les
    titulaires de titres de la Soci&eacute;t&eacute; qui d&eacute;sirent &ecirc;tre repr&eacute;sent&eacute;s par procuration doivent
    aussi s&rsquo;enregistrer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, tel que d&eacute;crit dans
    l&rsquo;invitation &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires. Les titulaires de titres d&eacute;mat&eacute;rialis&eacute;s
    doivent joindre &agrave; ce formulaire un certificat d&eacute;livr&eacute; par le teneur de compte agr&eacute;&eacute;, l&rsquo;organisme
    de liquidation comp&eacute;tent, ou de l&rsquo;interm&eacute;diaire financier pour les titres concern&eacute;s, confirmant le nombre de
    titres ayant &eacute;t&eacute; enregistr&eacute;s &agrave; leur nom &agrave; la date d&rsquo;enregistrement (soit le vendredi 20 octobre
    2023, &agrave; minuit (00h00, heure belge)) et avec lesquelles ils veulent participer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
    extraordinaire des actionnaires.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
    of securities of the Company who wish to be represented by proxy must also register for the extraordinary general shareholders&rsquo; meeting,
    as described in the notice convening the extraordinary general shareholders&rsquo; meeting. Holders of dematerialised securities must attach
    to the present form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant
    financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name
    on the registration date, (i.e., Friday, 20 October 2023, at midnight (12:00 a.m., Belgian time)) with which they want to participate
    to the extraordinary general shareholders&rsquo; meeting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">En
    cas de modification de l&rsquo;ordre du jour ou si des nouvelles propositions de r&eacute;solutions sont d&eacute;pos&eacute;es, la Soci&eacute;t&eacute;
    publiera un ordre du jour compl&eacute;t&eacute; avec, le cas &eacute;ch&eacute;ant, des points additionnels inscrits &agrave; l&rsquo;ordre
    du jour et des propositions de r&eacute;solutions additionnelles. Ceci sera fait au plus tard le quinzi&egrave;me jour calendrier
    avant l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, soit le, ou avant le, jeudi 19 octobre 2023 au plus
    tard. En outre, la Soci&eacute;t&eacute; mettra aussi &agrave; disposition un formulaire de vote par procuration modifi&eacute;.
    Les procurations qui parviennent &agrave; la Soci&eacute;t&eacute; ant&eacute;rieurement &agrave; la publication d&rsquo;un ordre du jour
    compl&eacute;t&eacute; demeurent valides pour les points inscrits &agrave; l&rsquo;ordre du jour auxquels les procurations s&rsquo;appliquent,
    sous r&eacute;serve, cependant, du droit applicable et des clarifications compl&eacute;mentaires d&eacute;crites dans les formulaires
    de procuration.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    case of amendments to the agenda or if new draft resolutions are tabled, the Company will publish an amended agenda with, as the
    case may be, additional agenda items and additional draft resolutions. This will be done no later than on the fifteenth calendar
    day prior to the extraordinary general shareholders&rsquo; meeting, i.e. on or before Thursday, 19 October 2023 at the latest. In addition,
    the Company will also make amended forms available for votes by proxy. Proxies that reach the Company prior to the publication of
    an amended agenda remain valid for the agenda items to which the proxies apply, subject, however, to applicable law and the further
    clarifications set out on the proxy form.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">La
    date limite pour la communication de cette procuration est un samedi, pendant laquelle il n&rsquo;y a g&eacute;n&eacute;ralement pas de
    service postal ordinaire. Ainsi, la Soci&eacute;t&eacute; recommande d&rsquo;utiliser le courrier &eacute;lectronique pour toute communication
    avec la Soci&eacute;t&eacute; concernant l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale d&rsquo;actionnaires.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    deadline for the submission of this proxy form is on a Saturday, during which there is usually no ordinary postal service. Therefore,
    the Company recommends to use e-mail for all communication with the Company regarding the general shareholders&rsquo; meeting.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Le/La
    soussign&eacute;(e),</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned,</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pr&eacute;nom
    / First name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nom
    de famille / Family name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adresse
    / Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ou
    / or</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D&eacute;nomination
    / Corporate name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forme
    juridique / Corporate form:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Si&egrave;ge
    / Registered office:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repr&eacute;sent&eacute;
    par (pr&eacute;nom, nom de famille et qualit&eacute;) / Represented by (first name, family name and capacity):</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">titulaire
    du (des) nombre(s) suivant(s) de titres &eacute;mis par MDxHealth SA, ayant son si&egrave;ge au CAP Business Center, Zone Industrielle
    des Hauts-Sarts, Rue d&rsquo;Abhooz 31, 4040 Herstal, Belgique,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">owner
    of the following number of securities issued by MDxHealth SA, with its registered office at CAP Business Center, Zone Industrielle
    des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nombre
    d&rsquo;actions / Number of shares:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">______________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forme
    des actions susmentionn&eacute;es / Form of the above mentioned shares:<BR>
    <I>(veuillez cocher la case appropri&eacute;e / please tick the appropriate box)</I> <BR></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    Nominatives / Registered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    D&eacute;mat&eacute;rialis&eacute;es / Dematerialised</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nombre
    de droits de souscription /<BR>
    Number of subscription rights:<SUP>1</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">______________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">constitue
    pour mandataire sp&eacute;cial, avec pouvoir de substitution:<SUP>&nbsp;&nbsp;</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appoints
    as his/her/its proxy holder, with power of substitution: </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
M./Mme / Mr./Ms.__________________________________________________________<SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
Pr&eacute;sident du conseil d&rsquo;administration / Chair of the board of directors<SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify; text-indent: -2.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>1
                                            </SUP>Conform&eacute;ment &agrave; l&rsquo;article 7:135 du Code des soci&eacute;t&eacute;s et
                                            des associations, les titulaires de droits de souscription ont le droit de participer &agrave;
                                            l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires mais seulement avec voix consultative.</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify; text-indent: -2.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify; text-indent: -2.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>2
    </SUP>Veuillez compl&eacute;ter tel qu&rsquo;appropri&eacute;. Une absence d&rsquo;instruction sera interpr&eacute;t&eacute;e comme une nomination
    du pr&eacute;sident du conseil d&rsquo;administration en tant que mandataire.</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>1
                                            </SUP>Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders
                                            of subscription rights have the right to attend the shareholders&rsquo; meeting, but only with
                                            an advisory vote.</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>2
    </SUP>Please complete as appropriate. An absence of instruction shall be tantamount to an appointment of the chair of the board of
    directors as proxy holder.</I></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>3
    </SUP>Le pr&eacute;sident du conseil d&rsquo;administration de la Soci&eacute;t&eacute; a le pouvoir de nommer un autre administrateur,
    un employ&eacute; ou rempla&ccedil;ant d&eacute;sign&eacute; de la Soci&eacute;t&eacute; comme suppl&eacute;ant en vertu d&rsquo;une sous-d&eacute;l&eacute;gation
    si le pr&eacute;sident est emp&ecirc;ch&eacute; d&rsquo;assister &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires. Veuillez
    noter que le pr&eacute;sident du conseil d&rsquo;administration de la Soci&eacute;t&eacute; ou, le cas &eacute;ch&eacute;ant, son suppl&eacute;ant,
    est un administrateur, un employ&eacute; ou un rempla&ccedil;ant d&eacute;sign&eacute; de la Soci&eacute;t&eacute; et a donc un conflit
    d&rsquo;int&eacute;r&ecirc;ts potentiel tel que d&eacute;fini dans l&rsquo;article 7:143, &sect;4 du Code des soci&eacute;t&eacute;s et des associations.
    Le pr&eacute;sident ou son suppl&eacute;ant ne vote qu&rsquo;en ex&eacute;cution de la procuration, conform&eacute;ment aux instructions
    de vote sp&eacute;cifiques figurant dans la procuration. Voir &eacute;galement la note 2 ci-dessous.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>3
    </SUP>The chair of the board of directors of the Company has the power to appoint another director, employee or substitute of the
    Company as a substitute pursuant to a sub delegation if the chair is hindered to attend the general shareholders&rsquo; meeting. Please
    note that the chair of the board of directors of the Company or, as the case may be, his substitute, is a director, employee or substitute
    of the Company and therefore has a potential conflict of interest as defined in article 7:143, &sect;4 of the Belgian Companies and
    Associations Code. The chair or his substitute may only vote in execution of the proxy, in accordance with the specific voting instructions
    included in the proxy. See also note 2 below.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lequel
    accepte ainsi d&rsquo;&ecirc;tre nomm&eacute;, et &agrave; qui le/la soussign&eacute;(e) donne les pouvoirs et instructions de vote sp&eacute;cifiques
    suivants:<SUP>4</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">who
                                            agrees to be so appointed, and to whom the undersigned gives the following powers and specific
                                            voting instructions:<SUP>4</SUP></FONT></P></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>4
                                            </SUP>Veuillez indiquer l&rsquo;instruction de vote dans les cases appropri&eacute;es pour les
                                            points &agrave; l&rsquo;ordre du jour. En l&rsquo;absence d&rsquo;une instruction de vote pour un point de
                                            l&rsquo;ordre du jour, ou dans le cas o&ugrave;, pour quelque raison que ce soit, il y aurait un
                                            manque de clart&eacute; concernant les instructions de vote, le mandataire sera pr&eacute;sum&eacute;
                                            avoir vot&eacute; &ldquo;en faveur&rdquo; des r&eacute;solutions propos&eacute;es soutenues
                                            par le conseil d&rsquo;administration et cela sera consid&eacute;r&eacute; comme une instruction
                                            de vote sp&eacute;cifique au sens de l&rsquo;article 7:143 &sect;4 2&deg; du Code des soci&eacute;t&eacute;s
                                            et des associations.</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>&nbsp;</SUP></I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>4
    </SUP>Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence of voting instructions
    for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions,
    the proxy holder will be presumed to have voted &ldquo;in favour&rdquo; of the proposed resolutions supported by the board of directors
    and that this will be deemed to be a specific voting instruction in the sense of article 7:143 &sect;4 2&deg; of the Belgian Companies
    and Associations Code.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.&nbsp;&nbsp;
    </B>De repr&eacute;senter le/la soussign&eacute;(e) &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires
    &agrave; tenir le vendredi 3 novembre 2023 &agrave; 15h00 (heure belge), dans les bureaux de Ma&icirc;tre Stijn Raes, notaire, &agrave;
    Kortrijksesteenweg 1147, 9051 Gand, Belgique, ou &agrave; tout autre endroit qui sera indiqu&eacute; &agrave; cette occasion.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.
    </B>To represent the undersigned at the extraordinary general meeting of shareholders to be held on Friday, 3 November 2023 at 3:00
    p.m. (Belgian time), at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such
    place as will be indicated at that place at that time.</FONT></TD></TR>

  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 4pt; padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ORDRE
                                            DU JOUR</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>assembl&eacute;e
    g&eacute;n&eacute;rale extraordinaire</B></FONT></P></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>agenda</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>extraordinary
    general meeting</B></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    &nbsp;&nbsp;&nbsp;<U>Pr&eacute;sentation du rapport sp&eacute;cial</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    &nbsp; <U>Submission of special report</U>&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pr&eacute;sentation
                                            et discussion du rapport sp&eacute;cial, r&eacute;dig&eacute; par le conseil d&rsquo;administration,
                                            dans le cadre du Regroupement d&rsquo;Actions et de la Radiation de la Cote (telles que d&eacute;finies
                                            aux points 2 et 3 de l&rsquo;ordre du jour).</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
                                            of and discussion on, the special report, prepared by the board of directors, in connection
                                            with the Share Consolidation and De-Listing (as defined below in points 2 and 3 of the agenda).</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
&nbsp;&nbsp;&nbsp;<U>Regroupement d&rsquo;Actions (sur la base d&rsquo;un ratio de 1 pour 10)</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    &nbsp; <U>Share Consolidation (1-for-10 reverse stock split)</U></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;
    <U>Proposition de r&eacute;solution</U></I></B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658;
    <U>Proposed resolution</U></I></B>:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conform&eacute;ment
                                            &agrave; l&rsquo;article 7:49 du Code des soci&eacute;t&eacute;s et des associations, l&rsquo;assembl&eacute;e
                                            g&eacute;n&eacute;rale extraordinaire des actionnaires d&eacute;cide d&rsquo;effectuer un regroupement
                                            d&rsquo;actions concernant toutes les actions en circulation de la Soci&eacute;t&eacute; au moyen
                                            d&rsquo;un regroupement d&rsquo;actions sur la base d&rsquo;un ratio de 1 pour 10 (le &ldquo;<B>Regroupement
                                            d&rsquo;Actions</B>&rdquo;), et d&rsquo;accorder au conseil d&rsquo;administration de la Soci&eacute;t&eacute;,
                                            pour une p&eacute;riode de six mois suivant la date de cette assembl&eacute;e g&eacute;n&eacute;rale
                                            extraordinaire des actionnaires, l&rsquo;autorisation de poursuivre la mise en &oelig;uvre du Regroupement
                                            d&rsquo;Actions. Si le conseil d&rsquo;administration n&rsquo;entame pas la proc&eacute;dure de mise en &oelig;uvre
                                            du Regroupement d&rsquo;Actions dans un d&eacute;lai de six mois &agrave; compter de la date de
                                            la pr&eacute;sente assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires,
                                            le pouvoir du conseil d&rsquo;administration d&rsquo;effectuer le Regroupement d&rsquo;Actions expirera, &agrave;
                                            moins qu&rsquo;il ne soit renouvel&eacute;. Le pouvoir du conseil d&rsquo;administration de mettre en
                                            &oelig;uvre le Regroupement d&rsquo;Actions est soumis aux conditions suivantes :</FONT></P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">In
                                            accordance with article 7:49 of the Belgian Companies and Associations Code, the extraordinary
                                            general shareholders&rsquo; meeting decides to effect a share consolidation with respect to all
                                            outstanding shares of the Company by means of a 1-for-10 reverse stock split (the &ldquo;<B>Share
                                            Consolidation</B>&rdquo;), and to grant the board of directors of the Company the authority
                                            for a six-month period following the date of this extraordinary general shareholders&rsquo; meeting
                                            to further implement the Share Consolidation. If the board of directors does not initiate
                                            the process for implementing the Share Consolidation within a six-month period following
                                            the date of this extraordinary general shareholders&rsquo; meeting, the board of director&rsquo;s authority
                                            to effect the Share Consolidation shall expire, unless renewed. The board of director&rsquo;s authority
                                            to implement the Share Consolidation is subject to the following terms and conditions:</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
    <U>&nbsp;Regroupement d&rsquo;Actions: </U>Toutes les actions en circulation de la Soci&eacute;t&eacute; seront regroup&eacute;es en un nombre
    nouveau et r&eacute;duit d&rsquo;actions selon le ratio d&rsquo;une (1) nouvelle action pour dix (10) actions existantes (le &ldquo;<B>Ratio</B>&rdquo;).
    Sous r&eacute;serve des conditions &eacute;nonc&eacute;es ci-dessous, le Regroupement d&rsquo;Actions sera effectu&eacute; simultan&eacute;ment
    pour toutes les actions en circulation de la Soci&eacute;t&eacute; conform&eacute;ment au Ratio, de sorte qu&rsquo;apr&egrave;s l&rsquo;ach&egrave;vement
    du processus de Regroupement d&rsquo;Actions, chaque nouvelle action repr&eacute;sentera la m&ecirc;me fraction du capital de la Soci&eacute;t&eacute;.
    Le Regroupement d&rsquo;Actions n&rsquo;entra&icirc;nera pas de r&eacute;duction ou d&rsquo;augmentation du capital de la Soci&eacute;t&eacute;.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;<U>Share Consolidation</U>: All of the outstanding shares of the Company shall be consolidated into a new and reduced number of shares
pursuant to the ratio of one (1) new share for ten (10) existing shares (the &ldquo;<B>Ratio</B>&rdquo;). Subject to the terms and conditions
set out below, the Share Consolidation will be carried out simultaneously for all outstanding shares of the Company in accordance with
the Ratio, so that after the completion of the Share Consolidation each new share shall represent the same fraction of the Company&rsquo;s
share capital. The Share Consolidation will not result in a reduction or increase of the Company&rsquo;s share capital.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;<U>Forme
et nature des nouvelles actions:</U> Le Regroupement d&rsquo;Actions n&rsquo;affectera pas la forme des actions en circulation (d&eacute;mat&eacute;rialis&eacute;es
ou nominatives) et les actions d&eacute;mat&eacute;rialis&eacute;es et nominatives en circulation seront trait&eacute;es s&eacute;par&eacute;ment
dans le cadre du Regroupement d&rsquo;Actions. Toutes les nouvelles actions apr&egrave;s l&rsquo;ach&egrave;vement du processus de Regroupement
d&rsquo;Actions seront assorties des m&ecirc;mes droits et avantages et seront pari passu &agrave; tous &eacute;gards, y compris en ce
qui concerne les droits aux dividendes et autres distributions, en application du Ratio.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
    <U>Form and nature of the new shares</U>: The Share Consolidation will not affect the form of the outstanding shares (dematerialized
    or registered) and the outstanding dematerialized and registered shares will be processed separately within the framework of the
    Share Consolidation. All new shares after the completion of the Share Consolidation shall have the same rights and benefits and shall
    rank <I>pari passu</I> in all respects, including as to entitlements to dividends and other distributions, in application of the
    Ratio.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Pas de fractions de nouvelles actions:</U> Dans le cadre du Regroupement d&rsquo;Actions, les actions existantes ne peuvent &ecirc;tre
regroup&eacute;es, conform&eacute;ment au Ratio, qu&rsquo;en un nombre entier de nouvelles actions. Aucune fraction de nouvelles actions
ne peut &ecirc;tre &eacute;mise. Sous r&eacute;serve des r&egrave;gles applicables en mati&egrave;re de droit des soci&eacute;t&eacute;s,
de droit financier et de droit des valeurs mobili&egrave;res, et sous r&eacute;serve des dispositions des paragraphes pr&eacute;c&eacute;dents,
le conseil d&rsquo;administration est autoris&eacute; &agrave; d&eacute;terminer la mani&egrave;re et la proc&eacute;dure &agrave; suivre
pour effectuer le Regroupement d&rsquo;Actions &agrave; l&rsquo;&eacute;gard des d&eacute;tenteurs d&rsquo;actions existantes de la Soci&eacute;t&eacute;
qui, au moment du Regroupement d&rsquo;Actions, ne disposent pas d&rsquo;un nombre suffisant d&rsquo;actions existantes pour recevoir
un nombre entier de nouvelles actions conform&eacute;ment au Ratio. Dans ce contexte, le conseil d&rsquo;administration aura le pouvoir
de d&eacute;terminer que (i) les positions des anciennes actions qui ne peuvent pas &ecirc;tre regroup&eacute;es en un nombre entier
de nouvelles actions conform&eacute;ment au Ratio peuvent &ecirc;tre agr&eacute;g&eacute;es pour &ecirc;tre regroup&eacute;es en nouvelles
actions, (ii) ces nouvelles actions peuvent &ecirc;tre vendues ou plac&eacute;es, par le biais d&rsquo;un placement priv&eacute; exempt&eacute;,
d&rsquo;une vente en bloc de titres, d&rsquo;une vente sur le march&eacute;, d&rsquo;une proc&eacute;dure (acc&eacute;l&eacute;r&eacute;
ou non) de constitution d&rsquo;un livre d&rsquo;ordres ou autrement, &agrave; ou aupr&egrave;s d&rsquo;investisseurs institutionnels,
qualifi&eacute;s ou professionnels ou de particuliers en Belgique et ailleurs, et (iii) le produit de cette vente ou de ce placement
sera distribu&eacute; au prorata aux d&eacute;tenteurs d&rsquo;actions existantes qui n&rsquo;ont pas un nombre suffisant d&rsquo;actions
existantes pour &ecirc;tre converties en nouvelles actions enti&egrave;res conform&eacute;ment au Ratio, &agrave; condition que le produit
ne soit pas inf&eacute;rieur &agrave; un centime d&rsquo;euro (EUR 0,01) par action existante. Si le produit est inf&eacute;rieur ou
ne peut &ecirc;tre distribu&eacute; au prorata comme indiqu&eacute; ci-dessus, il sera distribu&eacute; &agrave; la Soci&eacute;t&eacute;.
Les co&ucirc;ts et frais de transaction pertinents (y compris les commissions, honoraires et frais des agents et conseillers) et les
taxes, le tout tel qu&rsquo;applicable, seront support&eacute;s par la Soci&eacute;t&eacute;. Sous r&eacute;serve des dispositions applicables
de droit des soci&eacute;t&eacute;s, de droit financier et de droit des valeurs mobili&egrave;res, le conseil d&rsquo;administration
a &eacute;galement le pouvoir de d&eacute;cider que les positions des actions existantes qui ne peuvent &ecirc;tre regroup&eacute;es
conform&eacute;ment au Ratio en un nombre entier de nouvelles actions peuvent &ecirc;tre acquises par la Soci&eacute;t&eacute; ou l&rsquo;une
de ses filiales et que le produit de cette vente sera distribu&eacute; au prorata comme indiqu&eacute; ci-dessus.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;
  <U>No fractions of new shares</U>: Within the framework of the Share Consolidation, the existing shares can only be consolidated,
    in accordance with the Ratio, into a whole number of new shares. No fractions of new shares can be issued. Subject to applicable
    company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall
    be authorized to determine the manner and process to effect the Share Consolidation with respect to holders of existing shares of
    the Company who at the time of the Share Consolidation do not have a sufficient number of existing shares in order to receive a whole
    number of new shares in accordance with the Ratio. Within this context, the board of directors shall have the authority to determine
    that (i) the positions of old shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio can
    be aggregated for consolidation into new shares, (ii) such new shares can be sold or placed, via an exempt private placement, block
    trade, market sale, bookbuilding (accelerated or not) or otherwise, to or with institutional, qualified or professional investors
    or individuals in and outside of Belgium, and (iii) the proceeds of such sale or placement will be distributed on a pro rata basis
    to the holders of existing shares that do not have a sufficient number of existing shares to be converted into whole new shares in
    accordance with the Ratio, provided that the proceeds shall not be less than one euro cent (EUR 0.01) per existing share. If proceeds
    are less or cannot be distributed on a pro rata basis as aforementioned, these shall accrue to the Company. The relevant transaction
    costs and expenses (including commissions, fees and expenses of agents and advisors) and applicable taxes, all as applicable, will
    be borne by the Company. Subject to applicable provisions of company, financial and securities law, the board of directors shall
    also have the authority to determine that the positions of existing shares that cannot be consolidated in accordance with the Ratio
    into a whole number of new shares, can be acquired by the Company or one of its subsidiaries and that the proceeds of such sale will
    be distributed on a pro rata basis as aforementioned.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;<U>Annulation des actions existantes:</U> Apr&egrave;s l&rsquo;ach&egrave;vement du processus de Regroupement d&rsquo;Actions, les actions
existantes de la Soci&eacute;t&eacute; seront annul&eacute;es et ne seront plus en circulation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;<U>Cancellation
of existing shares</U>: Following the completion of the Share Consolidation, the existing shares of the Company shall be cancelled and
will no longer remain outstanding<I>.</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Calendrier
    du Regroupement d&rsquo;Actions:</U> Le conseil d&rsquo;administration est autoris&eacute; &agrave; d&eacute;terminer la date effective du Regroupement
    d&rsquo;Actions, &agrave; condition toutefois que le Regroupement d&rsquo;Actions soit mis en &oelig;uvre au plus tard dans un d&eacute;lai de
    six mois &agrave; compter de la date de la pr&eacute;sente assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires.
    Le conseil d&rsquo;administration a le pouvoir de ne pas proc&eacute;der &agrave; la mise en &oelig;uvre du Regroupement d&rsquo;Actions ou,
    dans le cas o&ugrave; la mise en &oelig;uvre du Regroupement d&rsquo;Actions a d&eacute;j&agrave; commenc&eacute;, de suspendre ou d&rsquo;annuler
    le processus de Regroupement d&rsquo;Actions si le conseil d&rsquo;administration d&eacute;termine que les circonstances du march&eacute; ne
    permettent pas de r&eacute;aliser le Regroupement d&rsquo;Actions dans des conditions jug&eacute;es satisfaisantes par le conseil d&rsquo;administration.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;<U>Timing
of the Share Consolidation:</U> The board of directors shall be authorized to determine the effective date of the Share Consolidation,
provided however, that the Share Consolidation is to be implemented within a six-month period following the date of this extraordinary
general shareholders&rsquo; meeting at the latest. The board of directors shall have the authority not to proceed with the implementation
of the Share Consolidation, or, in case the implementation of the Share Consolidation has already started, to suspend or cancel the completion
of the Share Consolidation if the board of directors determines that the market circumstances do not allow for the completion of the
Share Consolidation in circumstances deemed satisfactory to it.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;<U>Agents:
    </U>Une ou plusieurs banques ou institutions financi&egrave;res seront ou pourront &ecirc;tre d&eacute;sign&eacute;es par la Soci&eacute;t&eacute;
    aux fins de l&rsquo;organisation et de la mise en &oelig;uvre du Regroupement d&rsquo;Actions, y compris (mais sans s&rsquo;y limiter) le regroupement
    des positions des actions existantes qui ne peuvent &ecirc;tre regroup&eacute;es en un nombre entier de nouvelles actions conform&eacute;ment
    au Ratio, et la vente de nouvelles actions comme le permet le paragraphe (c).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;<U>Agents</U>:
    One or more banks or financial institutions shall or may be appointed by the Company for the purpose of the further organization
    and implementation of the Share Consolidation, including (but not limited to) the consolidation of positions of existing shares that
    cannot be consolidated into a whole number of new shares in accordance with the Ratio, and the sale of new shares as permitted by
    paragraph (c).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;<U>Ajustement
    du prix de souscription des Droits de Souscription:</U> &Agrave; l&rsquo;issue du Regroupement d&rsquo;Actions, le Regroupement d&rsquo;Actions sera
    effectu&eacute; en ce qui concerne les droits de souscription en circulation de la Soci&eacute;t&eacute; de la mani&egrave;re envisag&eacute;e
    dans les conditions respectives de ces droits de souscription, de sorte qu&rsquo;un d&eacute;tenteur de droits de souscription devra exercer
    des droits de souscription &agrave; l&rsquo;&eacute;gard d&rsquo;au moins 10 Actions avant le Regroupement d&rsquo;Actions pour pouvoir souscrire une
    Action apr&egrave;s le Regroupement d&rsquo;Actions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;<U>Adjustment
    of the subscription price of the Subscription Rights</U>: At completion of the Share Consolidation, the Share Consolidation shall
    be effected in relation to the outstanding subscription rights of the Company in the manner as contemplated in the respective terms
    and conditions of these subscription rights, so that a holder of subscription rights will have to exercise subscription rights with
    respect to at least 10 Shares prior the Share Consolidation in order to subscribe for one Share after the Share Consolidation.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;<U>Modification
    des statuts:</U> &Agrave; l&rsquo;issue du Regroupement d&rsquo;Actions, l&rsquo;article 5 des statuts de la Soci&eacute;t&eacute; sera modifi&eacute;
    et reformul&eacute; pour tenir compte du nombre d&rsquo;actions en circulation et existantes qui en r&eacute;sultera.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;<U>Amendment
    of the articles of association</U>: At completion of the Share Consolidation, Article 5 of the Company&rsquo;s articles of association
    shall be amended and restated to take into account the resulting number of outstanding and existing shares.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;<U>Mise
    en &oelig;uvre du Regroupement d&rsquo;Actions:</U> Sous r&eacute;serve des r&egrave;gles applicables en mati&egrave;re de droit des soci&eacute;t&eacute;s,
    de droit financier et de droit des valeurs mobili&egrave;res, et sous r&eacute;serve des dispositions des paragraphes pr&eacute;c&eacute;dents,
    le conseil d&rsquo;administration a le pouvoir de mettre en &oelig;uvre et l&rsquo;ex&eacute;cution du Regroupement d&rsquo;Actions, y compris (sans
    s&rsquo;y limiter) le pouvoir (i) de d&eacute;terminer la mise en &oelig;uvre pratique du Regroupement d&rsquo;Actions, (ii) de d&eacute;terminer
    le calendrier et la date effective du Regroupement d&rsquo;Actions comme pr&eacute;vu au paragraphe (e), (iii) de d&eacute;terminer la
    mani&egrave;re et le processus de traitement des positions d&rsquo;actions existantes qui ne peuvent pas &ecirc;tre regroup&eacute;es en
    un nombre entier de nouvelles actions conform&eacute;ment au Ratio comme pr&eacute;vu au paragraphe (c), (iv) de nommer une ou plusieurs
    banques ou institutions financi&egrave;res pour l&rsquo;organisation et la mise en &oelig;uvre du Regroupement d&rsquo;Actions tel qu&rsquo;envisag&eacute;
    au paragraphe (f), (v) de proc&eacute;der &agrave; la constatation de la modification et de la reformulation des statuts tels qu&rsquo;envisag&eacute;s
    au paragraphe (h) devant notaire, (vi) d&rsquo;entreprendre toutes les d&eacute;marches utiles ou n&eacute;cessaires aupr&egrave;s d&rsquo;Euronext,
    d&rsquo;Euroclear, de toute autre agence de r&egrave;glement comp&eacute;tente et de toute autorit&eacute; de r&eacute;glementation ou
    de cotation en rapport avec la mise en &oelig;uvre du Regroupement d&rsquo;Actions, (vii) d&rsquo;effectuer toutes les modifications dans les
    registres de titres pertinents de la Soci&eacute;t&eacute; refl&eacute;tant le Regroupement d&rsquo;Actions, et (viii) de prendre toutes
    les autres mesures utiles, appropri&eacute;es ou n&eacute;cessaires en rapport avec ce qui pr&eacute;c&egrave;de. Le conseil d&rsquo;administration
    est habilit&eacute; &agrave; d&eacute;l&eacute;guer la mise en &oelig;uvre et de l&rsquo;ex&eacute;cution du Regroupement d&rsquo;Actions (y
    compris les pouvoirs vis&eacute;s aux points (i) &agrave; (viii)), en tout ou en partie, &agrave; un ou plusieurs membres du management
    ou du personnel de la Soci&eacute;t&eacute;. Tout administrateur, tout membre du management et toute autre personne express&eacute;ment
    d&eacute;sign&eacute;e &agrave; cet effet par le conseil d&rsquo;administration est autoris&eacute; &agrave; faire constater, devant notaire,
    la modification et la reformulation des statuts vis&eacute;es au paragraphe (h).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Further
implementation of the Share Consolidation:</U> Subject to applicable company, financial and securities law rules, and subject to the
provisions of the foregoing paragraphs, the board of directors shall have the authority to further implement and effect the Share Consolidation,
including (without being limited to) the authority to (i) determine the practical implementation of the Share Consolidation, (ii) determine
the timing and the effective date of the Share Consolidation as contemplated by paragraph (e), (iii) determine the manner and process
to deal with positions of existing shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio
as contemplated by paragraph (c), (iv) appoint one or more banks or financial institutions for the further organization and implementation
of the Share Consolidation as contemplated by paragraph (f), (v) proceed with the recording of the amendment and the restatement of the
articles of association as contemplated by paragraph (h) before a notary public, (vi) take all useful or necessary steps with Euronext,
Euroclear, any other competent settlement agency, and any regulatory or listing authority in connection with the implementation of the
Share Consolidation, (vii) make all changes in the relevant securities register books of the Company reflecting the Share Consolidation,
and (viii) do such other things as shall be useful, appropriate or necessary in connection with the foregoing. The board of directors
shall have the authority to delegate the further implementation and execution of the Share Consolidation (including the powers referred
to in sub-sections (i) to (viii)), in whole or in part, to one or more members of the Company&rsquo;s executive management or personnel.
Any director, any member of the executive management, and any other persons that shall be expressly appointed for such purpose by the
board of directors shall be authorized to record the amendment and the restatement of the articles of association as contemplated by
paragraph (h) before a notary public.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&#9658;</I></B></FONT><B><I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Instruction de vote</U></FONT></I></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Voting instruction</U></FONT></I></B>:</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Pour / For</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Contre / Against</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Abstention</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-size: 10pt">3. &nbsp;&nbsp;&nbsp;<U>Radiation
    de la Cote d&rsquo;Euronext Brussels</U></FONT></TD>
    <TD STYLE="padding-right: 4pt; width: 50%; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt"><FONT STYLE="font-size: 10pt">3.&nbsp;&nbsp;&nbsp;
<U>De-Listing from Euronext Brussels</U></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;&nbsp;<U>Proposition de r&eacute;solution</U></I></B>:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&#9658; &nbsp;&nbsp;<U>Proposed resolution</U></I></B>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires d&eacute;cide d&rsquo;approuver la Radiation de la Cote de la Soci&eacute;t&eacute; du march&eacute; r&eacute;glement&eacute; d&rsquo;Euronext Brussels (la &ldquo;<B>Radiation de la Cote</B>&rdquo;), de modifier les statuts de la Soci&eacute;t&eacute; aux fins de cette Radiation de la Cote et d&rsquo;octroyer au conseil d&rsquo;administration de la Soci&eacute;t&eacute; le pouvoir de poursuivre la mise en &oelig;uvre de la Radiation de la Cote, sous r&eacute;serve des conditions suivantes :</FONT></TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">The extraordinary general shareholders&rsquo; meeting decides to approve a de-listing of the Company&rsquo;s shares from the regulated market of Euronext Brussels (the &ldquo;<B>De-Listing</B>&rdquo;), to amend the Company&rsquo;s articles of association for the purpose of such De-Listing, and to grant the board of directors of the Company the authority to further implement the De-Listing, subject to the following terms and conditions:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 12.6pt; text-indent: -0.1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;<U>Radiation de la Cote:</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires approuve et accepte qu&rsquo;il soit mis fin &agrave; l&rsquo;admission des actions de la Soci&eacute;t&eacute; &agrave; la cote et &agrave; la n&eacute;gociation et que, par cons&eacute;quent, les actions de la Soci&eacute;t&eacute; ne puissent plus &ecirc;tre cot&eacute;es et n&eacute;goci&eacute;es sur le march&eacute; r&eacute;glement&eacute; d&rsquo;Euronext Brussels (&ldquo;<B>Euronext Brussels</B>&rdquo;), &agrave; condition que les actions de la Soci&eacute;t&eacute; (ou, le cas &eacute;ch&eacute;ant, les American Depositary Shares ou les American Depositary Receipts relatifs &agrave; ces actions) soient admises &agrave; la n&eacute;gociation sur le Nasdaq Capital Market (le &ldquo;<B>Nasdaq</B>&rdquo;).</TD>
    <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;<U>De-Listing</U>: The general shareholders&rsquo; meeting approves and agrees that the admission of the Company&rsquo;s shares to listing and trading shall be terminated and, consequently, the Company&rsquo;s shares shall no longer be able to list and trade on the regulated market of Euronext Brussels (&ldquo;<B>Euronext Brussels</B>&rdquo;), provided that the Company&rsquo;s shares (or, as the case may be, American Depositary Shares or American Depositary Receipts in relation to such shares) shall be admitted to trading on the Nasdaq Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 30.25pt; text-align: justify; text-indent: -0.25in"></TD>
    <TD STYLE="padding-left: 33.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;<U>Date effective:</U> Le conseil d&rsquo;administration a le pouvoir de d&eacute;terminer la date effective de la Radiation de la Cote, sous r&eacute;serve d&rsquo;une p&eacute;riode de transition pr&eacute;alable d&rsquo;au moins trois semaine avant la date effective de la Radiation de la Cote (la &ldquo;<B>P&eacute;riode de Transition</B>&rdquo;) pendant laquelle les actions de la Soci&eacute;t&eacute; resteront admises &agrave; la n&eacute;gociation sur Euronext Brussels. Si, et pour autant que, le Regroupement d&rsquo;Actions a &eacute;t&eacute; mis en &oelig;uvre, la P&eacute;riode de Transition sera d&rsquo;au moins trois semaines apr&egrave;s que le Regroupement d&rsquo;Actions soit devenu effectif.
    <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;<U>Effective date</U>: The board of directors shall have the power to determine the effective date of the De-Listing subject to a prior transition period of at least three weeks prior to the effective date of the De-Listing Date (the &ldquo;<B>Transition Period</B>&rdquo;) during which the Company&rsquo;s shares shall remain admitted to trading on Euronext Brussels. If and to the extent the Share Consolidation has been effected, the Transition Period shall at least be three weeks after the Share Consolidation has become effective.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 30.25pt; text-align: justify; text-indent: -0.25in"></TD>
    <TD STYLE="padding-left: 33.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(c)&nbsp;&nbsp;&nbsp;<U>Modification des statuts:</U> &Agrave; la date effective de la Radiation de la Cote, les dispositions suivantes des statuts de la Soci&eacute;t&eacute; seront modifi&eacute;es et reformul&eacute;es comme suit (&agrave; l&rsquo;exception de la modification pr&eacute;vue au paragraphe (i), laquelle est effective imm&eacute;diatement apr&egrave;s l&rsquo;approbation de la modification par l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires) :
    <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;<U>Amendments to the articles of association</U>: Upon the effective date of the De-Listing, the following provisions of the Company&rsquo;s articles of association of the Company shall be amended and restated as follows (except that the amendment in paragraph (i) is effective immediately upon approval of the amendment by the extraordinary general shareholders&rsquo; meeting):</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;A
l&rsquo;article 9 (&ldquo;Nature des titres&rdquo;), les trois derniers paragraphes sont modifi&eacute;s et reformul&eacute;s comme suit :<BR>
<I></I></FONT></P>
                                                                                                                                                                   <P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><I>&ldquo;Un registre des actions nominatives est tenu au si&egrave;ge de la soci&eacute;t&eacute; et peut &ecirc;tre scind&eacute; par
d&eacute;cision du conseil d&rsquo;administration conform&eacute;ment aux dispositions du droit applicable. Le conseil d&rsquo;administration peut
d&eacute;signer un tiers de son choix pour conserver une partie du registre des actions nominatives scind&eacute;. Sous r&eacute;serve
des dispositions applicables de droit des soci&eacute;t&eacute;s, de droit financier et du droit des valeurs mobili&egrave;res, et sauf
d&eacute;cision contraire du conseil d&rsquo;administration conform&eacute;ment &agrave; l&rsquo;article 43 des statuts, les dividendes et autres
distributions (selon le cas) de la soci&eacute;t&eacute; sur les actions peuvent &ecirc;tre effectu&eacute;s en euros (EUR) ou en dollars
am&eacute;ricains (USD), en fonction de la composante du registre des actions (scind&eacute;) sur lequel les actions sont inscrites<FONT STYLE="font-family: Times New Roman, Times, Serif"><B><SUP>1</SUP>.<BR></B></FONT></I></FONT></P>
                                                                                                                                                                   <P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><I><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B>Le
registre (scind&eacute;) des actions nominatives et les registres des autres titres nominatifs, le cas &eacute;ch&eacute;ant, peuvent
&ecirc;tre conserv&eacute;s sous la forme &eacute;lectronique. Chaque d&eacute;tenteur de titres peut consulter le registre (scind&eacute;)
en ce qui concerne ses titres. Le conseil d&rsquo;administration peut d&eacute;signer un tiers de son choix pour conserver ce registre &eacute;lectronique
(scind&eacute;).<BR>
Toutes les inscriptions dans le registre (scind&eacute;) des actions nominatives et dans les registres d&rsquo;autres titres nominatifs, y
compris les cessions et les conversions, peuvent &ecirc;tre valablement effectu&eacute;es sur la base de documents ou d&rsquo;instructions
soumis par voie &eacute;lectronique ou par tout autre moyen par le c&eacute;dant, le cessionnaire et/ou le d&eacute;tenteur des titres,
le cas &eacute;ch&eacute;ant.&rdquo;</FONT></I></FONT></P></TD>
    <TD STYLE="padding-left: 53.2pt; text-align: justify; text-indent: -0.5in; width: 50%"><P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;In
article&nbsp;9&nbsp;(&ldquo;Nature of the securities&rdquo;), the three last paragraphs shall be amended and restated as follows:<BR></FONT></P>
                                                                                           <P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>&ldquo;A
                                            share register is kept at the registered office of the company and may be split by decision
                                            of the board of directors in accordance with the provisions of the applicable law. The board
                                            of directors can appoint a third party of its choice to keep any part of the split share
                                            register. Subject to applicable provisions of companies, financial and securities laws, and
                                            unless decided otherwise by the board directors in accordance with article 43 of the articles
                                            of association, dividends and other distributions (as the case may be) by the company on
                                            shares can be made in euro (EUR) or United States dollars (USD) depending on the component
                                            of the (split) share register on which the shares are reflected.&nbsp;<BR></I></P>
                                                                                           <P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>The
                                            (split) register of registered shares and the registers of other registered securities, as
                                            the case may be, can be kept electronically. Each holder of securities can consult the (split)
                                            register with respect to his/her/its securities. The board of directors can appoint a third
                                            party of its choice to keep this (split) electronic register.</I><BR></P><I>All recordings in the (split) share
    register and the registers of other registered securities, including transfers and conversions, can be validly made on the basis of documents
    or instructions submitted electronically or via any other means by the transferor, the transferee and/or the holder of the securities,
    as applicable.&rdquo;</I></TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;Le
texte de l&rsquo;article 14 (&ldquo;Obligation de transparence&rdquo;) est modifi&eacute; et reformul&eacute; comme suit :<BR></P>
                                                                <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>&ldquo;Chaque personne
physique ou morale qui acquiert ou c&egrave;de des titres avec droit de vote de la Soci&eacute;t&eacute;, qu&rsquo;ils repr&eacute;sentent
ou non le capital de la Soci&eacute;t&eacute;, doit se conformer aux obligations de notification et d&rsquo;information impos&eacute;es par
le droit applicable.&rdquo;<BR>
</I></P></TD>
  <TD><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;The text of article 14
(&ldquo;Transparency obligation&rdquo;) shall be amended and restated as follows:<BR></P>
      <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in">&ldquo;<I>Each natural or legal person acquiring or transferring voting
securities of the company, whether or not representing the share capital of the company, must comply with the relevant notification and
information obligations that are imposed by applicable law.</I>&rdquo;<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;Le
texte de l&rsquo;article 15 (&ldquo;Droits de vote&rdquo;) est modifi&eacute; et reformul&eacute; comme suit :<BR></P>
                                                                <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>&ldquo;Le non-respect des obligations
de notification et d&rsquo;information impos&eacute;es par le droit applicable en ce qui concerne l&rsquo;acquisition ou la cession de titres avec
droit de vote de la Soci&eacute;t&eacute;, qu&rsquo;ils repr&eacute;sentent ou non le capital de la Soci&eacute;t&eacute;, peut entra&icirc;ner,
conform&eacute;ment au droit applicable, une suspension des droits de vote attach&eacute;s aux titres avec droit de vote concern&eacute;s
ou toute autre cons&eacute;quence pr&eacute;vue par le droit applicable.&rdquo;</I></P></TD>
  <TD><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;The
text of article 15 (&ldquo;Voting rights&rdquo;) shall be amended and restated as follows:<BR></P>
      <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in">&ldquo;<I>Non-compliance with the relevant notification
and information obligations that are imposed by applicable law in relation to the acquisition or transfer of voting securities of the
company, whether or not representing the share capital of the company, may result, in accordance with applicable law, a suspension of
the voting rights attached to the relevant voting securities or such other consequence as provided for by applicable law.</I>&rdquo;</P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="text-align: justify; margin: 0"><SUP>1</SUP> <I><U>Note concernant le point 3(c)(i</U>) : A la suite d&rsquo;une erreur administrative,
la version fran&ccedil;aise de la convocation publi&eacute;e dans le Moniteur belge et (le cas &eacute;ch&eacute;ant) l&rsquo;Echo ne
contient pas la phrase suivante: &ldquo;Sous r&eacute;serve des dispositions applicables de droit des soci&eacute;t&eacute;s, de droit
financier et du droit des valeurs mobili&egrave;res, et sauf d&eacute;cision contraire du conseil d&rsquo;administration conform&eacute;ment
&agrave; l&rsquo;article 43 des statuts, les dividendes et autres distributions (selon le cas) de la soci&eacute;t&eacute; sur les actions
peuvent &ecirc;tre effectu&eacute;s en euros (EUR) ou en dollars am&eacute;ricains (USD), en fonction de la composante du registre des
actions (scind&eacute;) sur lequel les actions sont inscrites&rdquo;. Cependant la convocation faisant foi est celle publi&eacute;e sur
le site web de la Soci&eacute;t&eacute; le 2 octobre 2023, laquelle inclus la phrase mentionn&eacute;e ci-dessus entre guillemets et
soumise &agrave; l&rsquo;approbation des actionnaires.</I></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iv)&nbsp;&Agrave;&nbsp;l&rsquo;article
32 (&ldquo;Admission &mdash; Formalit&eacute;s pr&eacute;alables&rdquo;), les paragraphes suivants sont ajout&eacute;s apr&egrave;s le
premier paragraphe de l&rsquo;article 32 :<BR></P>
                                                                            <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>&ldquo;Le conseil d&rsquo;administration peut d&eacute;cider que le droit d&rsquo;assister aux assembl&eacute;es g&eacute;n&eacute;rales des actionnaires
et d&rsquo;y exercer le droit de vote (le cas &eacute;ch&eacute;ant) est d&eacute;termin&eacute; par l&rsquo;enregistrement de la propri&eacute;t&eacute;
des titres concern&eacute;s au nom du d&eacute;tenteur de ces titres le troisi&egrave;me (3e) jour ouvrable pr&eacute;c&eacute;dant la
date de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires concern&eacute;e (ou toute autre date indiqu&eacute;e dans la convocation
&agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires, mais qui ne peut &ecirc;tre ant&eacute;rieure au 15e jour calendrier
pr&eacute;c&eacute;dant l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires), &agrave; minuit &agrave; la fin de ce jour (heure
de Bruxelles) (cette date et cette heure &eacute;tant la date d&rsquo;enregistrement concern&eacute;e), au moyen de l&rsquo;enregistrement de ces
titres dans le registre pertinent (ou la partie du registre scind&eacute; pertinente) pour ces titres, dans les comptes d&rsquo;un teneur de
compte agr&eacute;&eacute; ou d&rsquo;un organisme de liquidation pour les titres concern&eacute;s. <BR></I></P>
                                                                            <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>Le conseil d&rsquo;administration peut subordonner
la participation aux assembl&eacute;es g&eacute;n&eacute;rales des actionnaires &agrave; l&rsquo;obligation pour les d&eacute;tenteurs de titres
concern&eacute;s de notifier &agrave; la Soci&eacute;t&eacute; ou &agrave; la personne d&eacute;sign&eacute;e &agrave; cet effet par
la Soci&eacute;t&eacute;, &agrave; une date d&eacute;termin&eacute;e par le conseil d&rsquo;administration avant la date de l&rsquo;assembl&eacute;e
pr&eacute;vue, leur intention d&rsquo;assister &agrave; l&rsquo;assembl&eacute;e, en indiquant le nombre de titres avec lesquels ils souhaitent participer.
Les modalit&eacute;s d&rsquo;&eacute;laboration de cette notification (selon le cas) doivent &ecirc;tre indiqu&eacute;es dans l&rsquo;avis de convocation
de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires.&rdquo;</I></P></TD>
  <TD STYLE="width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iv)&nbsp;In article
32 (&ldquo;Admission &ndash; Prior formalities&rdquo;), the following paragraphs shall be added after the first paragraph of article 32:<BR>
<I></I></P>
                         <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>&ldquo;The
board of directors shall have the ability to determine that the right to attend the general shareholders&rsquo; meetings and to exercise the
voting right at such meetings (as the case may be) is determined by the registration of the ownership of the securities concerned in
the name of the holder of such securities on the third (3rd) business day prior to the date of the relevant general shareholders&rsquo; meeting
(or such other date as shall be set out in the notice convening the general shareholders&rsquo; meeting, but which cannot be earlier than the
15th calendar date before the relevant general shareholders&rsquo; meeting), at midnight at the end of such day (Brussels time) (such date
and hour being the relevant registration date), by means of the registration of such securities in the relevant (portion of the split)
register book for such securities, or in the accounts of a certified account holder or relevant settlement institution for the securities
concerned.<BR></I></P>
                         <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>The board of directors may make participation to the general shareholders&rsquo; meetings dependent on a requirement of notification by the
securities holders concerned to the company, or to the person appointed for this purpose by the company, on a date to be determined by
the board of directors before the date of the scheduled meeting, that such securities holder intends to attend the meeting, stating the
number of securities with which such securities holder wishes to participate. The manner in which such notification must be made (as
the case may be) must be set out in the notice convening the general shareholders&rsquo; meeting.&rdquo;</I></P></TD></TR><TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(v)&nbsp;&nbsp;&Agrave;
l&rsquo;article 33 (&ldquo;Repr&eacute;sentation des actionnaires&rdquo;), la derni&egrave;re phrase du premier paragraphe est modifi&eacute;e
et reformul&eacute;e comme suit :<BR></P>
                                                                            <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I>&ldquo;Ces procurations doivent &ecirc;tre accord&eacute;es et soumises &agrave; la soci&eacute;t&eacute;
conform&eacute;ment au droit applicable et/ou comme indiqu&eacute; (conform&eacute;ment au droit applicable) dans l&rsquo;avis de convocation,
le cas &eacute;ch&eacute;ant.&rdquo;</I></P></TD>
  <TD STYLE="width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(v)&nbsp;&nbsp;In
article 33 (&ldquo;Representation of shareholders&rdquo;), the second paragraph shall be amended and restated as follows:<BR></P>
                         <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in">&ldquo;<I>Such
proxies must be granted and submitted to the company in accordance with the applicable law and/or as set out (in accordance with the
applicable law) in the convening notice, as the case may be.</I>&rdquo;</P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(vi)&nbsp;&nbsp;&Agrave;
    l&rsquo;article 35 (&ldquo;Ajournement de l&rsquo;assembl&eacute;e&rdquo;), les r&eacute;f&eacute;rences, dans les premier et deuxi&egrave;me paragraphes,
    <I>&agrave; &ldquo;cinq (5) semaines&rdquo; sont remplac&eacute;es par des r&eacute;f&eacute;rences &agrave; &ldquo;trois (3) semaines&rdquo;.</I>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(vi)&nbsp;&nbsp;In
    article 35 (&ldquo;Adjournment of the meeting&rdquo;), the reference in the first and second paragraph to &ldquo;<I>five (5) weeks</I>&rdquo;
    shall be replaced by &ldquo;<I>three (3) weeks</I>&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(vii)&nbsp;Le
texte de l&rsquo;article 36 (&ldquo;D&eacute;cisions sur les points non inclus dans l&rsquo;ordre du jour &mdash; Amendements&rdquo;) est modifi&eacute;
et reformul&eacute; comme suit :<BR>
<I>&ldquo;L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires ne peut valablement d&eacute;lib&eacute;rer
ou r&eacute;soudre sur les points qui ne sont pas inscrits ou implicitement inscrits &agrave; l&rsquo;ordre du jour, sauf si tous les actionnaires
sont pr&eacute;sents ou repr&eacute;sent&eacute;s &agrave; l&rsquo;assembl&eacute;e et y consentent &agrave; l&rsquo;unanimit&eacute; et si, dans
le cas d&rsquo;un vote par correspondance, le formulaire autorise un mandataire &agrave; prendre une telle d&eacute;cision. Le consentement
requis est pr&eacute;sum&eacute; exister si aucune objection n&rsquo;est consign&eacute;e dans le proc&egrave;s-verbal de l&rsquo;assembl&eacute;e.&rdquo;</I></P></TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(vii)&nbsp;The
text of article 36 (&ldquo;Decisions on matters not on the agenda - Amendments&rdquo;) shall be amended and restated as follows:<BR>
&ldquo;<I>The
general shareholders&rsquo; meeting cannot validly deliberate or decide on the items that are not included or implicitly contained in the agenda,
unless all shareholders are present or represented at the meeting and unanimously agree and if, in the case of a vote by mail, the form
authorises a proxy to make such a decision. The required consent is assumed to exist, if no objection is recorded in the minutes of the
meeting.</I>&rdquo;</P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(viii)&nbsp;&Agrave;
    l&rsquo;article 39 (&ldquo;Vote et participation &agrave; distance&rdquo;), la r&eacute;f&eacute;rence au &ldquo;<I>sixi&egrave;me jour calendrier&rdquo;
    est remplac&eacute;e par la r&eacute;f&eacute;rence au &ldquo;troisi&egrave;me jour ouvrable&rdquo;.</I></TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.625in; text-align: justify; text-indent: -0.25in">(viii)&nbsp;In
    article 39 (&ldquo;Remote voting or participation&rdquo;) the reference to &ldquo;<I>sixth calendar day</I>&rdquo; shall be replaced by &ldquo;<I>third
    business day</I>&rdquo;.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 50%"><P STYLE="margin-left: 0in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(ix)&nbsp;&nbsp;L&rsquo;intitul&eacute; de
l&rsquo;article 51 est modifi&eacute; et reformul&eacute; comme suit :<BR></P>
                                                                                                                                                           <P STYLE="margin-left: 0in; padding-left: 0.75in; text-align: justify; text-indent: 0in"><I>&ldquo;Certains termes d&eacute;finis&rdquo;, et le texte de l&rsquo;article
51 est modifi&eacute; et reformul&eacute; comme suit : &ldquo;Sauf si le contexte exige le contraire ou si les pr&eacute;sents statuts
en donnent une d&eacute;finition diff&eacute;rente, aux fins des pr&eacute;sents statuts, (a) le terme &ldquo;personnel&rdquo; a la signification
octroy&eacute;e par l&rsquo;article 1:27 du Code des soci&eacute;t&eacute;s et des associations, et (b) le terme &ldquo;jour ouvrable&rdquo; a
la signification octroy&eacute;e par l&rsquo;article 1:32 du Code des soci&eacute;t&eacute;s et des associations.&rdquo;</I></P></TD>
  <TD STYLE="margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ix)&nbsp;&nbsp;The
heading of article 51 shall be amended and restated as &ldquo;<I>Certain defined terms</I>&rdquo;, and the text of article 51 shall be
amended and restated as follows:&nbsp;</P>
                                                                                                        <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in">&ldquo;<I>Unless the context requires otherwise or unless otherwise defined in these articles of
association, for the purposes of these articles of association, (a)&nbsp;&ldquo;personnel&rdquo; shall have the meaning defined in Article
1:27 of the Belgian Companies and Associations Code, and (b)&nbsp;&ldquo;business day&rdquo; shall have the meaning defined in Article
1:32 of the Belgian Companies and Associations Code.</I>&rdquo;</P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt"><P STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;<U>Mise en &oelig;uvre de la Radiation de la Cote:</U>
Sous r&eacute;serve des r&egrave;gles applicables en mati&egrave;re de droit des soci&eacute;t&eacute;s, de droit financier et de droit
des valeurs mobili&egrave;res, et sous r&eacute;serve des dispositions des paragraphes pr&eacute;c&eacute;dents, le conseil d&rsquo;administration
a le pouvoir de mettre en &oelig;uvre et d&rsquo;effectuer la Radiation de la Cote, y compris (sans s&rsquo;y limiter) le pouvoir (i) de d&eacute;terminer
la mise en &oelig;uvre pratique de la Radiation de la Cote, (ii) de d&eacute;terminer le calendrier et la date effective de la Radiation
de la Cote ainsi que la dur&eacute;e de la P&eacute;riode de Transition, (iii) de d&eacute;terminer les modalit&eacute;s et le processus
de n&eacute;gociation des actions (ou, le cas &eacute;ch&eacute;ant, des American Depositary Shares ou des American Depositary Receipts
relatifs &agrave; ces actions) sur le Nasdaq, (iv) de nommer une ou plusieurs banques ou institutions financi&egrave;res pour l&rsquo;organisation
et la mise en &oelig;uvre de la Radiation de la Cote, (v) de proc&eacute;der &agrave; la constatation de la modification et de la reformulation
des statuts comme pr&eacute;vu au paragraphe (c) devant notaire, (vi) d&rsquo;entreprendre toutes les d&eacute;marches utiles ou n&eacute;cessaires
aupr&egrave;s d&rsquo;Euronext, d&rsquo;Euroclear, de toute autre agence de r&egrave;glement comp&eacute;tente et de toute autorit&eacute; de r&eacute;glementation
ou de cotation en rapport avec la mise en &oelig;uvre de la Radiation de la Cote, et (vii) de prendre toutes les autres mesures utiles,
appropri&eacute;es ou n&eacute;cessaires en rapport avec ce qui pr&eacute;c&egrave;de. Le conseil d&rsquo;administration est habilit&eacute;
&agrave; d&eacute;l&eacute;guer la mise en &oelig;uvre et l&rsquo;ex&eacute;cution de la Radiation de la Cote (y compris les pouvoirs vis&eacute;s
aux points (i) &agrave; (vii)), en tout ou en partie, &agrave; un ou plusieurs membres du management ou du personnel de la Soci&eacute;t&eacute;.
Tout administrateur, tout membre du management et toute autre personne express&eacute;ment d&eacute;sign&eacute;e &agrave; cet effet par
le conseil d&rsquo;administration est autoris&eacute; &agrave; faire constater, devant notaire, la modification et la reformulation des statuts
vis&eacute;es au paragraphe (c).&agrave; faire constater, devant notaire, la modification et la reformulation des statuts vis&eacute;es
au paragraphe (c).</P></TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;<U>Further
    implementation of the De-Listing</U>: Subject to applicable company, financial and securities law rules, and subject to the provisions
    of the foregoing paragraphs, the board of directors shall have the authority to further implement and effect the De-Listing, including
    (without being limited to) the authority to (i) determine the practical implementation of the De-Listing, (ii) determine the timing and
    the effective date of the De-Listing and the duration of the Transition Period, (iii) determine the manner and process for the shares
    (or, as the case may be, American Depositary Shares or American Depositary Receipts in relation to such shares) to be traded on Nasdaq,
    (iv) appoint one or more banks or financial institutions for the further organization and implementation of the De-Listing, (v) proceed
    with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph (c) before a notary
    public, (vi) take all useful or necessary steps with Euronext, Euroclear, any other competent settlement agency, and any regulatory or
    listing authority in connection with the implementation of the De-Listing, and (vii) do such other things as shall be useful, appropriate
    or necessary in connection with the foregoing. The board of directors shall have the authority to delegate the further implementation
    and execution of the De-Listing (including the powers referred to in sub-sections (i) to (vii)), in whole or in part, to one or more members
    of the Company&rsquo;s executive management or personnel. Any director, any member of the executive management, and any other persons that shall
    be expressly appointed for such purpose by the board of directors shall be authorized to record the amendment and the restatement of the
    articles of association as contemplated by paragraph (c) before a notary public.</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&#9658;</I></B></FONT><B><I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Instruction de vote</U></FONT></I></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Voting instruction</U></FONT></I></B>:</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Pour / For</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Contre / Against</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Abstention</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.&nbsp;</B>Si
    l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires sont ajourn&eacute;es ou suspendues, le mandataire sp&eacute;cial
    aura les pouvoirs de repr&eacute;senter le soussign&eacute; &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires qui
    seront tenues avec le m&ecirc;me ordre du jour, le cas &eacute;ch&eacute;ant (&eacute;tant entendu que les votes susmentionn&eacute;s
    s&rsquo;appliqueront en tout &eacute;tat de cause &eacute;galement &agrave; la deuxi&egrave;me assembl&eacute;e g&eacute;n&eacute;rale
    extraordinaire des actionnaires qui serait convoqu&eacute;e avec un ordre du jour identique &agrave; celui de la premi&egrave;re
    assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires dans le cas o&ugrave; le quorum de pr&eacute;sence l&eacute;galement
    requis pour d&eacute;lib&eacute;rer et voter valablement sur ces points de l&rsquo;ordre du jour n&rsquo;aurait pas &eacute;t&eacute; atteint
    lors de la premi&egrave;re assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires):</FONT></TD>
    <TD STYLE="padding-left: 4pt; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.
    </B>In case the aforementioned extraordinary general shareholders&rsquo; meeting would be postponed or suspended, the special proxy holder
    shall have the power to represent the undersigned at the general shareholders&rsquo; meeting that would be held having the same agenda,
    as relevant (it being understood that the aforementioned votes will in any event also apply to the second extraordinary general shareholders&rsquo;
    meeting which would be convened with an agenda identical to the agenda of the first extraordinary general shareholders&rsquo; meeting
    in case the legally required attendance quorum to validly deliberate and resolve on such agenda items would not be reached during
    the first extraordinary general shareholders&rsquo; meeting):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    oui</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    non</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    no</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Veuillez
    remplir la case appropri&eacute;e. Une absence d&rsquo;instruction ou si, pour quelque raison, il y a une absence de clart&eacute; &agrave;
    propos de l&rsquo;instruction donn&eacute;e, le soussign&eacute; sera suppos&eacute; avoir choisi &ldquo;oui&rdquo;. Veuillez noter qu&rsquo;aux
    fins de s&rsquo;appliquer &agrave; telle assembl&eacute;e subs&eacute;quente, les titulaires de titres doivent s&rsquo;enregistrer &agrave; nouveau
    pour cette assembl&eacute;e.</I></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
    tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to
    the instruction given, the undersigned shall be deemed to have selected &ldquo;yes&rdquo;. Please note that in order to apply for such
    subsequent meeting, holders of securities must again register for such meeting.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Si,
    pendant l&rsquo;assembl&eacute;e, il y a des modifications &agrave; une proposition de r&eacute;solution ou une nouvelle proposition de
    r&eacute;solution:<SUP>1</SUP></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case
    of amendments during the meeting to a proposed resolution or a new proposed resolution:<SUP>1</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; border-right: Black 1pt solid; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    le mandataire sp&eacute;cial votera pour la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify">&#9744;
    the proxy holder shall vote for the amended or new resolution</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; border-right: Black 1pt solid; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    le mandataire sp&eacute;cial votera contre la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    the proxy holder shall vote against the amended or new resolution</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; border-right: Black 1pt solid; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    le mandataire sp&eacute;cial s&rsquo;abstiendra de voter sur la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    the proxy holder shall abstain from the vote on the amended or new resolution</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; border-right: Black 1pt solid; padding-left: 0.625in; padding-right: 4pt; text-align: justify">&#9744;
    le mandataire sp&eacute;cial votera sur la r&eacute;solution modifi&eacute;e ou nouvelle selon la mani&egrave;re support&eacute;e
    ou recommand&eacute;e par le conseil d&rsquo;administration de la Soci&eacute;t&eacute;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    the proxy holder shall vote on the amended or new resolution in the manner supported or recommended by the board of directors of
    the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>1
    </SUP>Veuillez cocher tel qu&rsquo;appropri&eacute;. Une absence d&rsquo;instruction sera interpr&eacute;t&eacute;e comme une instruction de
    voter pour la r&eacute;solution modifi&eacute;e ou nouvelle selon la mani&egrave;re support&eacute;e ou recommand&eacute;e par le
    conseil d&rsquo;administration de la Soci&eacute;t&eacute;.</I></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>1
    </SUP>Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or
    new resolution as will be supported or recommended by the board of directors of the Company.</I></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">I<FONT STYLE="font-size: 10pt"><B>II.
    </B>Si un ordre du jour suppl&eacute;mentaire est publi&eacute; conform&eacute;ment &agrave; l&rsquo;article&nbsp;7:130 du Code des soci&eacute;t&eacute;s
    et des associations apr&egrave;s que cette procuration ait &eacute;t&eacute; notifi&eacute;e &agrave; la Soci&eacute;t&eacute;, le
    mandataire sp&eacute;cial aura le pouvoir de voter sur des nouveaux sujets qui ont &eacute;t&eacute; ajout&eacute;s &agrave; l&rsquo;ordre
    du jour, le cas &eacute;ch&eacute;ant:</FONT></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.
    </B>If a supplemented agenda is published in accordance with article 7:130 of the Belgian Companies and Associations Code after this
    proxy has been notified to the Company, the special proxy holder shall have the power to vote on the new items that have been added
    to the agenda, as relevant:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    oui</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    non</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    no</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Veuillez
    remplir la case appropri&eacute;e. Une absence d&rsquo;instruction ou si, pour quelque raison, il y a une absence de clart&eacute; &agrave;
    propos de l&rsquo;instruction donn&eacute;e, le soussign&eacute; sera suppos&eacute; avoir choisi &ldquo;oui&rdquo;. Si la r&eacute;ponse
    &rdquo; oui &rdquo; est s&eacute;lectionn&eacute;e ou r&eacute;put&eacute;e l&rsquo;&ecirc;tre, le mandataire sp&eacute;cial votera de la
    mani&egrave;re soutenue par le conseil d&rsquo;administration de la Soci&eacute;t&eacute;.</I></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
    tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to
    the instruction given, the undersigned shall be deemed to have selected &ldquo;yes&rdquo;. If &lsquo;yes&rdquo; is selected or deemed
    to be selected, the special proxy holder will vote in the manner supported by the board of directors of the Company.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conform&eacute;ment
    au Code des soci&eacute;t&eacute;s et des associations, le mandataire sp&eacute;cial peut, &agrave; propos des sujets auxquels il
    est fait r&eacute;f&eacute;rence &agrave; l&rsquo;ordre du jour pour lesquels en vertu de l&rsquo;article 7:130 du Code des soci&eacute;t&eacute;s
    et des associations de nouvelles propositions de r&eacute;solutions ont &eacute;t&eacute; soumises, s&rsquo;&eacute;carter &agrave; l&rsquo;assembl&eacute;e
    des instructions, le cas &eacute;ch&eacute;ant, donn&eacute;es par le soussign&eacute;, si l&rsquo;ex&eacute;cution de ces instructions
    risquerait de compromettre les int&eacute;r&ecirc;ts du soussign&eacute;. Le mandataire sp&eacute;cial doit en informer le soussign&eacute;.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with the Belgian Companies and Associations Code, the special proxy holder may, with respect to the items referred to in the agenda
    for which pursuant to article 7:130 of the Belgian Companies and Associations Code new proposed resolutions have been tabled, deviate
    at the meeting from the instructions, if any, given by the undersigned, if the execution of those instructions could prejudice the
    interests of the undersigned. The special proxy holder must notify the undersigned thereof.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV. </B>Le
    mandataire sp&eacute;cial est autoris&eacute;, au nom et pour le compte du soussign&eacute;, &agrave; signer toutes listes de pr&eacute;sence
    et proc&egrave;s-verbaux, &agrave; participer &agrave; toutes les d&eacute;lib&eacute;rations, &agrave; prendre part au vote sur
    toutes les d&eacute;cisions ou sujets pouvant, conform&eacute;ment &agrave; cet ordre du jour, &ecirc;tre soumis &agrave; l&rsquo;assembl&eacute;e.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV. </B>The
    special proxy holder has the power to, in the name of and on behalf of the undersigned, sign all attendance lists and minutes, participate
    in all deliberations, vote with respect to all decisions or items that can, pursuant to this agenda, be presented to said meeting.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V. </B>Le
    mandataire sp&eacute;cial est autoris&eacute;, en g&eacute;n&eacute;ral, &agrave; faire tout ce qui semble n&eacute;cessaire et/ou
    utile pour exercer cette procuration.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.&nbsp;</B>In
    general, the special proxy holder has the power to do all that appears necessary and/or useful for the exercise of this proxy.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Le/la
    soussign&eacute;(e) ratifie et approuve par la pr&eacute;sente tous les actes accomplis par le mandataire sp&eacute;cial susmentionn&eacute;.
    Le mandataire sp&eacute;cial votera pour le compte du/de la soussign&eacute;(s) conform&eacute;ment aux instructions sp&eacute;cifiques
    donn&eacute;es ci-dessus.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The undersigned hereby
    ratifies and approves all acts carried out by the aforementioned proxy holder. The special proxy holder will vote on behalf of the
    undersigned in accordance with the specific instructions given above.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">La
    pr&eacute;sente procuration vaut &eacute;galement notification au sens de l&rsquo;article 7:134, &sect;2, alin&eacute;a 3 du Code des soci&eacute;t&eacute;s
    et des associations en ce qui concerne l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires de la Soci&eacute;t&eacute;
    &agrave; tenir le vendredi 3 novembre 2023.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The present proxy shall
    also serve as notification within the meaning of article 7:134, &sect;2, paragraph 3 of the Belgian Companies and Associations Code
    with respect to the extraordinary general shareholders&rsquo; meeting of the Company to be held on Friday 3 November 2023.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Le
    soussign&eacute; confirme que la traduction anglaise de la pr&eacute;sente procuration n&rsquo;est qu&rsquo;une traduction libre en anglais et
    &agrave; titre informatif uniquement, et que la version fran&ccedil;aise pr&eacute;vaut sur la version anglaise.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify">The undersigned confirms that the English translation of the present proxy is a free English translation and for information purposes
only, and that the French version shall prevail over the English version.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>BON
    POUR PROCURATION</B></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GOOD FOR PROXY</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">_______________________________2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(date)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">_______________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(nom
/ name)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">_______________________________________
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(signature)</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 89%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></FONT></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Proxy </B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/12</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.9
<SEQUENCE>10
<FILENAME>ea186179ex99-9_mdxhealth.htm
<DESCRIPTION>VOTING BY MAIL FORM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="padding-top: 2pt; width: 50%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Assembl&Eacute;e
g&Eacute;n&Eacute;rale extraordinaire des Actionnaires</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>3 NOVEMBRE
    2023</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD>
    <TD STYLE="padding-top: 2pt; width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>extraordinary general shareholders&rsquo; meeting <BR>
3 November 2023</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>formulaire de vote par correspondance</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Voting by mail form</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Ce formulaire doit &ecirc;tre utilis&eacute; par les titulaires de titres de MDxHealth&nbsp;SA (la &ldquo;<B>Soci&eacute;t&eacute;</B>&rdquo;) qui d&eacute;sirent voter par correspondance &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires de la Soci&eacute;t&eacute; &agrave; tenir le vendredi 3 novembre 2023 &agrave; 15h00 (heure belge).</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">This form should be used by holders of securities of MDxHealth SA (the &ldquo;<B>Company</B>&rdquo;) who want to vote by mail at the extraordinary general shareholders&rsquo; meeting of the Company to be held on Friday, 3 November 2023, at 3:00 p.m. (Belgian time).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Le formulaire de vote par correspondance doit &ecirc;tre sign&eacute; par &eacute;crit ou &eacute;lectroniquement. Si une signature &eacute;lectronique est utilis&eacute;e, elle doit &ecirc;tre une signature &eacute;lectronique qualifi&eacute;e au sens du R&egrave;glement (UE) n&deg; 910/2014 du Parlement europ&eacute;en et du Conseil du 23 juillet 2014 sur l&rsquo;identification &eacute;lectronique et les services de confiance pour les transactions &eacute;lectroniques au sein du march&eacute; int&eacute;rieur et abrogeant la directive 1999/93/CE, tel que modifi&eacute;.</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">The voting by mail form must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Le formulaire de vote par correspondance sign&eacute; et compl&eacute;t&eacute; doit parvenir &agrave; la Soci&eacute;t&eacute; au plus tard le sixi&egrave;me jour calendrier qui pr&eacute;c&egrave;de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, soit <B><U>le, ou avant le, samedi 28 octobre 2023</U></B> au plus tard. Jusqu&rsquo;&agrave; cette date, les formulaires peuvent &ecirc;tre envoy&eacute;es &agrave; l&rsquo;adresse suivante&nbsp;: </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">The signed and completed voting by mail form must reach the Company at the latest on the sixth calendar day prior to the extraordinary general shareholders&rsquo; meeting, i.e. <B><U>on or before Saturday, 28 October 2023</U></B> at the latest. Until this date, forms can be sent to the following address:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">MDxHealth SA</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">MDxHealth SA</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A l&rsquo;attention de M. Ron Kalfus</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Attention Mr. Ron Kalfus</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Secr&eacute;taire de la Soci&eacute;t&eacute;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Company Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CAP Business Center</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CAP Business Center</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Zone Industrielle des Hauts-Sarts</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Zone Industrielle des Hauts-Sarts</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Rue d&rsquo;Abhooz 31,</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Rue d&rsquo;Abhooz, 31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">4040 Herstal</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">4040 Herstal,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Belgique</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Belgium</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ou par courrier &eacute;lectronique &agrave;&nbsp;:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">or by e-mail to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">agsm@mdxhealth.com</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">agsm@mdxhealth.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Les titulaires de titres de la Soci&eacute;t&eacute; qui d&eacute;sirent &ecirc;tre repr&eacute;sent&eacute;s par voter par correspondance doivent aussi s&rsquo;enregistrer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, tel que d&eacute;crit dans l&rsquo;invitation &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires. Les titulaires de titres d&eacute;mat&eacute;rialis&eacute;s doivent joindre &agrave; ce formulaire de vote par correspondance un certificat d&eacute;livr&eacute; par le teneur de compte agr&eacute;&eacute;, l&rsquo;organisme de liquidation comp&eacute;tent, ou de l&rsquo;interm&eacute;diaire financier pour les titres concern&eacute;s, confirmant le nombre de titres ayant &eacute;t&eacute; enregistr&eacute;s &agrave; leur nom &agrave; la date d&rsquo;enregistrement (soit le vendredi 20 octobre 2023, &agrave; minuit (00h00, heure belge)) et avec lesquelles ils veulent participer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires.</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Holders of securities of the Company who wish to vote by mail must also register for the extraordinary general shareholders&rsquo; meeting, as described in the notice convening the extraordinary general shareholders&rsquo; meeting. Holders of dematerialised securities must attach to the present voting by mail form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name on the registration date (i.e., Friday, 20 October 2023, at midnight (12:00 a.m., Belgian time)), with which they want to participate to the extraordinary general shareholders&rsquo; meeting.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">En cas de modification de l&rsquo;ordre du jour ou si des nouvelles propositions de r&eacute;solutions sont d&eacute;pos&eacute;es, la Soci&eacute;t&eacute; publiera un ordre du jour compl&eacute;t&eacute; avec, le cas &eacute;ch&eacute;ant, des points additionnels inscrits &agrave; l&rsquo;ordre du jour et des propositions de r&eacute;solutions additionnelles. Ceci sera fait au plus tard le quinzi&egrave;me jour calendrier avant l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, soit le, ou avant le, jeudi 19 octobre 2023 au plus tard. En outre, la Soci&eacute;t&eacute; mettra aussi &agrave; disposition un formulaire modifi&eacute; de vote par correspondance. Les formulaires qui parviennent &agrave; la Soci&eacute;t&eacute; ant&eacute;rieurement &agrave; la publication d&rsquo;un ordre du jour compl&eacute;t&eacute; demeurent valides pour les points inscrits &agrave; l&rsquo;ordre du jour auxquels les formulaires de vote par correspondance s&rsquo;appliquent, sous r&eacute;serve, cependant, du droit applicable et des clarifications compl&eacute;mentaires d&eacute;crites dans les formulaires de vote par correspondance. Conform&eacute;ment au Code des soci&eacute;t&eacute;s et des associations, un vote par correspondance pour un point de l&rsquo;ordre du jour pour lequel une nouvelle proposition de r&eacute;solution a &eacute;t&eacute; soumise par un ou plusieurs actionnaires d&eacute;tenant au moins 3 % du capital social, n&rsquo;est pas valable.</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">In case of amendments to the agenda or if
new draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional
draft resolutions. This will be done no later than on the fifteenth calendar day prior to the extraordinary general shareholders&rsquo; meeting,
i.e. on or before Thursday, 19 October 2023 at the latest. In addition, the Company will also make amended forms available for voting
by mail. Voting by mail forms that reach the Company prior to the publication of an amended agenda remain valid for the agenda items
to which the voting by mail forms apply, subject, however, to applicable law and the further clarifications set out in the voting by
mail form. In accordance with the Belgian Companies and Associations Code, a vote via vote by mail for an agenda item in relation to
which a new proposed resolution has been submitted by one or more shareholders holding at least 3% of the share capital, is invalid.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-align: justify; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0.125in 0pt 0pt">La date limite pour la communication de ce
vote par correspondance est un samedi, pendant laquelle il n&rsquo;y a g&eacute;n&eacute;ralement pas de service postal ordinaire. Ainsi, la
Soci&eacute;t&eacute; recommande d&rsquo;utiliser le courrier &eacute;lectronique pour toute communication avec la Soci&eacute;t&eacute; concernant
l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale d&rsquo;actionnaires.&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 50%">The deadline for the submission of this voting by mail form is on a Saturday, during which there is usually no ordinary postal service. Therefore, the Company recommends to use e-mail for all communication with the Company regarding the general shareholders&rsquo; meeting.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Le/La soussign&eacute;(e),</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned,</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt; width: 35%"><FONT STYLE="font-size: 10pt">Pr&eacute;nom / First name:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt; width: 65%"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Nom de famille / Family name:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Adresse / Address:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">ou / or</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">D&eacute;nomination / Corporate name:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Forme juridique / Corporate form:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Si&egrave;ge / Registered office:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.65pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Repr&eacute;sent&eacute; par (pr&eacute;nom, nom de famille et qualit&eacute;) / Represented by (first name, family name and capacity):</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 0pt; text-align: justify; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">titulaire du (des) nombre(s) suivant(s) de titres &eacute;mis par MDxHealth SA, ayant son si&egrave;ge au CAP Business Center, Zone Industrielle des Hauts-Sarts, Rue d&rsquo;Abhooz 31, 4040 Herstal, Belgique,</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">owner of the following number of securities issued by MDxHealth SA, with its registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium,</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Nombre d&rsquo;actions / Number of
shares: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_____________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Forme des actions susmentionn&eacute;es / Form of the above mentioned
shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><I>(veuillez cocher la case appropri&eacute;e / please tick the appropriate
box)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif">Nominatives
/ Registered</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif">D&eacute;mat&eacute;rialis&eacute;es
/ Dematerialised</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Nombre de droits de souscription / <BR>
Number of subscription rights: <SUP>1</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>______________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 3%"><FONT STYLE="font-size: 10pt"><I><SUP>1</SUP> </I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 47%"><FONT STYLE="font-size: 10pt"><I>Conform&eacute;ment &agrave; l&rsquo;article 7:135 du Code des soci&eacute;t&eacute;s et des associations,
les titulaires de droits de souscription ont le droit de participer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires
mais seulement avec voix consultative.</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 3%"><FONT STYLE="font-size: 10pt"><I><SUP>1</SUP></I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 47%"><FONT STYLE="font-size: 10pt"><I>Pursuant
    to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the
    shareholders&rsquo; meeting, but only with an advisory vote.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">vote irr&eacute;vocablement, comme indiqu&eacute; dans les cases correspondantes ci-dessous, sur les points inscrits &agrave; l&rsquo;ordre du jour suivant : <SUP>2 </SUP></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">votes irrevocably, as indicated in the corresponding boxes below, on the items on the following agenda: <SUP>2</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I><SUP>2</SUP> </I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Veuillez indiquer l&rsquo;instruction de vote dans les cases appropri&eacute;es pour les points &agrave;
l&rsquo;ordre du jour. En l&rsquo;absence d&rsquo;une instruction de vote pour un point de l&rsquo;ordre du jour, ou dans le cas o&ugrave;,
pour quelque raison que ce soit, il y aurait un manque de clart&eacute; concernant les instructions de vote, le/la soussign&eacute;(e)
sera pr&eacute;sum&eacute;(e) avoir vot&eacute; &ldquo;en faveur&rdquo; des r&eacute;solutions propos&eacute;es soutenues par le conseil
d&rsquo;administration.</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I><SUP>2 </SUP></I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence
of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards
to the voting instructions, the undersigned will be presumed&nbsp;&nbsp;to have voted in favour of the proposed resolutions supported
by the board of directors.</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 50%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ORDRE
    DU JOUR</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>assembl&eacute;e
g&eacute;n&eacute;rale extraordinaire</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%; padding-right: 5.4pt; padding-left: 0.25in">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>agenda</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>extraordinary
general meeting</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-align: left; padding-right: 5.4pt"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Pr&eacute;sentation du rapport sp&eacute;cial</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify; text-indent: -14.15pt"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Submission of special report</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">Pr&eacute;sentation et discussion du rapport sp&eacute;cial, r&eacute;dig&eacute; par le conseil d&rsquo;administration, dans le cadre du Regroupement d&rsquo;Actions et de la Radiation de la Cote (telles que d&eacute;finies aux points 2 et 3 de l&rsquo;ordre du jour).</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.375in; text-align: justify"><FONT STYLE="font-size: 10pt">Submission of and discussion on, the special report, prepared by the board of directors, in connection with the Share Consolidation and De-Listing (as defined below in points 2 and 3 of the agenda).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-top: 12pt; padding-left: 0.25in; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.375in; padding-left: 0.375in; padding-right: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Regroupement d&rsquo;Actions (sur la base d&rsquo;un ratio de 1 pour 10)</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Share Consolidation (1-for-10 reverse stock split)</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;&nbsp;&nbsp;<U>Proposition de r&eacute;solution</U></I></B>:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Proposed resolution</U></I></B>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">Conform&eacute;ment &agrave; l&rsquo;article 7:49 du Code des soci&eacute;t&eacute;s et des associations, l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires d&eacute;cide d&rsquo;effectuer un regroupement d&rsquo;actions concernant toutes les actions en circulation de la Soci&eacute;t&eacute; au moyen d&rsquo;un regroupement d&rsquo;actions sur la base d&rsquo;un ratio de 1 pour 10 (le &ldquo;<B>Regroupement d&rsquo;Actions</B>&rdquo;), et d&rsquo;accorder au conseil d&rsquo;administration de la Soci&eacute;t&eacute;, pour une p&eacute;riode de six mois suivant la date de cette assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, l&rsquo;autorisation de poursuivre la mise en &oelig;uvre du Regroupement d&rsquo;Actions. Si le conseil d&rsquo;administration n&rsquo;entame pas la proc&eacute;dure de mise en &oelig;uvre du Regroupement d&rsquo;Actions dans un d&eacute;lai de six mois &agrave; compter de la date de la pr&eacute;sente assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, le pouvoir du conseil d&rsquo;administration d&rsquo;effectuer le Regroupement d&rsquo;Actions expirera, &agrave; moins qu&rsquo;il ne soit renouvel&eacute;. </FONT></TD>
    <TD STYLE="text-indent: 0in; padding-right: 5.4pt; padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">In accordance with article 7:49 of the Belgian Companies and Associations Code, the extraordinary general shareholders&rsquo; meeting decides to effect a share consolidation with respect to all outstanding shares of the Company by means of a 1-for-10 reverse stock split (the &ldquo;<B>Share Consolidation</B>&rdquo;), and to grant the board of directors of the Company the authority for a six-month period following the date of this extraordinary general shareholders&rsquo; meeting to further implement the Share Consolidation. If the board of directors does not initiate the process for implementing the Share Consolidation within a six-month period following the date of this extraordinary general shareholders&rsquo; meeting, the board of director&rsquo;s authority to effect the Share Consolidation shall expire, unless renewed. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">Le pouvoir du conseil d&rsquo;administration de mettre en &oelig;uvre le Regroupement d&rsquo;Actions est soumis aux conditions suivantes :</FONT></TD>
    <TD STYLE="text-indent: 0in; padding-right: 5.4pt; padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">The board of director&rsquo;s authority to implement the Share Consolidation is subject to the following terms and conditions:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Regroupement d&rsquo;Actions : </U>Toutes les actions en circulation de la Soci&eacute;t&eacute; seront regroup&eacute;es en un nombre nouveau et r&eacute;duit d&rsquo;actions selon le ratio d&rsquo;une (1) nouvelle action pour dix (10) actions existantes (le &ldquo;<B>Ratio</B>&rdquo;). Sous r&eacute;serve des conditions &eacute;nonc&eacute;es ci-dessous, le Regroupement d&rsquo;Actions sera effectu&eacute; simultan&eacute;ment pour toutes les actions en circulation de la Soci&eacute;t&eacute; conform&eacute;ment au Ratio, de sorte qu&rsquo;apr&egrave;s l&rsquo;ach&egrave;vement du processus de Regroupement d&rsquo;Actions, chaque nouvelle action repr&eacute;sentera la m&ecirc;me fraction du capital de la Soci&eacute;t&eacute;. Le Regroupement d&rsquo;Actions n&rsquo;entra&icirc;nera pas de r&eacute;duction ou d&rsquo;augmentation du capital de la Soci&eacute;t&eacute;.</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Share Consolidation</U>: All of the outstanding shares of the Company shall be consolidated into a new and reduced number of shares pursuant to the ratio of one (1) new share for ten (10) existing shares (the &ldquo;<B>Ratio</B>&rdquo;). Subject to the terms and conditions set out below, the Share Consolidation will be carried out simultaneously for all outstanding shares of the Company in accordance with the Ratio, so that after the completion of the Share Consolidation each new share shall represent the same fraction of the Company&rsquo;s share capital. The Share Consolidation will not result in a reduction or increase of the Company&rsquo;s share capital.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.25in; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Forme et nature des nouvelles actions :</U> Le Regroupement d&rsquo;Actions n&rsquo;affectera pas la forme des actions en circulation (d&eacute;mat&eacute;rialis&eacute;es ou nominatives) et les actions d&eacute;mat&eacute;rialis&eacute;es et nominatives en circulation seront trait&eacute;es s&eacute;par&eacute;ment dans le cadre du Regroupement d&rsquo;Actions. Toutes les nouvelles actions apr&egrave;s l&rsquo;ach&egrave;vement du processus de Regroupement d&rsquo;Actions seront assorties des m&ecirc;mes droits et avantages et seront pari passu &agrave; tous &eacute;gards, y compris en ce qui concerne les droits aux dividendes et autres distributions, en application du Ratio.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT><U>Form and nature of the new shares</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">The Share Consolidation will not affect the form of the outstanding shares (dematerialized or registered) and the outstanding dematerialized and registered shares will be processed separately within the framework of the Share Consolidation. All new shares after the completion of the Share Consolidation shall have the same rights and benefits and shall rank </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>pari passu</I> <FONT STYLE="font-style: normal">in all respects, including as to entitlements to dividends and other distributions, in application of the Ratio.</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;<U>Pas de fractions de nouvelles actions :</U> Dans le cadre du Regroupement d&rsquo;Actions, les actions existantes ne peuvent &ecirc;tre regroup&eacute;es, conform&eacute;ment au Ratio, qu&rsquo;en un nombre entier de nouvelles actions. Aucune fraction de nouvelles actions ne peut &ecirc;tre &eacute;mise. Sous r&eacute;serve des r&egrave;gles applicables en mati&egrave;re de droit des soci&eacute;t&eacute;s, de droit financier et de droit des valeurs mobili&egrave;res, et sous r&eacute;serve des dispositions des paragraphes pr&eacute;c&eacute;dents, le conseil d&rsquo;administration est autoris&eacute; &agrave; d&eacute;terminer la mani&egrave;re et la proc&eacute;dure &agrave; suivre pour effectuer le Regroupement d&rsquo;Actions &agrave; l&rsquo;&eacute;gard des d&eacute;tenteurs d&rsquo;actions existantes de la Soci&eacute;t&eacute; qui, au moment du Regroupement d&rsquo;Actions, ne disposent pas d&rsquo;un nombre suffisant d&rsquo;actions existantes pour recevoir un nombre entier de nouvelles actions conform&eacute;ment au Ratio. Dans ce contexte, le conseil d&rsquo;administration aura le pouvoir de d&eacute;terminer que (i) les positions des anciennes actions qui ne peuvent pas &ecirc;tre regroup&eacute;es en un nombre entier de nouvelles actions conform&eacute;ment au Ratio peuvent &ecirc;tre agr&eacute;g&eacute;es pour &ecirc;tre regroup&eacute;es en nouvelles actions, (ii) ces nouvelles actions peuvent &ecirc;tre vendues ou plac&eacute;es, par le biais d&rsquo;un placement priv&eacute; exempt&eacute;, d&rsquo;une vente en bloc de titres, d&rsquo;une vente sur le march&eacute;, d&rsquo;une proc&eacute;dure (acc&eacute;l&eacute;r&eacute; ou non) de constitution d&rsquo;un livre d&rsquo;ordres ou autrement, &agrave; ou aupr&egrave;s d&rsquo;investisseurs institutionnels, qualifi&eacute;s ou professionnels ou de particuliers en Belgique et ailleurs, et (iii) le produit de cette vente ou de ce placement sera distribu&eacute; au prorata aux d&eacute;tenteurs d&rsquo;actions existantes qui n&rsquo;ont pas un nombre suffisant d&rsquo;actions existantes pour &ecirc;tre converties en nouvelles actions enti&egrave;res conform&eacute;ment au Ratio, &agrave; condition que le produit ne soit pas inf&eacute;rieur &agrave; un centime d&rsquo;euro (EUR 0,01) par action existante. Si le produit est inf&eacute;rieur ou ne peut &ecirc;tre distribu&eacute; au prorata comme indiqu&eacute; ci-dessus, il sera distribu&eacute; &agrave; la Soci&eacute;t&eacute;. Les co&ucirc;ts et frais de transaction pertinents (y compris les commissions, honoraires et frais des agents et conseillers) et les taxes, le tout tel qu&rsquo;applicable, seront support&eacute;s par la Soci&eacute;t&eacute;. Sous r&eacute;serve des dispositions applicables de droit des soci&eacute;t&eacute;s, de droit financier et de droit des valeurs mobili&egrave;res, le conseil d&rsquo;administration a &eacute;galement le pouvoir de d&eacute;cider que les positions des actions existantes qui ne peuvent &ecirc;tre regroup&eacute;es conform&eacute;ment au Ratio en un nombre entier de nouvelles actions peuvent &ecirc;tre acquises par la Soci&eacute;t&eacute; ou l&rsquo;une de ses filiales et que le produit de cette vente sera distribu&eacute; au prorata comme indiqu&eacute; ci-dessus.</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp; </FONT><U>No fractions of new shares</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">Within the framework of the Share Consolidation, the existing shares can only be consolidated, in accordance with the Ratio, into a whole number of new shares. No fractions of new shares can be issued. Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall be authorized to determine the manner and process to effect the Share Consolidation with respect to holders of existing shares of the Company who at the time of the Share Consolidation do not have a sufficient number of existing shares in order to receive a whole number of new shares in accordance with the Ratio. Within this context, the board of directors shall have the authority to determine that (i) the positions of old shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio can be aggregated for consolidation into new shares, (ii) such new shares can be sold or placed, via an exempt private placement, block trade, market sale, bookbuilding (accelerated or not) or otherwise, to or with institutional, qualified or professional investors or individuals in and outside of Belgium, and (iii) the proceeds of such sale or placement will be distributed on a pro rata basis to the holders of existing shares that do not have a sufficient number of existing shares to be converted into whole new shares in accordance with the Ratio, provided that the proceeds shall not be less than one euro cent (EUR 0.01) per existing share. If proceeds are less or cannot be distributed on a pro rata basis as aforementioned, these shall accrue to the Company. The relevant transaction costs and expenses (including commissions, fees and expenses of agents and advisors) and applicable taxes, all as applicable, will be borne by the Company. Subject to applicable provisions of company, financial and securities law, the board of directors shall also have the authority to determine that the positions of existing shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares, can be acquired by the Company or one of its subsidiaries and that the proceeds of such sale will be distributed on a pro rata basis as aforementioned.</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Annulation des actions existantes : </U>Apr&egrave;s l&rsquo;ach&egrave;vement du processus de Regroupement d&rsquo;Actions, les actions existantes de la Soci&eacute;t&eacute; seront annul&eacute;es et ne seront plus en circulation. </FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cancellation of existing shares</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">Following the completion of the Share Consolidation, the existing shares of the Company shall be cancelled and will no longer remain outstanding</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>.</I></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp; </FONT><U>Calendrier du Regroupement d&rsquo;Actions :</U> Le conseil d&rsquo;administration est autoris&eacute; &agrave; d&eacute;terminer la date effective du Regroupement d&rsquo;Actions, &agrave; condition toutefois que le Regroupement d&rsquo;Actions soit mis en &oelig;uvre au plus tard dans un d&eacute;lai de six mois &agrave; compter de la date de la pr&eacute;sente assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires. Le conseil d&rsquo;administration a le pouvoir de ne pas proc&eacute;der &agrave; la mise en &oelig;uvre du Regroupement d&rsquo;Actions ou, dans le cas o&ugrave; la mise en &oelig;uvre du Regroupement d&rsquo;Actions a d&eacute;j&agrave; commenc&eacute;, de suspendre ou d&rsquo;annuler le processus de Regroupement d&rsquo;Actions si le conseil d&rsquo;administration d&eacute;termine que les circonstances du march&eacute; ne permettent pas de r&eacute;aliser le Regroupement d&rsquo;Actions dans des conditions jug&eacute;es satisfaisantes par le conseil d&rsquo;administration.</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; width: 50%">(e)&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Timing of the Share Consolidation:</U> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">The board of directors shall be authorized to determine the effective date of the Share Consolidation, provided however, that the Share Consolidation is to be implemented within a six-month period following the date of this extraordinary general shareholders&rsquo; meeting at the latest. The board of directors shall have the authority not to proceed with the implementation of the Share Consolidation, or, in case the implementation of the Share Consolidation has already started, to suspend or cancel the completion of the Share Consolidation if the board of directors determines that the market circumstances do not allow for the completion of the Share Consolidation in circumstances deemed satisfactory to it.</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp; </FONT><U>Agents :</U> Une ou plusieurs banques ou institutions financi&egrave;res seront ou pourront &ecirc;tre d&eacute;sign&eacute;es par la Soci&eacute;t&eacute; aux fins de l&rsquo;organisation et de la mise en &oelig;uvre du Regroupement d&rsquo;Actions, y compris (mais sans s&rsquo;y limiter) le regroupement des positions des actions existantes qui ne peuvent &ecirc;tre regroup&eacute;es en un nombre entier de nouvelles actions conform&eacute;ment au Ratio, et la vente de nouvelles actions comme le permet le paragraphe (c).</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Agents</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">One or more banks or financial institutions shall or may be appointed by the Company for the purpose of the further organization and implementation of the Share Consolidation, including (but not limited to) the consolidation of positions of existing shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio, and the sale of new shares as permitted by paragraph (c).</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Ajustement du prix de souscription des Droits de Souscription :</U> &Agrave; l&rsquo;issue du Regroupement d&rsquo;Actions, le Regroupement d&rsquo;Actions sera effectu&eacute; en ce qui concerne les droits de souscription en circulation de la Soci&eacute;t&eacute; de la mani&egrave;re envisag&eacute;e dans les conditions respectives de ces droits de souscription, de sorte qu&rsquo;un d&eacute;tenteur de droits de souscription devra exercer des droits de souscription &agrave; l&rsquo;&eacute;gard d&rsquo;au moins 10 Actions avant le Regroupement d&rsquo;Actions pour pouvoir souscrire une Action apr&egrave;s le Regroupement d&rsquo;Actions.</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Adjustment of the subscription price of the Subscription Rights</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">At completion of the Share Consolidation, the Share Consolidation shall be effected in relation to the outstanding subscription rights of the Company in the manner as contemplated in the respective terms and conditions of these subscription rights, so that a holder of subscription rights will have to exercise subscription rights with respect to at least 10 Shares prior the Share Consolidation in order to subscribe for one Share after the Share Consolidation.</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Modification des statuts :</U> &Agrave; l&rsquo;issue du Regroupement d&rsquo;Actions, l&rsquo;article 5 des statuts de la Soci&eacute;t&eacute; sera modifi&eacute; et reformul&eacute; pour tenir compte du nombre d&rsquo;actions en circulation et existantes qui en r&eacute;sultera.</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT><U>Amendment of the articles of association</U>: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">At completion of the Share Consolidation, Article 5 of the Company&rsquo;s articles of association shall be amended and restated to take into account the resulting number of outstanding and existing shares.</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">(i)&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Mise en &oelig;uvre du Regroupement d&rsquo;Actions :</U> Sous r&eacute;serve des r&egrave;gles applicables en mati&egrave;re de droit des soci&eacute;t&eacute;s, de droit financier et de droit des valeurs mobili&egrave;res, et sous r&eacute;serve des dispositions des paragraphes pr&eacute;c&eacute;dents, le conseil d&rsquo;administration a le pouvoir de mettre en &oelig;uvre et l&rsquo;ex&eacute;cution du Regroupement d&rsquo;Actions, y compris (sans s&rsquo;y limiter) le pouvoir (i) de d&eacute;terminer la mise en &oelig;uvre pratique du Regroupement d&rsquo;Actions, (ii) de d&eacute;terminer le calendrier et la date effective du Regroupement d&rsquo;Actions comme pr&eacute;vu au paragraphe (e), (iii) de d&eacute;terminer la mani&egrave;re et le processus de traitement des positions d&rsquo;actions existantes qui ne peuvent pas &ecirc;tre regroup&eacute;es en un nombre entier de nouvelles actions conform&eacute;ment au Ratio comme pr&eacute;vu au paragraphe (c), (iv) de nommer une ou plusieurs banques ou institutions financi&egrave;res pour l&rsquo;organisation et la mise en &oelig;uvre du Regroupement d&rsquo;Actions tel qu&rsquo;envisag&eacute; au paragraphe (f), (v) de proc&eacute;der &agrave; la constatation de la modification et de la reformulation des statuts tels qu&rsquo;envisag&eacute;s au paragraphe (h) devant notaire, (vi) d&rsquo;entreprendre toutes les d&eacute;marches utiles ou n&eacute;cessaires aupr&egrave;s d&rsquo;Euronext, d&rsquo;Euroclear, de toute autre agence de r&egrave;glement comp&eacute;tente et de toute autorit&eacute; de r&eacute;glementation ou de cotation en rapport avec la mise en &oelig;uvre du Regroupement d&rsquo;Actions, (vii) d&rsquo;effectuer toutes les modifications dans les registres de titres pertinents de la Soci&eacute;t&eacute; refl&eacute;tant le Regroupement d&rsquo;Actions, et (viii) de prendre toutes les autres mesures utiles, appropri&eacute;es ou n&eacute;cessaires en rapport avec ce qui pr&eacute;c&egrave;de. Le conseil d&rsquo;administration est habilit&eacute; &agrave; d&eacute;l&eacute;guer la mise en &oelig;uvre et de l&rsquo;ex&eacute;cution du Regroupement d&rsquo;Actions (y compris les pouvoirs vis&eacute;s aux points (i) &agrave; (viii)), en tout ou en partie, &agrave; un ou plusieurs membres du management ou du personnel de la Soci&eacute;t&eacute;. Tout administrateur, tout membre du management et toute autre personne express&eacute;ment d&eacute;sign&eacute;e &agrave; cet effet par le conseil d&rsquo;administration est autoris&eacute; &agrave; faire constater, devant notaire, la modification et la reformulation des statuts vis&eacute;es au paragraphe (h).</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Further implementation of the Share Consolidation:</U> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall have the authority to further implement and effect the Share Consolidation, including (without being limited to) the authority to (i) determine the practical implementation of the Share Consolidation, (ii) determine the timing and the effective date of the Share Consolidation as contemplated by paragraph (e), (iii) determine the manner and process to deal with positions of existing shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio as contemplated by paragraph (c), (iv) appoint one or more banks or financial institutions for the further organization and implementation of the Share Consolidation as contemplated by paragraph (f), (v) proceed with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary public, (vi) take all useful or necessary steps with Euronext, Euroclear, any other competent settlement agency, and any regulatory or listing authority in connection with the implementation of the Share Consolidation, (vii) make all changes in the relevant securities register books of the Company reflecting the Share Consolidation, and (viii) do such other things as shall be useful, appropriate or necessary in connection with the foregoing. The board of directors shall have the authority to delegate the further implementation and execution of the Share Consolidation (including the powers referred to in sub-sections (i) to (viii)), in whole or in part, to one or more members of the Company&rsquo;s executive management or personnel. Any director, any member of the executive management, and any other persons that shall be expressly appointed for such purpose by the board of directors shall be authorized to record the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary public.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Instruction de vote</U></FONT></I></B>: </FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-top: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Voting instruction</U></FONT></I></B>: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 3pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Pour / For</I></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 3pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Contre / Against</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abstention</I></FONT></TD></TR>
  <TR>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Radiation de la Cote d&rsquo;Euronext Brussels</U></FONT></TD>
    <TD STYLE="padding-left: 5.4pt; padding-right: 3pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>De-Listing from Euronext Brussels</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;&nbsp;&nbsp;<U>Proposition de r&eacute;solution</U></I></B>:</FONT></TD>
    <TD STYLE="padding-left: 5.4pt; padding-right: 3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Proposed resolution</U></I></B>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires d&eacute;cide d&rsquo;approuver la Radiation de la Cote de la Soci&eacute;t&eacute; du march&eacute; r&eacute;glement&eacute; d&rsquo;Euronext Brussels (la &ldquo;<B>Radiation de la Cote</B>&rdquo;), de modifier les statuts de la Soci&eacute;t&eacute; aux fins de cette Radiation de la Cote et d&rsquo;octroyer au conseil d&rsquo;administration de la Soci&eacute;t&eacute; le pouvoir de poursuivre la mise en &oelig;uvre de la Radiation de la Cote, sous r&eacute;serve des conditions suivantes :</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The extraordinary general shareholders&rsquo; meeting decides to approve a de-listing of the Company&rsquo;s shares from the regulated market of Euronext Brussels (the &ldquo;<B>De-Listing</B>&rdquo;), to amend the Company&rsquo;s articles of association for the purpose of such De-Listing, and to grant the board of directors of the Company the authority to further implement the De-Listing, subject to the following terms and conditions:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="text-indent: -0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;<U>Radiation de la Cote :</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires approuve et accepte qu&rsquo;il soit mis fin &agrave; l&rsquo;admission des actions de la Soci&eacute;t&eacute; &agrave; la cote et &agrave; la n&eacute;gociation et que, par cons&eacute;quent, les actions de la Soci&eacute;t&eacute; ne puissent plus &ecirc;tre cot&eacute;es et n&eacute;goci&eacute;es sur le march&eacute; r&eacute;glement&eacute; d&rsquo;Euronext Brussels (&ldquo;<B>Euronext Brussels</B>&rdquo;), &agrave; condition que les actions de la Soci&eacute;t&eacute; (ou, le cas &eacute;ch&eacute;ant, les American Depositary Shares ou les American Depositary Receipts relatifs &agrave; ces actions) soient admises &agrave; la n&eacute;gociation sur le Nasdaq Capital Market (le &ldquo;<B>Nasdaq</B>&rdquo;).</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;<U>De-Listing</U>: The general shareholders&rsquo; meeting approves and agrees that the admission of the Company&rsquo;s shares to listing and trading shall be terminated and, consequently, the Company&rsquo;s shares shall no longer be able to list and trade on the regulated market of Euronext Brussels (&ldquo;<B>Euronext Brussels</B>&rdquo;), provided that the Company&rsquo;s shares (or, as the case may be, American Depositary Shares or American Depositary Receipts in relation to such shares) shall be admitted to trading on the Nasdaq Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="text-indent: -0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;<U>Date effective :</U> Le conseil d&rsquo;administration a le pouvoir de d&eacute;terminer la date effective de la Radiation de la Cote, sous r&eacute;serve d&rsquo;une p&eacute;riode de transition pr&eacute;alable d&rsquo;au moins trois semaine avant la date effective de la Radiation de la Cote (la &ldquo;<B>P&eacute;riode de Transition</B>&rdquo;) pendant laquelle les actions de la Soci&eacute;t&eacute; resteront admises &agrave; la n&eacute;gociation sur Euronext Brussels. Si, et pour autant que, le Regroupement d&rsquo;Actions a &eacute;t&eacute; mis en &oelig;uvre, la P&eacute;riode de Transition sera d&rsquo;au moins trois semaines apr&egrave;s que le Regroupement d&rsquo;Actions soit devenu effectif.</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;<U>Effective date</U>: The board of directors shall have the power to determine the effective date of the De-Listing subject to a prior transition period of at least three weeks prior to the effective date of the De-Listing Date (the &ldquo;<B>Transition Period</B>&rdquo;) during which the Company&rsquo;s shares shall remain admitted to trading on Euronext Brussels. If and to the extent the Share Consolidation has been effected, the Transition Period shall at least be three weeks after the Share Consolidation has become effective.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 3pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification des statuts :</U> &Agrave; la date effective de la Radiation de la Cote, les dispositions suivantes des statuts de la Soci&eacute;t&eacute; seront modifi&eacute;es et reformul&eacute;es comme suit (&agrave; l&rsquo;exception de la modification pr&eacute;vue au paragraphe (i), laquelle est effective imm&eacute;diatement apr&egrave;s l&rsquo;approbation de la modification par l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires) :</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;<U>Amendments to the articles of association</U>: Upon the effective date of the De-Listing, the following provisions of the Company&rsquo;s articles of association of the Company shall be amended and restated as follows (except that the amendment in paragraph (i) is effective immediately upon approval of the amendment by the extraordinary general shareholders&rsquo; meeting):</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;l&rsquo;article 9 (&ldquo;Nature des titres&rdquo;), les trois derniers paragraphes sont modifi&eacute;s et reformul&eacute;s comme suit:</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;In article 9 (&ldquo;Nature of the securities&rdquo;), the three last paragraphs shall be amended and restated as follows:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 0.5in"><I>&ldquo;Un registre des actions nominatives est tenu au si&egrave;ge de la soci&eacute;t&eacute; et peut &ecirc;tre scind&eacute; par d&eacute;cision du conseil d&rsquo;administration conform&eacute;ment aux dispositions du droit applicable. Le conseil d&rsquo;administration peut d&eacute;signer un tiers de son choix pour conserver une partie du registre des actions nominatives scind&eacute;. Sous r&eacute;serve des dispositions applicables de droit des soci&eacute;t&eacute;s, de droit financier et du droit des valeurs mobili&egrave;res, et sauf d&eacute;cision contraire du conseil d&rsquo;administration conform&eacute;ment &agrave; l&rsquo;article 43 des statuts, les dividendes et autres distributions (selon le cas) de la soci&eacute;t&eacute; sur les actions peuvent &ecirc;tre effectu&eacute;s en euros (EUR) ou en dollars am&eacute;ricains (USD), en fonction de la composante du registre des actions (scind&eacute;) sur lequel les actions sont inscrites<B><SUP>1</SUP></B>.</I> &nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;A share register is kept at the registered office of the company and may be split by decision of the board of directors in accordance with the provisions of the applicable law. The board of directors can appoint a third party of its choice to keep any part of the split share register. Subject to applicable provisions of companies, financial and securities laws, and unless decided otherwise by the board directors in accordance with article 43 of the articles of association, dividends and other distributions (as the case may be) by the company on shares can be made in euro (EUR) or United States dollars (USD) depending on the component of the (split) share register on which the shares are reflected.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 0.5in"><I>Leregistre (scind&eacute;) des actions nominatives et les registres des autres titres nominatifs, le cas &eacute;ch&eacute;ant, peuvent &ecirc;tre conserv&eacute;s sous la forme &eacute;lectronique. Chaque d&eacute;tenteur de titres peut consulter le registre (scind&eacute;) en ce qui concerne ses titres. Le conseil d&rsquo;administration peut d&eacute;signer un tiers de son choix pour conserver ce registre &eacute;lectronique (scind&eacute;).</I> &nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The (split) register of registered shares and the registers of other registered securities, as the case may be, can be kept electronically. Each holder of securities can consult the (split) register with respect to his/her/its securities. The board of directors can appoint a third party of its choice to keep this (split) electronic register. </I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Toutes les inscriptions dans le registre (scind&eacute;) des actions nominatives et dans les registres d&rsquo;autres titres nominatifs, y compris les cessions et les conversions, peuvent &ecirc;tre valablement effectu&eacute;es sur la base de documents ou d&rsquo;instructions soumis par voie &eacute;lectronique ou par tout autre moyen par le c&eacute;dant, le cessionnaire et/ou le d&eacute;tenteur des titres, le cas &eacute;ch&eacute;ant.&rdquo;</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>All recordings in the (split) share register and the registers of other registered securities, including transfers and conversions, can be validly made on the basis of documents or instructions submitted electronically or via any other means by the transferor, the transferee and/or the holder of the securities, as applicable.&rdquo;</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 48.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;Le texte de l&rsquo;article 14 (&ldquo;Obligation de transparence&rdquo;) est modifi&eacute; et reformul&eacute; comme suit :</FONT></TD>
    <TD STYLE="padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;The text of article 14 (&ldquo;Transparency obligation&rdquo;) shall be amended and restated as follows:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Chaque personne physique ou morale qui acquiert ou c&egrave;de des titres avec droit de vote de la Soci&eacute;t&eacute;, qu&rsquo;ils repr&eacute;sentent ou non le capital de la Soci&eacute;t&eacute;, doit se conformer aux obligations de notification et d&rsquo;information impos&eacute;es par le droit applicable.&rdquo;</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Each natural or legal person acquiring or transferring voting securities of the company, whether or not representing the share capital of the company, must comply with the relevant notification and information obligations that are imposed by applicable law.</I>&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 48.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 48.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;Le texte de l&rsquo;article 15 (&ldquo;Droits de vote&rdquo;) est modifi&eacute; et reformul&eacute; comme suit :</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;The text of article 15 (&ldquo;Voting rights&rdquo;) shall be amended and restated as follows:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Le non-respect des obligations de notification et d&rsquo;information impos&eacute;es par le droit applicable en ce qui concerne l&rsquo;acquisition ou la cession de titres avec droit de vote de la Soci&eacute;t&eacute;, qu&rsquo;ils repr&eacute;sentent ou non le capital de la Soci&eacute;t&eacute;, peut entra&icirc;ner, conform&eacute;ment au droit applicable, une suspension des droits de vote attach&eacute;s aux titres avec droit de vote concern&eacute;s ou toute autre cons&eacute;quence pr&eacute;vue par le droit applicable.&rdquo;</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Non-compliance with the relevant notification and information obligations that are imposed by applicable law in relation to the acquisition or transfer of voting securities of the company, whether or not representing the share capital of the company, may result, in accordance with applicable law, a suspension of the voting rights attached to the relevant voting securities or such other consequence as provided for by applicable law.</I>&rdquo;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Note concernant le point
    3(c)(i)</U> : A la suite d&rsquo;une erreur administrative, la version fran&ccedil;aise de la convocation publi&eacute;e dans le
    Moniteur belge et (le cas &eacute;ch&eacute;ant) l&rsquo;Echo ne contient pas la phrase suivante: &ldquo;Sous r&eacute;serve des
    dispositions applicables de droit des soci&eacute;t&eacute;s, de droit financier et du droit des valeurs mobili&egrave;res, et sauf
    d&eacute;cision contraire du conseil d&rsquo;administration conform&eacute;ment &agrave; l&rsquo;article 43 des statuts, les dividendes
    et autres distributions (selon le cas) de la soci&eacute;t&eacute; sur les actions peuvent &ecirc;tre effectu&eacute;s en euros (EUR)
    ou en dollars am&eacute;ricains (USD), en fonction de la composante du registre des actions (scind&eacute;) sur lequel les actions
    sont inscrites&rdquo;. Cependant la convocation faisant foi est celle publi&eacute;e sur le site web de la Soci&eacute;t&eacute;
    le 2 octobre 2023, laquelle inclus la phrase mentionn&eacute;e ci-dessus entre guillemets et soumise &agrave; l&rsquo;approbation
    des actionnaires.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) &Agrave; l'article 32 (&quot;Admission &mdash; Formalit&eacute;s pr&eacute;alables&quot;), les paragraphes suivants sont ajout&eacute;s apr&egrave;s le premier paragraphe de l'article 32 :</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) In article 32 (&quot;Admission &ndash; Prior formalities&quot;), the following paragraphs shall be added after the first paragraph of article 32:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; padding-left: 0.5in; text-indent: 0pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&quot;Le conseil d'administration peut d&eacute;cider que le droit d'assister aux assembl&eacute;es g&eacute;n&eacute;rales des actionnaires et d'y exercer le droit de vote (le cas &eacute;ch&eacute;ant) est d&eacute;termin&eacute; par l'enregistrement de la propri&eacute;t&eacute; des titres concern&eacute;s au nom du d&eacute;tenteur de ces titres le troisi&egrave;me (3e) jour ouvrable pr&eacute;c&eacute;dant la date de l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires concern&eacute;e (ou toute autre date indiqu&eacute;e dans la convocation &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires, mais qui ne peut &ecirc;tre ant&eacute;rieure au 15e jour calendrier pr&eacute;c&eacute;dant l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires), &agrave; minuit &agrave; la fin de ce jour (heure de Bruxelles) (cette date et cette heure &eacute;tant la date d'enregistrement concern&eacute;e), au moyen de l'enregistrement de ces titres dans le registre pertinent (ou la partie du registre scind&eacute; pertinente) pour ces titres, dans les comptes d'un teneur de compte agr&eacute;&eacute; ou d'un organisme de liquidation pour les titres concern&eacute;s.</I></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Le
conseil d'administration peut subordonner la participation aux assembl&eacute;es g&eacute;n&eacute;rales des actionnaires &agrave; l'obligation
pour les d&eacute;tenteurs de titres concern&eacute;s de notifier &agrave; la Soci&eacute;t&eacute; ou &agrave; la personne d&eacute;sign&eacute;e
&agrave; cet effet par la Soci&eacute;t&eacute;, &agrave; une date d&eacute;termin&eacute;e par le conseil d'administration avant la
date de l'assembl&eacute;e pr&eacute;vue, leur intention d'assister &agrave; l'assembl&eacute;e, en indiquant le nombre de titres avec
lesquels ils souhaitent participer. Les modalit&eacute;s d'&eacute;laboration de cette notification (selon le cas) doivent &ecirc;tre
indiqu&eacute;es dans l'avis de convocation de l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires.&quot;</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; padding-left: 0.625in; text-indent: 0pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&quot;The board of directors shall have the ability to determine that the right to attend the general shareholders' meetings and to exercise the voting right at such meetings (as the case may be) is determined by the registration of the ownership of the securities concerned in the name of the holder of such securities on the third (3rd) business day prior to the date of the relevant general shareholders' meeting (or such other date as shall be set out in the notice convening the general shareholders' meeting, but which cannot be earlier than the 15th calendar date before the relevant general shareholders' meeting), at midnight at the end of such day (Brussels time) (such date and hour being the relevant registration date), by means of the registration of such securities in the relevant (portion of the split) register book for such securities, or in the accounts of a certified account holder or relevant settlement institution for the securities concerned.</I></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
board of directors may make participation to the general shareholders' meetings dependent on a requirement of notification by the securities
holders concerned to the company, or to the person appointed for this purpose by the company, on a date to be determined by the board
of directors before the date of the scheduled meeting, that such securities holder intends to attend the meeting, stating the number
of securities with which such securities holder wishes to participate. The manner in which such notification must be made (as the case
may be) must be set out in the notice convening the general shareholders' meeting.&quot;&nbsp;</I></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp; &Agrave; l'article 33 (&quot;Repr&eacute;sentation des actionnaires&quot;), la derni&egrave;re phrase du premier paragraphe est modifi&eacute;e et reformul&eacute;e comme suit :</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&quot;Ces
                                            procurations doivent &ecirc;tre accord&eacute;es et soumises &agrave; la soci&eacute;t&eacute;
                                            conform&eacute;ment au droit applicable et/ou comme indiqu&eacute; (conform&eacute;ment au
                                            droit applicable) dans l'avis de convocation, le cas &eacute;ch&eacute;ant.&quot;</I></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) In article 33 (&quot;Representation of shareholders&quot;), the second paragraph shall be amended and restated as follows:</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<I>Such proxies must be granted and submitted to the company in accordance with the applicable law and/or as set out (in accordance with the applicable law) in the convening notice, as the case may be.</I>&quot;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;&nbsp;&Agrave; l'article 35 (&quot;Ajournement de l'assembl&eacute;e&quot;), les r&eacute;f&eacute;rences, dans les premier et deuxi&egrave;me paragraphes, <I>&agrave; &quot;cinq (5) semaines&quot; sont remplac&eacute;es par des r&eacute;f&eacute;rences &agrave; &quot;trois (3) semaines&quot;</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;&nbsp;In article 35 (&quot;Adjournment of the meeting&quot;), the reference in the first and second paragraph to &quot;<I>five (5) weeks</I>&quot; shall be replaced by &quot;<I>three (3) weeks</I>&quot;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) Le texte de l'article 36 (&quot;D&eacute;cisions sur les points non inclus dans l'ordre du jour &mdash; Amendements&quot;) est modifi&eacute; et reformul&eacute; comme suit :</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&quot;L'assembl&eacute;e
                                            g&eacute;n&eacute;rale des actionnaires ne peut valablement d&eacute;lib&eacute;rer ou r&eacute;soudre
                                            sur les points qui ne sont pas inscrits ou implicitement inscrits &agrave; l'ordre du jour,
                                            sauf si tous les actionnaires sont pr&eacute;sents ou repr&eacute;sent&eacute;s &agrave;
                                            l'assembl&eacute;e et y consentent &agrave; l'unanimit&eacute; et si, dans le cas d'un vote
                                            par correspondance, le formulaire autorise un mandataire &agrave; prendre une telle d&eacute;cision.
                                            Le consentement requis est pr&eacute;sum&eacute; exister si aucune objection n'est consign&eacute;e
                                            dans le proc&egrave;s-verbal de l'assembl&eacute;e.&quot;</I></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) The text of article 36 (&quot;Decisions on matters not on the agenda - Amendments&quot;) shall be amended and restated as follows:</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<I>The general shareholders' meeting cannot validly deliberate or decide on the items that are not included or implicitly contained in the agenda, unless all shareholders are present or represented at the meeting and unanimously agree and if, in the case of a vote by mail, the form authorises a proxy to make such a decision. The required consent is assumed to exist, if no objection is recorded in the minutes of the meeting.</I>&quot;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.625in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
    &Agrave; l'article 39 (&quot;Vote et participation &agrave; distance&quot;), la r&eacute;f&eacute;rence au &quot;<I>sixi&egrave;me
    jour calendrier&quot; est remplac&eacute;e par la r&eacute;f&eacute;rence au &quot;troisi&egrave;me jour
    ouvrable&quot;.</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 48.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
    In article 39 (&quot;Remote voting or participation&quot;) the reference to &quot;<I>sixth calendar day</I>&quot; shall be replaced
    by &quot;<I>third business day</I>&quot;.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><P STYLE="margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix) &nbsp;L'intitul&eacute; de l'article 51 est modifi&eacute; et reformul&eacute; comme suit : <I>&quot;Certains termes d&eacute;finis&quot;, et le texte de l'article 51 est modifi&eacute; et reformul&eacute; comme suit :</I></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&quot;Sauf
si le contexte exige le contraire ou si les pr&eacute;sents statuts en donnent une d&eacute;finition diff&eacute;rente, aux fins des
pr&eacute;sents statuts, (a) le terme &quot;personnel&quot; a la signification octroy&eacute;e par l'article 1:27 du Code des soci&eacute;t&eacute;s
et des associations, et (b) le terme &quot;jour ouvrable&quot; a la signification octroy&eacute;e par l'article 1:32 du Code des soci&eacute;t&eacute;s
et des associations.&quot;</I></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 48.5pt; text-align: justify; text-indent: -0.25in; width: 50%"><P STYLE="margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)&nbsp;&nbsp;The heading of article 51 shall be amended and restated as &quot;<I>Certain defined terms</I>&quot;, and the text of article 51 shall be amended and restated as follows:</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<I>Unless the context requires otherwise or unless otherwise defined in these articles of association, for the purposes of these articles of association, (a)&nbsp;&quot;personnel&quot; shall have the meaning defined in Article 1:27 of the Belgian Companies and Associations Code, and (b)&nbsp;&quot;business day&quot; shall have the meaning defined in Article 1:32 of the Belgian Companies and Associations Code.</I>&quot;</FONT></P></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 48.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 48.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; padding-bottom: 1pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp; <U>Mise en &oelig;uvre de la Radiation de la Cote :</U> Sous r&eacute;serve des r&egrave;gles applicables en mati&egrave;re de droit des soci&eacute;t&eacute;s, de droit financier et de droit des valeurs mobili&egrave;res, et sous r&eacute;serve des dispositions des paragraphes pr&eacute;c&eacute;dents, le conseil d'administration a le pouvoir de mettre en &oelig;uvre et d'effectuer la Radiation de la Cote, y compris (sans s'y limiter) le pouvoir (i) de d&eacute;terminer la mise en &oelig;uvre pratique de la Radiation de la Cote, (ii) de d&eacute;terminer le calendrier et la date effective de la Radiation de la Cote ainsi que la dur&eacute;e de la P&eacute;riode de Transition, (iii) de d&eacute;terminer les modalit&eacute;s et le processus de n&eacute;gociation des actions (ou, le cas &eacute;ch&eacute;ant, des American Depositary Shares ou des American Depositary Receipts relatifs &agrave; ces actions) sur le Nasdaq, (iv) de nommer une ou plusieurs banques ou institutions financi&egrave;res pour l'organisation et la mise en &oelig;uvre de la Radiation de la Cote, (v) de proc&eacute;der &agrave; la constatation de la modification et de la reformulation des statuts comme pr&eacute;vu au paragraphe (c) devant notaire, (vi) d'entreprendre toutes les d&eacute;marches utiles ou n&eacute;cessaires aupr&egrave;s d'Euronext, d'Euroclear, de toute autre agence de r&egrave;glement comp&eacute;tente et de toute autorit&eacute; de r&eacute;glementation ou de cotation en rapport avec la mise en &oelig;uvre de la Radiation de la Cote, et (vii) de prendre toutes les autres mesures utiles, appropri&eacute;es ou n&eacute;cessaires en rapport avec ce qui pr&eacute;c&egrave;de. Le conseil d'administration est habilit&eacute; &agrave; d&eacute;l&eacute;guer la mise en &oelig;uvre et l'ex&eacute;cution de la Radiation de la Cote (y compris les pouvoirs vis&eacute;s aux points (i) &agrave; (vii)), en tout ou en partie, &agrave; un ou plusieurs membres du management ou du personnel de la Soci&eacute;t&eacute;. Tout administrateur, tout membre du management et toute autre personne express&eacute;ment d&eacute;sign&eacute;e &agrave; cet effet par le conseil d'administration est autoris&eacute; &agrave; faire constater, devant notaire, la modification et la reformulation des statuts vis&eacute;es au paragraphe (c).</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 0.625in; padding-bottom: 1pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;<U>Further implementation of the De-Listing</U>: Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall have the authority to further implement and effect the De-Listing, including (without being limited to) the authority to (i) determine the practical implementation of the De-Listing, (ii) determine the timing and the effective date of the De-Listing and the duration of the Transition Period, (iii) determine the manner and process for the shares (or, as the case may be, American Depositary Shares or American Depositary Receipts in relation to such shares) to be traded on Nasdaq, (iv) appoint one or more banks or financial institutions for the further organization and implementation of the De-Listing, (v) proceed with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph (c) before a notary public, (vi) take all useful or necessary steps with Euronext, Euroclear, any other competent settlement agency, and any regulatory or listing authority in connection with the implementation of the De-Listing, and (vii) do such other things as shall be useful, appropriate or necessary in connection with the foregoing. The board of directors shall have the authority to delegate the further implementation and execution of the De-Listing (including the powers referred to in sub-sections (i) to (vii)), in whole or in part, to one or more members of the Company's executive management or personnel. Any director, any member of the executive management, and any other persons that shall be expressly appointed for such purpose by the board of directors shall be authorized to record the amendment and the restatement of the articles of association as contemplated by paragraph (c) before a notary public.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: Black 1.5pt solid; padding-left: 5.4pt; border-left: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Instruction
    de vote</U></FONT></I></B>: </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Voting
    instruction</U></FONT></I></B>: </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt solid; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Pour
    / For</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Contre
    / Against</I></FONT></TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Abstention</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; width: 50%"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Le/la soussign&eacute;(e) confirme que les votes susmentionn&eacute;s s'appliquent &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires qui se tiendra le vendredi 3 novembre 2023. Dans le cas o&ugrave; l'assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires susmentionn&eacute;es serait report&eacute;e ou ajourn&eacute;e, les votes susmentionn&eacute;s s'appliqueront &eacute;galement &agrave; la ou &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires qui seront tenues avec le m&ecirc;me ordre du jour, le cas &eacute;ch&eacute;ant (&eacute;tant entendu que les votes susmentionn&eacute;s s'appliqueront en tout &eacute;tat de cause &eacute;galement &agrave; la deuxi&egrave;me assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires qui serait convoqu&eacute;e avec un ordre du jour identique &agrave; celui de la premi&egrave;re assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires dans le cas o&ugrave; le quorum de pr&eacute;sence l&eacute;galement requis pour d&eacute;lib&eacute;rer et voter valablement sur ces points de l'ordre du jour n'aurait pas &eacute;t&eacute; atteint lors de la premi&egrave;re assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires):</FONT></P>
                                                                                <P STYLE="margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 4pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned
    confirms that the aforementioned votes apply to the extraordinary general shareholders' meeting to be held on Friday, 3 November
    2023. In case the aforementioned extraordinary general shareholders' meeting would be postponed or suspended, the aforementioned
    votes will also apply to the general shareholders' meeting(s) that would be held having the same agenda, as relevant (it being understood
    that the aforementioned votes will in any event also apply to the second extraordinary general shareholders&rsquo; meeting which
    would be convened with an agenda identical to the agenda of the first extraordinary general shareholders&rsquo; meeting in case the
    legally required attendance quorum to validly deliberate and resolve on such agenda items would not be reached during the first extraordinary
    general shareholders' meeting):</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         &#9744; oui</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     &#9744; non</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; yes</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    &#9744; no</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Veuillez
    remplir la case appropri&eacute;e. Une absence d'instruction ou si, pour quelque raison, il y a une absence de clart&eacute; &agrave;
    propos de l'instruction donn&eacute;e, le soussign&eacute; sera suppos&eacute; avoir choisi &quot;oui&quot;. Veuillez noter qu'aux
    fins de s'appliquer &agrave; telle assembl&eacute;e subs&eacute;quente, les titulaires de titres doivent s'enregistrer &agrave; nouveau
    pour cette assembl&eacute;e. </I></FONT></TD>
    <TD STYLE="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <I>Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with
    regard to the instruction given, the undersigned shall be deemed to have selected &quot;yes&quot;. Please note that in order to apply
    for such subsequent meeting, holders of securities must again register for such meeting.</I></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Si, pendant
    l'assembl&eacute;e, il y a des modifications &agrave; une proposition de r&eacute;solution ou une nouvelle proposition de r&eacute;solution:<SUP>1</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case
    of amendments during the meeting to a proposed resolution or a new proposed resolution:<SUP>1</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    le/la soussign&eacute;(e) votera pour la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    the undersigned shall vote for the amended or new resolution</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    le/la soussign&eacute;(e) votera contre la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    the undersigned shall vote against the amended or new resolution</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    le/la soussign&eacute;(e) s'abstiendra de voter sur la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    the undersigned shall abstain from the vote on the amended or new resolution</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify; width: 50%">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    la personne suivante sera consitut&eacute;e comme mandataire sp&eacute;cial, avec droit de substitution, pour voter au nom du/ de
    la soussign&eacute;(e) sur la r&eacute;solution modifi&eacute;e ou nouvelle : le pr&eacute;sident du conseil d'administration de
    la Soci&eacute;t&eacute;<SUP>2</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify; width: 50%">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    the following person will be appointed as proxy holder, with the right of substitution, to vote on behalf of the undersigned on the
    amended or new resolution: the chair of the board of directors of the Company<SUP>2</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.55in; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>1 </SUP></I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Veuillez cocher tel qu'appropri&eacute;. Une absence d'instruction
sera interpr&eacute;t&eacute;e comme une instruction de voter pour la r&eacute;solution modifi&eacute;e ou nouvelle selon la mani&egrave;re
support&eacute;e ou recommand&eacute;e par le conseil d'administration de la Soci&eacute;t&eacute;. <SUP>&nbsp;</SUP></I>&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>1</SUP></I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
    complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or new resolution
    as will be supported or recommended by the board of directors of the Company.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>2</SUP> </I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Si le pr&eacute;sident du conseil d'administration de la
Soci&eacute;t&eacute; est constitu&eacute; comme mandataire sp&eacute;cial, le pr&eacute;sident (ou, le cas &eacute;ch&eacute;ant, un
autre administrateur, un employ&eacute; ou un rempla&ccedil;ant d&eacute;sign&eacute; par la Soci&eacute;t&eacute; si le pr&eacute;sident
est emp&ecirc;ch&eacute; d'assister &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires) vote dans ce cas sur les propositions
de r&eacute;solution modifi&eacute;es ou nouvelles selon la mani&egrave;re support&eacute;e ou recommand&eacute;e par le conseil d'administration.
Veuillez noter que le pr&eacute;sident du conseil d'administration de la Soci&eacute;t&eacute; (ou, le cas &eacute;ch&eacute;ant, le
rempla&ccedil;ant du pr&eacute;sident) est un administrateur, un employ&eacute; ou un rempla&ccedil;ant d&eacute;sign&eacute; de la Soci&eacute;t&eacute;
et a donc un conflit d'int&eacute;r&ecirc;ts potentiel tel que d&eacute;fini dans l'article 7:143, &sect;4 du Code des soci&eacute;t&eacute;s
et des associations.</I> &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>2</SUP></I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If the chair of the board of directors of the Company is
appointed as a proxy holder, the chair (or, as the case may be, another director, an employee or a substitute designated by the Company
if the chair is hindered to attend the general shareholders' meeting) shall in such case vote on the amended or new proposed resolutions
in the manner supported or recommended by the board of directors. Please note that the chair of the board of directors of the Company
(or, as the case may be, his substitute) is a director, employee or substitute of the Company and therefore has a potential conflict
of interest as defined in article 7:143, &sect;4 of the Belgian Companies and Associations Code.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ce formulaire de vote par correspondance sert &eacute;galement
    de notification au sens de l'article 7:134, &sect;2, alin&eacute;a 3 du Code des soci&eacute;t&eacute;s et des associations pour
    l'assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires de la Soci&eacute;t&eacute; qui se tiendra le vendredi
    3 novembre 2023.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This voting by mail form
    shall also serve as notification within the meaning of article 7:134, &sect;2, paragraph 3 of the Belgian Companies and Associations
    Code with respect to the extraordinary general shareholders' meeting of the Company to be held on Friday 3 November 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Le soussign&eacute; confirme
    que la traduction anglaise du pr&eacute;sent formulaire n'est qu'une traduction libre en anglais et &agrave; titre informatif uniquement,
    et que la version fran&ccedil;aise pr&eacute;vaut sur la version anglaise.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned confirms
    that the English translation of the present form is a free English translation and for information purposes only, and that the French
    version shall prevail over the English version.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 17.85pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fait
    &agrave; _______________________</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Done at _______________________</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 17.85pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">_______________________ 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(date)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(nom
/ name)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(signature)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 95%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance</B></FONT></TD><TD STYLE="width: 5%; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary General Shareholders' Meeting of MDxHealth SA - Voting by mail form</B></FONT></TD><TD STYLE="text-align: right; padding-right: 9.15pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->/11</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.10
<SEQUENCE>11
<FILENAME>ea186179ex99-10_mdxhealth.htm
<DESCRIPTION>OUTSTANDING SHARES AND VOTING RIGHTS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Free English translation for information purposes
only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MDxHealth SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><BR>
Limited Liability Company<BR>
(<I>soci&eacute;t&eacute; anonyme</I>)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CAP Business Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Zone Industrielle des Hauts-Sarts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rue d&rsquo;Abhooz 31<BR>
4040 Herstal, Belgium<BR>
VAT BE 0479.292.440 (RLP Li&egrave;ge, division Li&egrave;ge)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Outstanding
    Shares and voting rights</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>extraordinary
    general shareholders&rsquo; MEETING</B></FONT><B><BR>
    </B>to be held on Friday, 3 November 2023, at 3:00 p.m.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This overview has been prepared by MDxHealth SA
(the &ldquo;<B>Company</B>&rdquo;) in accordance with article 7:129, &sect;3, 2&deg; of the Belgian Companies and Associations Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 4 October, the total number of outstanding
shares and voting rights of the Company amounted to 270,380,936.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>&nbsp;</SUP></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A .(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BN:UOQ3
M)::DND:39-?ZF1N9 <+$/5C5"36_%VDQFZU/1[:>T7E_LLF71?7'>G85T=I1
M7)WGCFV>.UBT2!M1O;I=R0KQL'J_I4#ZOXST]&NKW1[2>V7EH[>3+J._UHL+
MF1V=%4-(U>TUO3H[VS<F-N"IZJ>X/O6;K_BI-)N8]/L[5[[4Y1E+>/L/5CVH
ML.ZW.AKD+^XF7XH:7 )G$+6;EHPQVD_-SB@ZKXS@4SS:%:RQ=3%%-\X'^-95
MKK-MKGQ(TBZMMZD6DB212##1N-V5(II$MGHE%<OXQ35TA@NM-ED$<.3(L9Y^
MON*N>&O$,6N6>&PMU&/WB>ON/:M'1?L_:+5?D<BQL/K+PTDT^E]GZ&Y17,>)
M->>!QIU@2UR_#,O5?8>]:VAPWD&EQI?.6FZ\G) ]":XXU5*;@NAUJ:<N5'/_
M  _N)[BWU@SS22E=0=5WL3@8' KL:\N\*Z_)IJZI8V-E)?:C-?R.D*\!5X&Y
MCV%;MSKWBW2XVNK_ $.WEM5Y<6\N61>YKH:U!/0[2BJ6DZK:ZUIL-_9ONBD'
M?JI[@^]8VI^*95U1M)T2Q.H7R<RG=MCB_P!X^M*Q5SIJ*XZ77_$^D)]IU;1H
M)+,']X]I)N:,>N*ZFQOK?4K**[M9!)#*NY6%%@3+%%<OJ_BUX-4.DZ-8MJ&H
M+S( <)%_O&J[ZWXMTY#<:AH4,ULO+BUERZCUQWHL%T=A7(7EQ,/BGI]N)G$+
M6+,8PQVDY;G%6-#\71:]K]U96J(UI% DJ2Y.XD@9!';!)'X52O?^2MZ=_P!>
M#?S:FD)NYUM[=)8V,]U(K,D*%V"]2 ,U#I&IQ:QI5OJ$*.D<Z[E5\9')'./I
M6#XKN]>CL[^*UTVWEL#;MNF:;# 8YXK'\*W_ (HB\,6"66CVLUL$.R1Y]I8;
MCVHMH%]3T.N-^'UQ/<0ZP9YI)-M^ZKO8G ]!70:/<:K<02-JUG#:R!L(L4F_
M(QU->?\ A77I--_M6RL;*2^U&>_D9(5X"K_>8]A0D#>J/4J*XRYU[Q;I<;7=
M_H=O+:KRXMY<LB]S6O'KJZEI5M?Z:0T,N<EARI'\)]^OY4K#N;E%5HYKAHD+
M0\E03SC]**0SE? 2B:XU^^D&ZXEU!T9SUVKT'TYKLR 001D'M7'?#]2MMK60
M1G4Y>H^E=C3>Y,=CA? >GVUMKGB)XHP&CN?+0_W5R3@?Y[5W5<?X,!&L^)<@
MC_31_6NPH>X1V.+\)8M_%OB:RB 6W299%0= 3G--\#HMYJ^OZK,,W379A!/5
M4'0#_/:G^&E(\=^)R00"T>#CKP:AO8K[P?XBNM6M;22[TF^(:YCB&7B?^\!Z
M50CN:X6YLH+;XNV$T2A6N+5WD [L PS^( _*KA^(^@M&/LYNKB<_=@C@;>3Z
M>E86G?VK/\3K&^U2'R'N+9VC@Z^4@#  GUZG\:20-IGI=>>>(/LMAXAA;0G<
M:@S'S8H1E1Z_C[5L^--7U&P@@M=/B<-<Y!E4$D>P]ZD\)^&AI%O]JNANOI1E
MB>=@/;Z^M;P]R#DWOI8Y,13AB)*FULT[]O1C/"<-@ZM.7\S4/^6GF=5^G^-=
M37)>(=&FM9_[5TW<CJ<R*G;W']:W-$OIM0TR.>>/9(>#Q@-[UYE!\C]DUJOQ
M/4G2A&//3V_(Y?X<01@:Y<;!YK7S(6[[1R!^IKN" P((R#P17&?#I66VUG<I
M&=1?J/85VE=;W.>.QPW@)OLNEZ]'$/DM[Z7RU],#I^E9/@G6KVRT:2:+0+N]
MEN9FDEN8V&'.?Z5N> $.S7E=2 =2DZCJ*J6=Q<> ;RYM+NUFFT.:0RP7$*[O
M))ZJP]*KN3V--O%.INI5O"=^5(P067D56\%Q:AINCZJMS9RVL:2O+;12]0I!
M./T%6)?B'H93%BUQ?7#?<@@A;<3^(K>TJ>\O-,CEU&T6VG<'="&W8';/X4BE
MJ]SF_AM"C>'7U!AFYNYW>5SU)!Z?Y]:[*N @GN_ -_<PSVL]SH4\ADBFA7<8
M">H(]*T)?B)I,J>7I<=S?W;<)#%"PY]R>@H:NP325F5- LH+'XFZY%;J%1H$
MDVCH"V"?U-37O_)6]._Z\&_FU4/!\&HQ>/-7;5,?:I;=)'"]%W8.T?0<?A6A
M>JW_  MG3FP=OV!N<<=6I]2>AT/B'_D7=1_Z]G_]!-4/ W_(E:9_US/_ *$:
MV-0M?MNG7-KG'G1,F?J,5PWASQ;:>&]+71=>CFL[JT+*"8RRNN2001]:2V*>
MC/0JX7X<01@ZY/M'FF^="V.<#G'ZUTFAZ]#K\4TUO;7,4", DDR;1)[CVK ^
M'2LL&M;E(SJ#]11T8;M':$ @@C(/4&N,^'2"&VUF!.(X]0=47T&!7:5QO@!2
MHUW((SJ,G4>PI+8'NCLJ***10U._UIU%% #5ZM]:=110 U?OM3CTHHH R[3_
M )",M:1_U@^E%% D*>WUI:**!@>E(.@HHH 1._UIU%% #4[_ %H?[A^E%% &
M=IG^NE^M:=%% D-D_P!6WTK/TS[\O^]113 T!_K#1_RT'THHI#'5G:GUB_WJ
<**!,OI]Q?I0G?ZT44#'4U._UHHH =1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  A .(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBOS7_:
MB_;VUOX>?%K3OV8?V9?A/??M#?M+7^GVVL:WX<M+W^S/"'PXT.\-NT.J>.=>
M *6DQM+F+4OL#2VB16<EFUW>V\FI6,4W@NL_M2?\%1?V?--NOB/^T-^RQ\,?
MB!\*-,D-YXJ'P/\ %4E]XS\)Z!"DD][JITV:^OQJ*V,*9G=;<V4:AI;F]M85
M:9>F.$JRC%WIP<TG3A4JPA4J)[.,).]I?9<G!2^S>Z;Y)XVC"4XVK35-M5:E
M*A4J4Z32NU.<$U>*UDHJ;A]JVJ7[145^3GQ*_P""JO@'4])^%GAW]D7P7JG[
M37QL^,VAQ^(/"_P^T:4Z=!X/T@22Q7M_\2[L"67P[)83VM[;3Z:YBE1[66XN
M;NSLFM[BYX?5?VB?^"M'P>L;[XB_%C]E3X0?$/X=Z<R7NM^&/A'XQGNO'^AZ
M$L@FU*]@@6]U1-5GTO3TGG>.SL[Z.7RL,\8;S%%A*S2YO9TY.ZC"K5A2J3LW
M'W83:=KII.7(FU9-[B>/PZ;Y/:UHQ2<ZE"C4K4X)Q4ES3@FK\K4FH\\HIWDE
ML?LW17A7[.7[1/PU_:B^%>@_%OX7:E+>:%J_FVM]IU]&MMK7AO7+,JFI^']=
ML@[_ &74K"4@,%=X+F!X+RUEFMKB*1OFG]KO]OG2/V>_%_A[X'_"WX=Z_P#'
M_P#::\:V1OO#7PD\)R>4--L'CD>VU?QCJR17/]B:?=&(FW0027+VX>_E%M81
MM='.-&K*HZ2@_:1<E*+M'DY?B<W)J,5'=RDTDM;NZOM/$484E7E4C[*2BX2C
M>7/S_ H**E*<I;1C&+DW=65G;]"Z_(;XL>,/%EI_P61_9<\&6OB?7[;PAJG[
M./Q!U/4_"T&KW\/A[4=1M[?X@F"_OM&CG73[J\A-O;F*YGMWFC-O!L=?+7 _
MQ]_X*T>%K:7QGXH_8W^$?BGPM&D-Y=>"?!/Q+23X@VUA))&\T=C$=0U"+4-3
MM[9GV645M<2S31^2T<3,73Y4\!?M,?#W]JO_ (*U?LC_ !'\ IK&E2V7[/'Q
M5\,>-?!?B>PDTOQ;X \:Z1:^/SK7A+Q-I\G^HU'3VN866:,M;WEM-#<V[%),
M+V4,/.'MI-TJD%A<2G*G4A549>ST4N76+=GRMI)M/EE?0X<3BH5/J\$JU*;Q
MF$:A5I5*,IP]J^9QYM)I77,E)M)KFBD[G]$E%?F#_P %)=._:CT_0/!7Q'^
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M]3^(FK_$.#2_$UI8W?AN[7Q)<Q>&I+N"26;24:=K2!()?M0CC<2.7:)/D/\
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M-;>*JW>WLU\E1HV7R/@<O26#HI)*ZJ-Z;MUJ]V_-O>Y^&O\ P20NW\"?!O\
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MH>R^?YFBW?R_(9)_JY/]QO\ T$TRW_U,?^[_ %-%%1]K_MW_ -N1?V?^WO\
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?Y&G6;IW2Z_Z^&_\ 05HHHZ/Y?J#W7S_(TJ***0S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex99-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K 28# 2(  A$! Q$!_\0
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=-A%J<FI):QK>2#:\P'S$<?X"A,;5R[1112&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex99-5_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  A .(# 2(  A$! Q$!_\0
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MVF>$-=TFZO[?PM:2A(C=6^DMHNG"\EMX8[>;5-3OKJ%1-=3I'W>M_P#!8_\
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M5_&ES\//$NOPPP1!8[>*[UO4]0U2"VC1(;:WOX;>!$ABC4=K\4O^4V'[-/\
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=1^/\S114%+9>B_)#J:O\7^\?Z444#'4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
